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Abstract 
 
Background 
   Cost-effectiveness outcomes collected in multinational health economic studies may 
vary across countries and geographic areas due to numerous clinical and socio-
economic factors. The between-country variability poses the question of generalizability 
of the cost-effectiveness estimates, i.e. applicability of the trial-wide results for the 
decision-making in particular jurisdiction.  
Objectives 
   The purpose of this research is to illustrate how selected methods can improve 
generalizability of the results of patient-level health economic studies by a) exploring 
between-country variability in incremental costs, effectiveness and resource use, b) 
calculation of trial-wide and country-level incremental cost, effectiveness and resource 
use while accounting for patient- and country-level covariates, and c) assessing the 
potential of covariates to predict cost and effectiveness estimates for the settings outside 
the study.  
Methods 
   Review of published health-economic evidence and international HTA guidelines was 
conducted to evaluate applied or recommended methods and analytical strategies to 
improve generalizability of the health economic outcomes. In the case study, qualitative 
and quantitative homogeneity test by Simon and Gail is used to explore between-
country heterogeneity of the treatment effects measured by incremental costs, 
effectiveness, resource use (length of hospitalization) and incremental net monetary 
benefit. Hierarchical modelling is applied to calculate trial-wide and country-level 
estimates, while accounting for clustering and incorporating country- and patient-level 
covariates. 
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Results 
   Simon and Gail test indicated qualitative homogeneity for incremental effectiveness, 
costs, length of hospitalization and net monetary benefit between treatment and control 
arms. Trial-wide and country-level mean incremental costs and effectiveness were 
estimated using hierarchical models with and without covariates. Results of hierarchical 
modelling suggested, that new treatment was more efficacious, saved costs and resource 
use in majority of the countries.  
Conclusions 
   Homogeneity test and hierarchical models are complementary methods to explore 
heterogeneity and to estimate trial-wide and country-level parameters for cost-
effectiveness analysis. Hierarchical models allow for country-level estimates and 
adjustment for covariates. In the case study the patient-level covariates showed effect on 
incremental cost and effectiveness; country-level covariates had very small impact on 
estimates. The use of country-level covariates as predictors for incremental cost and 
resource use to improve generalizability of health economic studies beyond the study 
setting merits further investigation. 
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1  Introduction and Research Purpose 
 
Data collection in multinational trials 
   Cost-effectiveness analysis for informing health policy decision making is often 
conducted using patient-level data from multinational clinical trials. There are two main 
advantages of conducting the trials in several jurisdictions or countries. The first 
practical advantage is potentially fast recruitment of the study patients. The second 
advantage relates to the diversity of recruited population coming from different 
locations with different clinical and socio-economic background. The latter could 
potentially improve generalizability of health economic outcomes beyond the study 
setting. However, variation in multiple health economic parameters across the 
jurisdictions raises the question about the generalizability of the study results. 
Definition of generalizability 
   Applicability of the health economic evidence collected in multinational trails for the 
decision-making in particular jurisdiction is a complex issue. Clinical and economic 
parameters collected in different settings vary within and between countries due to 
numerous clinical and economic factors. As a consequence, trial-wide cost-effectiveness 
estimates may not be directly applicable for the decision-making for reimbursement of a 
therapy in a particular country (Sculpher et al., 2004; Drummond & Pang, 2001; 
Boulenger et al., 2005; Mason & Mason, 2006; Li, 2007). This issue is discussed in 
health economic literature using different terminology, such as transferability, 
portability, extrapolation, external validity and others. For the purpose of this research 
we will use the definition suggested by Sculpher and colleagues (2004), who defined 
generalizability as “the extent to which the results of a study based on measurement in a 
particular patient population and/or a specific context hold true for another population 
and/or in a different context” (Sculpher et al., 2004, p. ix). Further on, for the analysis of 
patient-level studies we will refer to “internal” generalizability in considering the 
validity of the results for the countries or settings included into particular study, and to 
“external” generalizability in discussion about applicability or adjustment of the 
estimated outcomes to the external settings not participated in the study. 
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Current methodological approach and need for further research 
   Assessment of the generalizability of the results is not yet established part of the 
analysis of multinational health economic trials. It is generally assumed, that clinical 
efficacy of a therapy should be similar across different countries. Homogeneity of 
relative clinical effects is usually tested before the data from multinational trails is 
pooled. However, statistically significant differences in treatment effects in different 
countries are rarely observed or may go undetected due to small sample size (Cook et 
al., 2003). The variation in resource use and cost between the countries posses a 
challenge for cost-effectiveness analysis, as it may prevent from pooling of economic 
parameters and not allowing for robust sub-group analysis with country-specific data 
due to small sample size. The application of the unit prices from one country to the 
pooled resource use across all participated countries was often done in early health 
economic studies as a way to overcome small sample size issue in individual countries. 
The appropriateness of aggregating the economic data across the jurisdictions is rarely 
investigated. 
   The acknowledgement of methodological issues and growing demand for qualitative 
data for jurisdiction-specific decision-making with increasing volume of multinational 
health economic studies, has rapidly evolved the development of analytical methods to 
improve generalizability. Task Force of International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) has been set up and worked out a guideline to address 
this issue (Drummond et al., 2009). With regard to patient-level trials, homogeneity test 
and hierarchical models have made their way in the literature. These methods are also 
suggested by ISPOR guideline as possible strategies to explore heterogeneity and 
account for variability and hierarchical data structure (Drummond et al., 2009). Broad 
application of these methods in studies conducted in different locations and clinical 
indications will help to understand and quantify between-country heterogeneity, 
improve the generalizability of the results and, thus, increase the volume of available 
evidence. 
Research purpose and objectives 
   The overall aim of the research is to explore analytical methods to improve 
generalizability of multinational health economic evaluations. The purpose of the thesis 
can be specified in terms of the following research objectives: 
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1) To review available methods to assess heterogeneity and to improve generalizability 
of health economic evaluations conducted in multinational settings.  
2) To evaluate applicability of selected methods to the patient-level data in a case study 
investigating between-country variability of cost-effectiveness parameters, 
heterogeneity factors explaining between-country heterogeneity and to calculate 
country-level and trial-wide cost-effectiveness estimates. 
   Analytical approach of the case study is essentially the following. We first explore 
between-country variability and hypothesize major heterogeneity factors. We then 
calculate country-level and trial-wide estimates for study settings (internal 
generalizability). Finally, based on heterogeneity factors and country-level estimates, 
we explore possibility to generalize results to non-study settings (external 
generalizability). 
Thesis structure 
   This thesis is structured as following. Chapter 2 discusses Public Health relevance of 
the research subject, describes theoretical link between Public Health and Economics, 
and outlines the theoretical framework for Health Technology Assessment (HTA) and 
health economic evaluations. Chapter 3 summarizes current analytical approaches to 
improve generalizability described in published evidence and methods used in the case 
study analysis. Specifically, we used homogeneity test to explore and assess 
variability/country-by-treatment interaction for incremental effectiveness, costs, length 
of hospitalization and incremental net monetary benefit with implications for internal 
generalizability, i.e. applicability of the results for the decision-making in the countries 
participated in the study. Hierarchical models were used to calculate country-specific 
estimates with and without covariates, to assess covariates effect on cost and 
effectiveness estimates and possibility to generalize results of  the study to non-study 
settings on hand of explored covariates, i.e. external generalizability. Chapter 4 
describes dataset, costing methodology and results of a case study. Chapter 5 discusses 
findings, limitations of the methods and analysis, and suggests possible extensions for 
the future research. Finally, chapter 6 provides top summary of the results and 
conclusions. 
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2 Theoretical Perspectives on Public Health 
and Health Economic Evaluations 
 
   Methods to improve generalizability are essentially analytical tools for application in 
the analysis of multinational studies. Health economic studies, being part of HTA, are 
deemed to inform political decisions. Health policy and so the informing evidence 
should be jurisdiction-specific. Here, the generalizability methods aid to customize 
available data to the specific decision context. Development and application of the 
analytical tools, such as generalizability methods, usually require underlying theoretical 
considerations.  
   Theoretical foundations of health policy and research methods for health economic 
evaluations are rooted in Public Health and Economic realms, what is the subject of this 
chapter. We review theoretical and instrumental concepts related to Public Health and 
policy to understand theoretical implications for generalizability research and to 
establish the relevance of the generalizability issue to Public Health context. The 
discussion will start with normative theoretical perspectives of Public Health, 
Neoclassical Economics, Non-welfarism and New Institutional Economics. We then 
move towards instrumental concepts such as health policy, HTA and health economic 
evaluations, concluding with arguments about relevance of generalizability methods for 
Public Health, policy and research. 
 
2.1 Normative Theory and Instrumental Concepts 
 
Need for normative analysis 
   Methods to improve generalizability of health economic evaluations are in essence 
analytical instruments. Why then does normative theoretical analysis matter? Welfare 
economic theory suggests, that characteristics of health care market may impede 
optimal allocation of resources and public intervention should correct free market 
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failure. Indeed, great proportion of health care expenditures in the developed countries 
is financed from the public budget either explicitly or through taxation (OECD, 2005). 
Non-market institutions and political instruments play essential role in regulation and 
allocation of resources. Therefore, normative analysis should guide both policy 
formulation and empirical research. 
   There are many possible ways and instruments to implement political decisions. If the 
role for the invisible hand working through markets is in practice quite circumscribed in 
health sector, how do we know, what health policy and institutional designs will 
produce an efficient and equitable allocation of health care resources? Indeed, it is a 
difficult task to demonstrate that policy failed, but it is even more complex to design the 
one which will succeed. Normative economics is precisely about the attempt to 
determine the “ideal” or “desired” state, resource allocation and political measures to 
achieve it. Market failures, that pervade health care sector, create an important role both 
for non-market institutional arrangements (i.e. the “visible hand”) and for normative 
economic analysis to help design the "good" policies (Hurley, 2000).  
   Different methods for assessment of outcomes such as health benefits, preferences and 
utility could produce different estimates and lead to contrary political decisions and 
implications. Examination of theoretical foundations can provide a rationale for 
selecting appropriate analytical methods. The validity of the measured outcomes using 
specific methods should be verified by underlying theory. More importantly, recourse to 
fundamental theoretical considerations will help to maintain continuity and integrity in 
political decision-making (Hall et al., 2006). 
Link between Public Health, economic theories and generalizability methods 
   Understanding the relationship between theoretical and instrumental concepts related 
to health policy will help to identify implications for generalizability research. Figure 1 
provides a graphical presentation of the logical links between health economic theories 
and Public Health instruments. Generalizability methods are anchored within HTA 
domain. In our theoretical quest we first step back and start with neoclassical economic 
theory, followed by newer health economic theories navigating toward health policy, 
HTA and health economic evaluations as instrumental concepts. 
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   The logical connection between individual constructs is essentially the following:  
1) Public Health and Economics. 
• Public Health and Economics are linked empirically: population health is a national 
resources and directly influence economic performance and activities. 
• Neoclassical theory advocates public intervention (health policy) to correct free 
market failure in health care.  
2) Beyond Neoclassical theory toward Public Health paradigm. 
• The assumptions of neoclassical theory (utility maximization, welfarism) have been 
challenged for the application to health care.  
• Alternative theories, such as non-welfarism, extra-welfarism, communitarianism and 
others have contributed to convergence of Public Health and Economic paradigms. 
3) New Institutional Economics (NIE) to guide health policy. 
• Neoclassical framework is of limited use to study health policy, as it is essentially 
institution free; New Institutional Economics provides an alternative theoretical 
foundation to study incentives, efficiency and policy in health care. 
• New Institutional Economics can aid to explain geographic heterogeneity in inputs 
and outputs of health care market as well as to study and evaluate outcomes of 
different political instruments. 
4) HTA and health economic studies to inform health policy. 
• Health policy should be informed by jurisdiction-specific evidence in order to 
improve health and reduce inequalities.  
• Generalizability methods aid to customize available limited evidence to reflect 
jurisdiction-specific context.  
We elaborate the above arguments in more details in the following sections.  
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Figure 1: Relationship Between Public Health, Economic Theories and Instruments 
 
Source: compiled by the author 
 
2.2 Public Health and Neoclassical Economics  
Current Public Health concerns 
   In 1952 WHO defined Public Health as a mean of promoting health and preventing 
diseases through organized efforts of society (WHO, 1952). Despite the differences in 
health care systems across the countries, essentially any national health policy should 
aim to achieve Public Health goal – improvement of community health.  
   Although the question about financing of the health care systems seems to be 
unavoidable, there is a loud criticism of the involvement of economic consideration 
about access to medical technologies in the political decision making process. The 
opponents warn of the “economization” and “medicalization” of the health care 
systems, what leads to disproportional increase in drug expenditures and distract 
political focus and resources from the public health measures, e.g. prevention 
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programmes. Indeed, many health historians agree, that medical therapies played only 
negligible role in the historical decline of the population’s mortality rates. Effective 
medicine is fairly recent phenomena. Production of health care services in the 
magnitude affecting national health was only possible in the twentieth century. It is 
clear, that public health measures and rising living standards attribute to the largest 
share of credits in the community health improvement (Folland et al., 2006).  
   Technological progress contributes significantly to the increasing expenditures in the 
health care sector. The introduction of the economic mechanisms to control the costs 
with e.g. “physician drug budgets” and “patients co-payments” does not always find 
support of clinical community. Potentially these mechanisms could place a significant 
financial burden to the disadvantaged stratum of the society and increase inequality 
(Rosenbrock, 2001; Kühn & Rosenbrock, 1994; Lützenkirchen, 2000). 
   Facing the above concerns, we first investigate the complex relationship between 
national economy and global (community) health and will seek to understand, in 
general, why Health Economics should have it place in Public Health realm, and, in 
particularly, what is the theoretical rationale for health policy.  
Wealth and Health of Nations 
   This and following sections explore the macro-level relationship between economic 
performance and population health. Under “macro-economy” and “population health” 
we understand economy and community health on the national level, although the 
application to the worldwide regional levels (e.g. European Union, North America) is 
also possible. Presented evidence suggests the direct or indirect dependence between 
national economy and community health. National economy benefits from community 
health improvement and vice versa. This is a rational for not to study Public Health 
measures explicitly apart from economical considerations. 
   The dependency and interactions between national economy, health provision and 
outcomes is a complex issue. The majority of these interactions can be separated into 
two groups. The first group focuses on impact of health on macro-economic activities, 
such as economic growth, labor supply and consumption. The second group considers 
the reverse effect of economic development on health outcomes and national health care 
system (Rugger et al., 2001).  
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Health influences Wealth  
   Population health status influences economic growth and development directly in e.g. 
provisioning of labor supply and labor productivity, level of consume and preferences, 
saving rates, utilization of health services.  
   Health and health care are generally treated as economic goods in both developing and 
industrialized countries with the respective attributes: price, supply and demand. From 
macroeconomic perspective, health sector plays major role in global economic activity 
with ca. 10% of total global product in 1998 and has significant potential to affect 
economic development and growth (Rugger et al., 2001). In 2003, countries of 
Organization of Economic Cooperation and Development (OECD) dedicated ca. 8.8% 
of their gross domestic product (GDP) to health spending comparing to 7.1% in 1990. 
The proportion of GDP spent on health care varies from 15% in the United States, 
followed by Switzerland and Germany with 11.5% and 11.1% to less than 6% in the 
Slovak Republic and Korea (OECD, 2005).  
   Considering health as a human capital (elaborated by Becker, 1964), high mortality, 
early retirement and reduced labour productivity can ultimately contribute to reduction 
of income at individual and national level (number of studies available, see e.g. Thomas 
& Strauss, 1998). 
   Poor health status and disability have economic consequences on individual and 
national levels, as the production of health is financed from GDP through public or 
private channels. This is of relevance for both wealthy and low income economies. For 
example, a study of the impact of HIV/AIDS on national economy of India estimated 
annual costs of HIV/AIDS roughly at 1% of the GDP (Anand et al., 1999). The 
industrialized nations are facing the challenge of financing the treatment and care of the 
increasing number of patients with chronic diseases (Rosenbrock, 2001).  
Wealth influences Health 
   The reverse linkage reflects the influence of economic development on health and 
health care production. In fact, life expectancy at birth is positively linked to the level of 
national income in OECD countries (Rugger et al., 2001). However, life expectancy 
varies substantially across countries with similar level of economic development. Based 
on level of GDP per capita, projected life expectancy in Hungary and US is higher than 
  
 25
the real value and vice versa in Japan and Spain, where real life expectancy is higher 
than predicted outcome (OECD, 2005).  
   The trend of rising health care expenditures is common across industrial and 
developing countries. Several causes of this trend are being discussed. Increasing drug 
costs are of particular concern. From 1997 majority of OECD countries observed above 
5% annual increase of drug costs, which outpaced the growth of overall health care 
expenditures. Although the trend of rising costs is global, there are substantial 
differences in resource distribution within various health care systems. This variation 
may be associated with different non-market institutions, structures and political 
decisions, which have impact on access, reimbursement and implementation of new 
medical technologies (OECD, 2005).  
   The differences in health expenditures and health outcomes suggest significant 
variation in efficiency in the health care systems, with which they “produce” health. 
Some countries “produce” more health for less money; others achieve similar outcomes 
by higher level of expenditures (Rugger et al., 2001). Rising expenditures itself do not 
indicate inefficiency of resource allocation or production of health services. 
Development of new technologies in the areas where no treatment where available and 
increased willingness to pay for maintenance of good health or health gain could justify 
dedication of additional resources (Schwermann et al., 2003; Schulenburg & Greiner, 
2000). Nevertheless, given the changes in health care production, in the demand for new 
technologies and in the underlying demographic and epidemiological factors, the 
efficient allocation of resources is necessary to maximize health output.   
   As discussed above, the relationship between health and economy is complex (see 
Figure 2). Ultimately, wealth is health and health is wealth (Brouwer et al., 2006; WHO, 
1986). Despite the critics of “economization” of health provision, the market for health 
care production exists and is growing. For many industries the “invisible hand” of free-
market leads to the efficient allocation of resources. If it so, could we gain potentially 
more health without regulating the market with political instruments? Following 
sections investigate the applicability of the competitive (free) market conditions to the 
health care. 
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Efficiency of “invisible hand” 
   The production and distribution of health depends on the functioning of health care 
market. Economic theory suggests that for many goods and services the mechanism of 
competitive market will force efficient allocation of resources – the “invisible hand” 
solution (The First Fundamental Theorem of Welfare Economics). According to the 
economist Wilfred Pareto, the efficient allocation will be the optimal outcome for the 
society, as no one will be able to improve his lot without “hurting” someone else. This 
implies, that Pareto efficient outcome can be achieved in a competitive market (Second 
Fundamental Theorem of Welfare Economics) (Mankiw, 2008).  
   In most cases, health care is a mean to obtain or restore particular health status. It is an 
intermediate product. The concept of efficiency of health care production considers the 
ratio between input factors (resource use, investments and labour) and intermediate or 
end products (prevented cases, successfully treated patients, QALYs). Efficient 
production means that the outcome is maximized at a given resource endowment. The 
analysis focused on intermediate parameters (e.g. duration of hospitalization) without 
considering health endpoints, may misinform or provide partial evidence for health 
policy decisions (Drummond et al., 2005). From Public Health perspective, health 
outcomes and not intermediate products should be maximized. 
   In fact, health care provision is highly regulated in the majority of countries. But if 
“invisible hand” solution does not need a hypothetical decision-maker heavily armed 
with health economic data, why do health policy and institutions matter?  
Pre-requisites of free market economy 
   In 1963 economist Kenneth Arrow demonstrated necessity of public intervention in 
his milestone article “Uncertainty and the Welfare Economics of Medical Care” (Arrow, 
1963). Arrow explored the “uncertainty in the incidence of disease and the efficacy of 
treatment” which contributed to the inefficient allocation of the resources in the 
competitive market. Adequate non-market institutions (health economic decision-
makers) will correct and compensate the free-market failure. Since 1963 the changes in 
global economy and health care market are being accelerated by technological progress. 
However, Arrow’s publication stood the test of time. It provides the insight into the root 
of problems of the health care market and is broadly cited in Health Economics and 
other disciplines today.  
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   The major criticism of the applicability of the “invisible hand” solution for the health 
care market concerns the vital condition of the free market competition (or market 
ability to obtain competitive framework). Perfectly competitive market must have no 
entry or exit restrictions for the market players; all participants should be perfectly 
(symmetrically) informed and trade with a homogenous product; numerous buyers and 
sellers should not have sufficient power to influence the price. Perfect market does not 
allow for uncertainty in events, externalities, monopolies or public goods (Folland et al., 
2006). The health care market departs from competitive market in a several ways. 
Selected issues are discussed in the following. 
Violations of free market conditions in health 
   Condition of perfect information is a key assumption for optimality of free-market. 
The market players should have the same (symmetric) information to be able to assess 
the value of the product. In health care, however, patients are very often not in the 
position to evaluate the effectiveness of the treatment. No are the patients able to make a 
proper choice for the therapy, because of uncertainty in diagnosis. The information 
about the supply (e.g. treatment) and the demand (patient health/disease condition) is 
distributed asymmetrically between the pharmaceutical companies, medical personnel 
and the patients. Associated problem with the patients’ lack of information is supplier 
induced demand, what can lead to the unnecessary use of resources (e.g. inappropriate 
drug-intake). Thus, the actions to enhance information of all market players could lead 
to improved allocation. Nevertheless, the fulfillment of the condition of symmetric 
information is rarely possible (Arrow, 1963; Witter et al., 2000; Folland et al., 2006). 
   The uncertain nature of health status, diagnosis and treatment outcomes violates 
another condition of free-market. The occurrence of disease and it severeness is often 
difficult to predict. Individuals are not able to calculate the risk and budget for health 
care, as they do for regular goods. To pool the risk and distribute the costs across 
population requires an insurance system. Insurance tends to change the prices of care to 
the insured population. Insurance companies or government (being in monopoly 
position) can often negotiate the prices with the suppliers, removing herewith the price 
setting mechanism from the market completely (Arrow, 1963; Witter et al., 2000; 
Folland et al., 2006). 
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   Externalities occur in health care markets, where either production costs or utility of 
particular goods are not limited to the actors engaged into the transaction of this good. A 
positive externality may occur to the patient’s partner, when the first has been treated 
successfully. Another example is vaccination, which provides protection for immunized 
person and those who might come into contact. Negative externality can occur to the 
family members of the patients suffering from severe chronic diseases, where the 
burden of the family care-givers can not always be adequately measured and reflected in 
the therapy price. When the externality occur, the price of the product does not reflect it 
benefits, what can lead to over- or under- consumption comparing to the social optimum 
(Witter et al., 2000; Folland et al., 2006) 
Social justice is inadequately addressed within free-market economy 
   Ethical and equity dimensions go far beyond economic allocative efficiency, and 
therefore free market equilibrium should not necessarily reflect socially desired 
outcome. Besides, equity and social justice are complex issues and do not have 
universal understanding (Schreyögg, 2004). Following the “difference principle” from 
one of the modern concepts “A Theory of Justice” (1971) by John Rawls: “Social and 
economic inequalities are to be arranged so that…they are to be of the greatest benefit 
to the least-advantaged members of society …” (Rawls, 1971, p. 303). To pursue this 
principle under the condition of inverse gradient relationship between socioeconomic 
status and health level in the society, a redistributive mechanism should be introduced in 
the economy (for inverse gradient see Rosenbrock, 2001). Health policy should focus on 
enhancing equity in financing and delivery of the health care services, what is 
challenging for both developing and developed countries. Current evidence suggests 
that the political agenda in industrial countries is subject to controversial discussions 
about the health care objectives, financial arrangements and distributional 
considerations of costs and outcomes (Wagstaff et al., 1999; Call to Action, 2008). 
   Many health care systems have introduced the mechanisms to control the costs and 
reduce overuse of health care through co-payments, drug budgets, medical consultation 
fees paid by the patients. Studies have shown that these instruments indeed reduce 
health care use; however, they are “blunt” in achieving their objective. In most cases, 
they are not able to distinguish between appropriate and inappropriate use by deprived 
or well-off individuals. The use of “blunt” instruments could have a disproportional 
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impact on poor and medically indigent (Rugger et al., 2001; Lützenkirchen, 2000). 
Health policy should be conducted in hand with economic expertise to achieve desired 
equitable public health outcomes and distributional effects. 
Health markets need political regulation 
   The issues discussed above explain several violations of the competitive market 
conditions as applied to health care: consume is driven by the expected health status 
with high uncertainty around treatment effects and health outcomes,  positive and 
negative externalities, and asymmetrical information. 
   Separately the above aspects exist in other markets, but the interaction and 
combination of these issues poses a challenge for sound economic analysis and health 
policy (Folland et al., 2006; Hurley, 2000). We must accept that the real world health 
care market perfection is not fully attainable, what will inevitably lead to the free-
market failure to achieve social optimum. The wealth and health of nations are not only 
the matter of “invisible hand”. The market failure justifies political regulation through 
non-market institutions (Arrow, 1963; see Figure 2). We are coming back to necessity 
of a decision maker (or political intervention), who should, where possible and 
necessary, encourage more competition and let the market mechanism play it effective 
role and, in situations where the market fails, correct the resulting inefficiencies. 
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Figure 2: Macro-link Between National Health and Economy 
Source: compiled by the author  
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(2) there is need of political intervention to correct free market failure.  
   Health care is different from other economic sectors in the ways it generates market 
failure. The complex relationship between economic, social and cultural factors requires 
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re-work of established economic, social, ethical, medical paradigms to formulate sound 
health policy.  
   The realism and relevance of mainstream neoclassical theory to Public Health realm 
has been challenged by many health researches. Dissatisfaction with this conventional 
model among economists encouraged the development of alternative frameworks in 
Health Economics known as “non-welfarism” by Sen, “extra-welfarism” developed by 
Culyer and “communitarianism” elaborated by Mooney. There is no unanimous 
agreement about the appropriateness and relevance of the newer concepts to the Public 
Health realm. They share some common features as well as several differences, which 
are outlined in the next section. 
Concept of welfarism 
   Mainstream health economic analysis is essentially founded in neo-classical welfare 
economics (Hurley, 1998). The framework of welfare theory is based on the following 
key features: 
1) Consistent and rational preferences. 
   The assumption about rational behavior and consistent choice. “Neo-classical” 
individuals are able to compare and consistently rank available options and select the 
one which will maximize their personal utility.  
2) Individual autonomy. 
   The notion that utility and welfare is a private entity. Individual assessment and 
choice, and not that of a decision-maker or the society, is relevant for preferences, 
available options and constrains. 
3) Consequentialism and welfarism. 
   The assumption that available options are valued based on their final outcomes and 
actions are driven by utility maximization. Action is seen in terms of the end product 
and not as the process. The individuals are expected to take actions driven by the notion 
of increased utility and welfare. All non-utility terms, incentives (such as altruism) and 
processes are being ignored (Mannion and Small, 1999). 
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   Social welfare is a function of the utility levels attained by members of the group, 
whereas the sources of individual utility are often restricted to consumption of goods 
and services. Ordinal utility theory relaxed assumption of cardinal assessment and 
comparability of utility function between individuals and suggested Pareto Optimization 
instead of maximizing the sum of individual utilities (Hurley, 2000). Resource 
allocation is considered Pareto Optimal (i.e. allocatively efficient) in the case it is 
impossible to improve individual or group’s utility without diminishing or holding 
utility of the others constant.  
   Two fundamental theorems of welfare economics have been influential in setting 
market allocation as the reference standard in normative economic analysis and in 
justifying major focus on efficiency concerns over distributional equity. The first 
theorem predicates that the allocation of resources achieved within perfectly 
competitive market is Pareto optimal. The second theorem states that any Pareto optimal 
allocation can be achieved through the perfect competition. These theorems provide the 
rationale within welfare economics for taking a market allocation as the referenced 
state. The only reason for non-market arrangements is market failure caused by 
deviation from one or several model assumptions (Hurley, 2000). 
Critique of welfarism: foundation of non-welfarism 
   There are many arguments pointing out the limitations of neo-classical economics. 
This section cannot comprehensively review all aspects related to health sector. The 
issues discussed below are mainly based on Sen’s non-welfarism framework (Sen, 
1977; Sen, 1987). His capability framework addressed critical assumption of traditional 
neoclassical economics in application to health care. Alternative theories such as extra-
welfarism and communitarianism discussed in the next sections, draw on Sen’s work.  
   The distinctiveness of Sen’s alternative approach lies in accentuation the impact of 
individual functioning and capabilities on personal well-being and health. Sen’s concept 
reaches out to Antonovsky’s salutogenic Public Health paradigm (1987), who discussed 
relationship between health, stress and coping as factors of individual health status 
(Antonovsky, 1979; 1987). 
   Sen pointed out several limitations of neoclassical assumptions. Consequentialism and 
welfarism imply consumption and endowments as essential objectives and outcomes of 
individual actions. Even if the concept of utility can be extended from consumption to 
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well-being, consequentialism and aggregating utility over individuals remain critical 
and not fully feasible for application in health care (Sen, 1987). To address neoclassical 
flaws, Sen emphasizes personal functioning and capability as intrinsic characteristics of 
individuals. Personal functioning relates to the ability of individual to execute actions 
and to benefit from capabilities. Capabilities are the options and opportunities available 
for individual choice. These characteristics influence personal ability to translate 
available resources into well-being. A handicapped person may require additional or 
different capabilities to achieve the same level of functioning comparing to a healthy 
individual. “The valued functionings may vary from such elementary ones as being 
adequately nourished and being free from avoidable disease, to very complex activities 
or personal states, such as being able to take part in the life of the community and 
having self-respect” (Sen 1997, p. 199). Sen criticized consequentialism for neglecting 
the value of process itself and ability to select among alternatives, which could 
contribute to well-being in addition to the final outcomes of actions. Furthermore, 
individuals may pursue not to benefit from their capabilities, what is precluded in 
welfaristic model (Hall et al., 2006). 
   Sen argues against “homo economicus” in favor of individuals with social 
responsibilities. Personal behavior and choice in neoclassical economics is driven by 
maximization of individual utility function. Instead, Sen predicates that preferences and 
actions taken by individuals are driven by notion of potential direct benefit and self-
interest as well as humanistic considerations about the societal value of pursued actions 
(Sen, 1977; Sen, 1985). He believes in “… a variety of human acts and states as 
important in themselves (not just because they may produce utility, nor just to the extent 
that they yield utility)” (Sen 1985, p. 22).  
   Beyond the issues discussed above, welfare framework does not adequately address 
the questions of social justice. Ethical and equity aspects are assumed to be incorporated 
into “right” distribution of resources through the political process. In the presence of 
substantial transactional costs and distortion of incentives by political intervention, 
efficiency and distributional concerns obviously cannot be separated (Reinhardt, 1992; 
Hurley, 2000).  
   Finally, the pragmatic limitation of welfare framework lies in the requirement of a 
competitive market, which is unattainable for the majority of Public Health activities. 
Application of Pareto criteria for policy formulation is impractical, as only rare cases 
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will allow for improvement of some groups without negative impact to the others. 
Application of a potential Pareto improvement when the gained benefits are 
substantially large to out weight utility loss, is linked, again, to the not-addressed 
distributional equity consideration (Hurley, 1998; Hurley, 2000).  
Concept of extra-welfarism  
   Numerous works of Culyer (1990) contributed substantially to development of 
alternative theory – extra-welfarism. Extra-welfarism builds on Sen’s critique of 
neoclassical framework, specifically, on limitation in assessment of health status using 
utility function. It is based on two key features: the emphasis on health and rejection of 
individual preferences to measure social welfare. 
1) Emphasis on health. 
   Extra-welfarism rejects utility and focus on health as the targeted endpoint in 
theoretical considerations about health care provision. This consideration is essential 
difference between extra-welfarism and welfarism. Sen, as a well-known critic of 
welfarism, recommends to focus on functionings and capabilities in normative analyses, 
rather than utility (Sen, 1987). Drawing on Sen’s research, Culyer argues for health as 
“characteristic” of individuals and suggest to include all non-good and non-utility 
aspects as sources of well-being (Culyer, 1990; Culyer & Evans, 1996).  
2) Rejection of individual preferences to measure social welfare. 
   Extra-welfarism criticizes individualism arguing that some groups are not always able 
to assess available options and rationally consume optimal level for their health. Thus, 
social welfare should not be built on individual preferences alone, what requires 
involvement of a third party in decision of what to be measured and maximized. This 
argument conflicts with neoclassical assumption of individualism and consumer 
sovereignty.  
   For normative political considerations, extra-welfarism “. . . has taken “health” as the 
proximate maximand” and suggests to use it as the primer endpoint for health care 
services (Culyer, 1990). Pareto optimization may be incorporated within extra-
welfarism framework, if utility is conceptualizing health measured by quality adjusted 
life years (Hurley, 2000; Mooney & Russel, 2003).  
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Critique of extra-welfarism 
   Critics argue that neoclassical limitations are not adequately addressed in extra-
welfarism framework. The main criticism emphasizes the failure to accommodate 
equity and justice considerations. Efficiency and equity aspects may not be considered 
separately and introduction of external decision-maker will not imply optimal allocation 
(Mooney, 2005; Birch & Donaldson, 2003; Hurley, 1998). 
   The focus on health as primary outcome is another limitation by neglecting other 
important sources of well-being, like freedom of choice and speech, access to education 
and others. This failure to accommodate various non-utility and non-health aspects 
restricts application of extra-welfarism to broader economic activities (Culyer, 1998; 
Hall et al., 2006). 
   In extra-welfarism social welfare is determined by a decision-maker, who may over-
ride individual preference. Practically, decision-maker may not be capable to decide and 
achieve optimal allocation by neglecting preferences and choices of individuals or 
particular groups of people, neither could it be done from justice and equitable point of 
view (Birch & Donaldson, 2003; Hall et al., 2006). In broader sense, both non-
welfarism and extra-welfarism recognize individual and social values, but there is 
limited operationalization on how these two sets should be combined and considered in 
maximizing social welfare (Mooney, 2005; Birch & Donaldson, 2003). 
Concept of communitarianism 
   Personal values and preferences play important role in neoclassical and extra-
welfarism theories. Many researches oppose to this view pointing out the potential 
failure of individuals to act rational, to demand and to consume optimally for their 
health. In extra-welfarism approach, there is also insufficient basis for third party 
judgment on concept of health, which may vary across different cultures and ethnical 
groups (Mooney & Russel, 2003). Mooney (1998) suggested to address the above 
limitations in alternative paradigm – communitarianism - with the emphasis on societal 
and community role in decisions about equity and allocation of resources in health care. 
The communitarian framework declines welfarism’s assumptions of individualism and 
consequentialism of the pursued actions and failure to accommodate societal values in 
individual preferences and utility function (Mooney, 1998; Mooney & Russell, 2003; 
Hall et al., 2006). 
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   Following aspects are essential premises for the communitarian framework: 
1) Non-existence of rationally choosing individuals.  
   Concept of health and well-being may vary between genders, different cultural and 
ethnical groups. The use of universal metrics for flourishing and well-being limited to 
utility function may not be appropriate. The implication of neglecting this aspect may 
reveal the failure of individuals or groups to desire adequately according to common 
metrics as well as inability to act rationally in self-interest of their health.  
2) Community preferences.  
   Community plays the central role in the framework and should aid to 
operationalization of equity and justice concepts within fundamental principles and 
institutional organization of health care. The weight of equity in the objective function 
is decided by community and not individuals. Thus, societal preferences and objective 
function may deviate from totaled individual utility functions.  
3) Health as community good.  
   Communities decide about the needs, allocation of resources and institutions implying 
health as a societal commodity. Communitarian claims are drawing on considerations of 
Broome (1991) about individuals taking social role and obligations in the communities 
they are living in (Broome, 1991; Mooney & Jan, 1997). Here, the equity and justice 
aspects are getting appropriate weights in the community decision-making about the 
resource allocation (Hall et al., 2006; Mooney, 2005).  
   Communitarian view on social justice strongly builds on Sen’s arguments about 
individual capabilities and functionings as central elements in ability to achieve well-
being by transforming resources into health and flourishing (Mooney & Russell, 2003; 
Mooney, 2005; Mooney & Jan, 1997). In communitarianism, individuals can not be 
seen without the societal context. The objective function contains both individual and 
community values and preferences. Personal assessment of health may rely on QALY 
metrics; the appropriate metrics for the community values is yet to be developed. 
Community is responsible for the provision of health care services to individuals, which 
are assumed to benefit from the value of the outcome, and consider health care delivery 
as good itself (Mooney, 1998). 
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Critique of communitarianism 
   Communitarian approach ignores non-utility aspects, meaning that non-health 
characteristics and other process-related features of medical intervention are irrelevant 
for political decisions. This notion is aligned with QALY assessment in evaluation of 
social welfare function. However, acknowledgement of health as major objective for 
social welfare function requires additional analysis to understand the feasibility of the 
concept in different settings (Mooney, 1998; Mooney, 2005). 
   Another limitation is related to underweighting or disregard of individual preferences. 
Communitarianism allow deviation of community preferences from aggregated 
individual functions. The practical implementation implies involvement of a 
bureaucratic decision-maker, who will be deciding on objective function, equity 
considerations and, finally, distribution and allocation of resources. This requires setting 
of specific rules and assessment of individual-level data about health preferences and 
status (QALY) with respective weights of competing claims. Collected data should than 
inform and substantiate preferences and objective function of community. In addition, 
functioning of communitarian decision bodies would require monitoring of activities by 
members of community. These requirements are hardly feasible within capabilities of 
current political structures (Mooney, 2005). 
   Finally, in addressing equity and justice issues, communitarianism does not provide 
specific considerations about operationalization for efficiency concept within health 
care (Hall et al., 2006). 
 
2.4 New Institutional Economics for Studying Political 
Instruments 
 
   In previous sections we stated that (1) Public Health and Economics need common 
normative theoretical foundation, and (2) Neoclassical economics advocates the need of 
political intervention to correct market failure, however (3) neoclassical assumption are 
challenged by non-welfarism, extra-welfarism and communitarianism as not fully valid 
for normative Public Health research. 
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   Developments in neoclassical economics elaborated different aspects of economic 
behavior and performance. However, neoclassical view is essentially “institution free”, 
what posses serious limitations for studying health policy within this framework. In 
addition, ethics, justice, consumer preferences and non-utility outcomes are either 
implemented in a simplified way or ignored completely in neoclassical framework. 
Market and public structures are assumed to operate perfectly and costless, firms are 
“black-boxed” and characterized by production function, all actors have perfect 
information and decision-makers implement policies “in the public interests”. The listed 
assumptions are not feasible for health care. Thus, normative and positive analysis 
require out of “black-box” view. New Institutional Economics is filling the vacuum for 
theoretical analysis of policy, institutions, incentives and efficiency across and within 
organizations (Robinson, 1997; Hirschman, 1970). Its application to health policy is 
outlined in following sections. 
New Institutional Economics  
   In majority of the countries health care is regulated and controlled by public 
institutions. Recent research added substantially to the understanding of the key aspects 
important for the institutional performance. Principal-agent theory, property rights, 
transaction cost economics, and public choice theory investigated implications, pros and 
cons of different forms of institutional arrangements, which are essential for health care 
analysis. These areas are being developed in a common research stream of New 
Institutional Economics (Precker & Harding, 2000). 
   New Institutional Economics seeks to assess and explain the impact and incentives of 
various socio-economic and political institutions on economic behavior, interactions and 
performance (Joskow, 2008). Overall, New Institutional Economics suggests that 
institutions matter and are susceptible to the analysis. New Institutional Economics is a 
product of evolutionary multidisciplinary work and not an integrated theory, such as 
neoclassical economics, based on a set of common hypothesis, but rather a combination 
of different concepts coming from different traditions among which are law, sociology, 
organizational economics and many others. The foundation was given by works of 
Ronald Coase (1937b), Douglas North (1990, 2005) and Oliver Williamson (1975, 
1985). These individual works, being not fully coherent  and consistent, are providing a 
new perspective and framework for economic analysis (Joskow, 2008). 
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Principal Agency Theory  
   Notion of asymmetric information, i.e. different level of knowledge between actors 
participating in economic transaction, is an essential foundation for the principal agency 
theory (Ross, 1973; Stiglitz, 1974). Simple principal-agency models investigate 
maximization of two distinctive utility functions of an ill-informed participant, the 
principal, and informed participant, the agent. The principal with a limited knowledge 
and expertise requires agent’s involvement and know-how for execution of a particular 
task, but is restricted or not able to monitor agent’s performance and evaluate quality of 
the final outcomes. The conjoint effect of two specific characteristics – asymmetric 
information and independent utility functions of principal and agent – is relevant and 
has major impact in various economic activities and interactions between supervisors 
and  subordinates, insurance companies and clients, patients and doctors (Ryan, 1994; 
Precker & Harding, 2000). The central theoretical questions in the principal agency 
theory is the optimal arrangement of incentives and compensation. More generally, 
specification of explicit and transparent agreements for execution of labor and services 
on agreed remuneration terms between principal and agent is aiming to align objectives 
of different utility functions, set incentives and minimize impact of asymmetric 
information to achieve social and political objectives (Joskow, 2008)  
   Asymmetric information, distinctive interests and utility functions of interdependent 
actors are pervasive in health care provision. The relationship between patients, clinical 
personnel, health insurance, contracting agencies and governmental institutions are 
classical examples of principal-agent structures. The research of key determinants of 
utility functions of individual actors, alignment of incentives, rewards and feasible 
options to monitor the quality of outcomes are central questions to optimize contractual 
arrangements and so the efficiency of health care provision (Precker & Harding, 2000). 
Transactional Costs Economics  
   The theoretical framework for studying the origination and impact of transactional 
costs is founded on the works of Coase (1937a, 1937b) and Williamson (1973, 1975) 
and is strongly related to principal agency theory outlined above. Principal-agent 
interaction may be influenced by opportunism and bounded rationality behaviors, where 
transactional costs are the outcomes of deficient contracts (Hart, 1995; 2003). 
Opportunistic agents will act predominantly in self-interest and pursue the strategies 
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leading to the achievement of their own goals independently of those of the principal or 
the organization. Bounded rationality will limit the ability of both principal and agent to 
make informed decisions and act accordingly due to uncertainty of the actions or 
outcomes of relevant events and overall complexity of the decision-making process. 
Comprehensive contracts between principal and agents may describe in details the tasks 
of involved participants and restrain possibilities for opportunistic behavior. However, 
taking into account uncertainty of actions and outcomes, the exact formulation of the 
contractual arrangements may become difficult. Flexible hierarchy and informal 
settlements may be more practical and efficient, the downside of which is the lack of the 
detailed specification of the individual roles and potentially more space to act 
opportunistically. Nonrigid management structure within organization and monitoring 
activities may help to overcome this tendency. Nevertheless, both specific and flexible 
contractual arrangements between principal and agents to manage bounded rationality 
and opportunism will produce some level of transactional costs (Marini & Street, 2007; 
Precker & Harding, 2000). 
   The application of transactional costs economics in the health care sector is relevant, 
since production of health and deliver of health care services is done via complex 
sequences of transactions among patients, providers, and other stakeholders. Sometimes 
these exchanges are concrete and observable (e.g. medication is injected), but most of 
the time the transactions are complex, intangible and abstract (e.g., information and 
service provision in mixed public-private settings). Information is either incomplete or, 
conversely, too overwhelming for participants to integrate fully into their decision-
making. Numerous public agencies directly regulate or indirectly effect health care 
delivery and financial transactions. High entry barriers in health care markets make it 
prohibitively costly for new organizational arrangements. Actors pursue their own 
interests, often professionally justified, at the expense of their exchange partners. 
Mismatches occur between objectives and allocated resources. Finally, the environment 
is unpredictable and highly uncertain (Stiles & So, 2003). Application of transactional 
costs economics in health care often refers to analysis of the optimal contractual 
arrangements within public and private organizations in health care context (Bartlett, 
1991; Ashton, 1998; Keen & Ferguson, 1996; Hughes et al., 1997). 
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Property Rights Theory  
   Property rights theory investigates effect of private and public ownership on 
incentives, efficiency and broader economic activities of the public and privately own 
organizations. This theory has mutual conceptual roots with principal agency and 
transaction costs theory (Kim & Mahoney, 2005).  
   Private ownership has historically proved to have strong positive incentives on 
efficiency. Property rights theory investigates this phenomena from the perspective of 
residual decision rights and the ability to allocate the residual returns. The possession of 
residual decision rights allows to determine the allocation of assets or resources, and the 
ownership of residual return claims entitles to decision about the distribution of profit or 
loss (Milgrom & Roberts, 1992; Precker & Harding, 2000). 
   There are different forms of property and ownership. The owner of an asset may or 
may not be in possession of both residual decision rights and claims. The implications 
of possession of residual rights may be obvious for the commodities, such as a vehicle 
or house, but become much more complicated if the effects are considered within 
multilayered organizations. Large companies and public institution may accommodate 
or be entitled to administration of big assets. The relationship between owners of assets 
and those having rights for the decision about residual revenue may have complex effect 
on incentives and efficiency within organizations and sharpen principal-agent dilemma 
(Precker & Harding, 2000). 
   Property rights theory has strong application in health care sector to study incentives 
and efficiency of the whole system and particular branches. State’s subsidization and 
various forms of interference may induce inefficient operation and production within 
non-profit organizations comparing to commercial competitors. Empirical foundation of 
this proposition can be found in analysis of different data sources from US health care 
market, e.g. HMOs (Frech, 1976), assisted living facilities (Frech, 1985; Tuckman & 
Chang, 1988), public and private wards and clinics (Clarkson, 1972; Friedman & Pauly, 
1981; Bruning & Register, 1989; Register et al., 1991). 
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Public Choice Theory 
   Theoretical considerations about public choice in political and governmental context 
were developed by James Buchanan (1963), George Stigler (1971) and Sam Peltzman 
(1976). The research of George Stigler, James Buchanan, and Gary Becker were 
awarded the Nobel Prize in Economics.  
   Public Choice theory investigates performance, efficiency and optimal size of 
governmental structures and policy. This field of research elaborates the impact of the 
self-interested behavior of politicians, interest groups, and bureaucrats on public policy. 
Bureaucrats are seen as maximizers of their own utility function, which can be 
expressed in term of assigned administrative budget. The theory suggests, that under 
particular conditions, the politicians may attempt to get administrative rights over higher 
share of national resources than is needed to provide specific service or execute their 
central functions. In fact, government or administrative structures may “outgrow” the 
needed size, bind or inefficiently allocate available resources. As a result, governmental 
bodies will potentially fail to perform their core-functions and introduce additional 
distortion into economic activities (Precker & Harding, 2000).  
   Public choice theory uses analytic tools such as decision and game theory to uncover 
and explain causes and trends for inefficient bureaucratic structures and decision-
making. The failure of political interventions is rooted in existence of asymmetric 
information, bounded rationality, opportunism and transactional costs. Public choice 
theory is often invoked in discussions of limiting state’s intervention and liberalization 
of market activities and transactions (McPake & Normand, 2002). 
   Public choice theory finds broad application in health care sector, where drug 
approval process is heavily regulated by such bodies as FDA and other National Health 
Authorities. In UK reimbursement decisions and coverage issues of drugs and therapies 
are subject of influential activities by different actors, such as NHS, NICE, PCTs, 
patient groups, industry, academics, medical experts etc.   
Health Policy is steered and influenced by multiple institutions 
   Neoclassical theory justifies political interventions in health sector to secure allocative 
efficiency, which is achieved when resources are allocated to maximize the welfare of 
the community (Drummond, 1991). Health care “production” process, as depicted in 
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Figure 3, is essentially black-boxed in neoclassical framework. Branches of New 
Institutional Economics, including public choice, transactional costs, principal agency 
and property right theories, provide a theoretical basis to study essential aspects of 
health market such as asymmetric information, free-riding, monopolies, adverse 
selection and others. Specifically, New Institutional Economics explores the incentives 
of regulations and institutions, which influence efficiency of the transforming resources 
in terms of capital and labor inputs into health care outcomes. With regard to 
generalizability issue, new institutional economics suggests that institutions may 
moderate or have direct impact on health economic outcomes. Geographic variability in 
institutional arrangements of health care provision and regulations may produce 
different health outcomes at different costs for the same intervention for comparably 
homogeneous clinical population.    
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Figure 3: Theoretical Aspects of New Institutional Economic for Health Policy 
 
Source: compiled by the author 
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2.5 HTA and Health Economic Evaluations for 
Informed Health Policy  
 
   Previous sections reviewed main economic theories relevant for Public Health and 
policy research. We stated that (1) from normative view, Public Health and Economics 
should not be studied explicitly apart from each other, (2) neoclassical economics 
advocates the need of political intervention to correct market failure, however (3) 
neoclassical assumption are challenged by non-welfarism, extra-welfarism and 
communitarianism as not fully valid in Public Health context, and, finally, (4) New 
Institutional Economics suggested the major role of institutional arrangements for 
studying approach, implementation and efficiency of political measures. Our analysis 
failed to identify common theoretical foundation between Public Health and Economics, 
however, there seems to be consensus about the need of public intervention to promote 
health in the community through thoroughly designed health policy. The instrumental 
concept to inform, implement and monitor health political decisions is Health 
Technology Assessment. This concept is rooted in multiple Economic and Public Health 
theories. Generalizability methods are analytic tools to produce evidence for HTA. The 
concept and requirements of HTA are summarized below. 
Health Technology Assessment 
   Historically, the outcomes of health interventions were often determined in 
uncontrolled experiments, individual cases and by opinions. Admittedly, availability of 
several treatment alternatives for the same clinical indication is fairly recent 
phenomenon. Few decades ago there were only selected technologies feasible for 
comparative assessment (Jonsson, 2002). After technological progress advanced 
medical care and provided clinicians with new treatment options, health care systems in 
industrialized countries faced rising expenditures in perceiving the dissemination of new 
technologies to provide high-quality services to broader population. Even today, almost 
any health innovation is welcomed as a potential treatment for a disease. Several new 
treatments, however, failed to provide substantial benefit (Jonsson & Banta, 1999). The 
question of costs, effectiveness and quality of the clinical interventions and measures 
come up. 
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   Health technology assessment measures the impact of the treatment or diagnostics 
procedures on society and provides scientific basis for acceptance, modification or 
rejection of technologies. The central research question addressed by HTA investigates 
whether a new technology is superior to existing alternatives in terms of clinical, 
economic and social outcomes (Hutton et al., 2006). The concept of HTA is sometimes 
misleadingly associated with the rigid cost-control mechanisms, which is not its primary 
purpose. HTA is aimed to contribute to efficient use of limited resources under 
considerations of quality, safety and equity. The improved efficiency within the health 
care system will enable to stimulate, reward and extend the access to the valuable 
innovations (Jonsson & Banta, 1999; Kulp & Greiner, 2006). 
   Acceptance and implementation of HTA is difficult due to different values and 
opinions of the involved parties - decision makers, clinicians, patients, providers, payers 
and other actors. This can be partly due to the fact that the conclusions of HTA do not 
always confirm clinical opinions or even disenchant expectations. It is also not 
universally accepted, that assessment of health technologies should be done from 
perspectives other than that of clinicians (Jonsson, 2002). HTAs are designed to inform 
decision makers, who are assumed to act in the interest of general population. The 
opposite view have many key-players, in particularly clinicians, who are educated and 
trained in spirit of caring for and addressing the needs of individual patients (Rosen & 
Gabbay, 1999).  
Implementation of HTA in different countries 
   In 1992 Australian Pharmaceutical Benefits Advisory Committee was the first 
regulatory body which implemented HTA in the decision-making process regarding 
reimbursement of a new medical technology. Since then, many European authorities 
elaborated and established application of country-specific health economic guidelines 
and standards. The official formation of HTA decision-making body was initiated in 
UK in 1999 with establishment of  National Institute for Clinical Excellence (NICE). 
   Following UK example, several European countries institutionalized HTA bodies in 
political decision-making process. Submission of health economic evidence is now 
mandatory in Belgium, Scotland, Netherlands, Norway, Spain, Portugal, Poland, 
Hungary and other countries. The extent, to which HTA influences policy and resource 
distribution in health care, differs between countries. Variation in decision-making 
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process and administrative bodies can be partially attributed to differences in underlying 
political and institutional organization. HTA authorities in Scotland, Belgium and 
Sweden, like NICE, go beyond clinical efficacy and demand evaluation of health 
economic impact from broad societal perspective. In Italy and France the evaluation of 
unmet need and budget impact analysis is done by different regulatory bodies (Hutton et 
al., 2006). In Germany, HTA evaluation is governed by Institute for Health Care 
Quality (IQWiG). German methodological requirements, however, depart from the 
international requirements and are being criticized by academic research. In general, 
with all variety of forms and structures, HTA and health economic evaluations are now 
formally or informally used to inform health policy decision-making. 
Methods for health economic analysis 
   The most relevant types of health economic analysis are the following : 
• cost-of-illness analysis  
• cost-effectiveness analysis  
• cost-utility analysis  
• cost-benefit analysis.  
   Cost-of-illness analysis determines overall socio-economic burden of clinical 
condition in estimating associated direct, indirect and intangible costs. 
   Cost-effectiveness analysis is a comparative analysis of feasible treatment 
alternatives. In this type of analysis the difference in costs between new and standard 
therapy is related to differences in effectiveness. The ratio may differ in the magnitude 
between alternative programmes. The result is stated in the terms of costs per additional 
unit of effectiveness , e.g. costs per additionally cured patient. 
   Cost-utility analysis in it structure and approach is analogous to cost-effectiveness 
analysis. Here, the incremental costs of a program are compared to incremental health 
improvement, where the health improvement is measured by quality-adjusted life years 
(QALY). The outcomes are expressed as costs per QALY. 
   Cost-benefit analysis values resources and benefits of different medical technologies 
or interventions. The result of such analyses might be stated either in the form of a ratio 
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of costs to the benefits, or as an absolute positive or negative value depicting the net 
loss or benefit of new intervention comparing to alternative (Goodman, 2004; 
Drummond et al., 2005). 
Theoretical foundations of health economic methods 
   The above methods are now the standard tools within health economic evaluations. 
However, the theoretical foundations of these methods are not fully established. Cost-
benefit analysis compares the net costs with the net benefit. Taking welfaristic point of 
view, only individuals can appropriately valuate their own health status and the utility of 
the new treatment. Thus, individual willigness-to-pay is legitimate measure of the 
benefit including those of health care. Cost-benefit analysis justifies the implementation 
of the interventions which raises the net benefit, what is clearly welfaristic approach to 
the analysis (Dolan & Edlin, 2002; Johannesson & Karlsson, 1997). 
   Contrary to cost-benefit analysis, the theoretical foundation of cost-effectiveness and 
cost-utility analysis is less clear. These forms of analysis are often criticized by 
economists within the health sector because of the difficulties (conceptual, ethical, 
practical) in monetarizing life-years gained, as well as by extra-welfarists who 
emphasize the health as primary outcome for normative analysis in the health sector. 
Cost-effectiveness analysis compares the incremental costs with incremental 
effectiveness, i.e. how change in costs is counterbalanced with gain or loss in clinical 
effectiveness. The costs are measured in monetary terms and the effectiveness in the 
natural units. The outcomes are presented in term of cost-effectiveness ratio, i.e. 
additional costs per additional unit gain. In cost-utility analysis, costs are again 
measured in monetary units, but the outcome is measured in terms of quality-adjusted 
life-years (QALYs) that reflect both the quantity and quality of life years gained as a 
result of the intervention (Hurley, 2000). Typically, the programs with cost-per unit 
outcome below particular threshold – shadow price or willingness-to pay of the decision 
maker - will be funded. For a cost-utility analysis that uses utility-based QALYs as the 
measure of outcome, the theoretical considerations could be linked to 
communitarianism (Hall et al., 2006). The normative foundation of cost-effectiveness 
analysis with measures incorporating non-utility weights may be found in extra-
welfarism (Garber & Phelps 1997; Hurley, 2000). 
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Requirements for informed decision-making 
   The formal implementation of health economic analysis to inform decisions about the 
reimbursement of new treatments or technologies in different countries possess 
substantial challenge on health economic data and methods. Sculpher and colleagues 
(2006b) and Claxton and colleagues (2002) outlined following major requirements: 
1) Precise definition of research purpose. 
   Clinical patient population must be clearly defined in any economic analysis and all 
available and relevant treatment options should be identified. The specification of 
relevant treatment options may involve comparison to both on- and off-label 
technologies and interventions, as well as different sequences, combinations and dosing 
of therapeutic and diagnostic procedures. 
2) Explicit specification of the measurement of health benefits. 
   Many coverage decisions require maximization of a  specific objective function 
constrained by available budget within the health care system. The objective function is 
likely to optimize particular health outcome, measured either in natural units or in 
quality adjusted life years. Concept of QALY is broadly used in economic analysis of 
various technologies and indications. However, researchers need to consider and include 
all outcome measures relevant to the patients and clinical practice. The assessment of 
health gain should be clearly explained in order to evaluate the “level of substitution” 
comparing to health outcomes under alternative treatments. This is essential to maintain 
consistency in analysis and decision-making in rejecting or adopting new technology. 
3) Sufficient timeframe.  
   Important requirement in health economic assessment is the need to evaluate the 
effects and implications of the new technology over the relevant time period within 
major costs and clinical outcomes are likely to occur. Sufficient time horizon may often 
extend over a life-time period, particularly when clinical events are rare, condition is 
chronic and or have effect on mortality. 
4) Inclusion of comprehensive evidence.  
   Analysis based on incomplete evidence may come to ambiguous outcomes and 
misleading recommendations. Treatment effect should be compared to the full range of 
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the treatment options used both as indicated and off-label, if feasible. Valuation of 
resource use and costs should avoid assessment of selected episodes or resources, as it 
may ignore potential costs “shift” between the services (e.g. from stationary to 
ambulatory care). 
5) Relevance to the jurisdiction of interest.  
   Health economic decisions are essentially jurisdiction-specific and so is the need of 
health economic data. The central generalizability question remains important in 
assessment of the applicability of external evidence to the context of a specific 
jurisdiction. 
6) Evaluation of uncertainty.  
   Uncertainty is related to the imprecision in estimation of the relevant clinical and 
economic outcomes. The correct quantification of uncertainty in parameter estimates is 
essential to evaluate the need for additional research and the probability of making the 
“wrong” decision based on current evidence. The implications of making “wrong” 
decision will result in inefficient resource allocation and lost opportunity to health gain 
using alternative treatment options (Sculpher et al., 2006b; Claxton et al., 2002).  
Limitations of evidence available for decision-making 
   Decisions about reimbursement of a new technology are often made based on 
incomplete evidence. The main vehicles for comparative health economic analysis of a 
new technology are the patient-level health economic studies conducted along phase III 
or phase IV clinical studies, and decision models, which use data on treatment efficacy 
and resource use from the patient-level trials. Thus, health economic analysis is 
inevitably influenced by clinical development, what posses several methodological 
challenges.  
   First challenge is the focus of clinical trials on maximization of internal validity, i.e. 
the estimation of treatment effect as unbiased reflection of the observed value in the trial 
participants in a strictly controlled environment (Mason & Mason, 2006; Kinosian & 
Glick, 1998). The hierarchy of clinical evidence suggest the strongest internal validity in 
well-designed, randomized, blinded clinical trials followed by nonrandomized trials, 
prospective/retrospective cohort studies, prospective/retrospective case-control studies 
and, finally, opinions and beliefs, which should be considered as of very limited internal 
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validity (Goodman, 2004). Health economic analysis deems to estimate resource 
utilization in a real-life setting with emphasis on external validity. Thus, there is a 
certain trade-off between internal and external validity and health economic analysis 
should balance both (Jonsson & Weinstein, 1997). 
   Second challenge relates to uncertainty and variability of the clinical and economic 
estimates. Economic literature is not aligned in defining these concepts. In following we 
apply the taxonomy described by Coyle (2003) and Thompson (2002). Variability 
reflects the differences in the parameters across the population or sample. It relates to 
the randomness of the event in the population and cannot be reduced. Rather, more 
information can allow stratification into more homogeneous population groups. 
Uncertainty expresses the imprecision or lack of information regarding the true value of 
the outcome in the given population. Variability and uncertainty are distinctive. 
Uncertainty can be addressed through better measurement e.g. additional studies; 
although, further knowledge may fail to reduce uncertainty over the optimal decision. 
Knowledge about uncertainty, unlike variability, can be represented by probability 
distributions (Coyle, 2003; Thompson, 2002). 
Improving generalizability of available evidence for informed decision-making 
   Generalizability of health economic evaluations for informing decision in particular 
context is dealing with both internal/external validity and variability/uncertainty issues 
(see Figure 4). The evidence available to the decision-making can be collected in 
randomized clinical studies, not randomized studies, observational cohort studies and 
finally by individual clinical judgement. Different research designs and methodology 
have strengths and weakness. E.g. randomized clinical studies are considered as “golden 
standard” for assessment of clinical efficacy, but may lack of external validity due to 
restrictive selection criteria and procedures irrelevant or not feasible for routine clinical 
practice (Bombardier & Maetzel, 1999). Observational studies may overcome 
limitations imposed by strict clinical protocol for randomized clinical studies, but may 
fail to control for possible confounding or selection bias resulting in high uncertainty 
around the clinical and economic outcomes. Finally, individual clinical judgements and 
opinions may have limited validity, if based on few selected observations.  
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Figure 4: Evidence Required for Decision-Making in Health Policy 
Source: compiled by the author 
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technology and availability of the economic evidence from use of this technology in the 
clinical praxis. Therefore, the limited economic data from international studies should 
be utilized using generalizability methods to inform decision-makers at the early stage 
of the technology introduction. 
   As mentioned earlier, broader application of economic evaluations (incl. 
generalizability methods) will contribute to promotion and implementation of public 
health programmes. Assessment of the outcomes of public health interventions is 
important, as in absence of economic data, decision makers might favour programmes 
with good evidence on cost-effectiveness from randomized clinical trial for e.g. medical 
treatment and abandon the programmes, where no economic evidence is available 
(Rychlik et al., 2005; Banta, 2003).  
   Researchers will benefit from the development of generalizability methods, which will 
extend the understanding about causes of variability in costs and outcomes between 
settings and it implications for other settings. Potentially, generalizability methods will 
increase utilization of data, methods and results of the available studies. This knowledge 
will help to avoid redundant studies and save research fundings (Sculpher et al., 2004). 
In addition, efficient utilization of available data will help to formulate future research 
to close critical knowledge gaps. Furthermore, economic perspective and outcomes of 
many actions in the area of New Public Health might be difficult to evaluate such as 
those in health promotion or environmental improvement (Rychlik et al., 2005). 
Development of generalizability methods will increase the methodological stock, which 
should be used to assess and quantify economic outcomes for public health 
programmes.  
   Essentially, generalizability methods should help to provide jurisdiction-specific 
evidence to inform local policy, support promotion of HTA in policy formulation and 
implementation, increase evidence stock, efficiency of resource allocation and 
formulation of future research. 
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2.6 Summary of Chapter 2  
   This section embeds and links generalizability methods for international health 
economic studies to the theoretical and instrumental concepts in Public Health and 
Economics. We reviewed theoretical paradigms mainly from economic perspective 
starting from neoclassical mainstream economics followed by newer theories such as 
non-welfarism and New Institutional Economics, linking these to the instruments of 
health policy. Summary of the conclusions is presented below.  
Positive and normative analysis is a foundation for Public Health instrumental 
concepts such as health economic evaluations and generalizability methods. 
   Positive economic analysis describes the effect of the political intervention on a 
particular setting. Normative economic analysis attempts to outline the “ideal” policy 
with desired socio-economic outcomes. Additionally, normative analysis should guide 
the development of evaluation methods to assess and interpret effects and outcomes of 
various health care interventions. The major underlying theories of normative health 
economics are neo-classical welfare theory (welfarism), extra-welfarism, 
communitarianism and New Institutional Economics. 
Health policy is anchored in Economic and Public Health theories. Neoclassical 
economics advocates political intervention to improve allocative efficiency. 
   The mainstream economic theory agrees that the “invisible hand” of the competitive 
market will not necessarily allocate limited resources to get maximum health gain, due 
to violation of free market conditions, attributed to asymmetric information, 
uncertainties and externalities. Thus, imperfection of free-market in health care creates 
an important role for non-market institutional arrangements (i.e., the political visible 
hand) to compensate for free market failure. In order to improve health care system 
performance (and not to do more harm than good, as competitive market incentives are 
applicable for many health care sectors), political decision-making should be informed 
by setting-specific evidence. 
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Neoclassical Economics is not fully aligned with Public Health perspective on 
ethics, health, capabilities and well-being. Non-welfarism, extra-welfarism and 
communitarianism are emerging theories toward Public Health concept.  
   The framework of welfare theory is based on the utility maximization, consumer 
sovereignty, consequentialism and welfarism. Social welfare is an aggregated function 
over individual utilities, whereas the source of individual utility is generally restricted to 
consumption of goods and services. Welfarism focuses on efficiency and neglects ethics 
and equity issues. These assumptions are broadly criticized by researchers. Alternative 
non-welfaristic framework, developed by Sen, is particularly influential in health 
economics. He emphasizes importance of individual characteristics and capabilities as 
determinants of personal well-being along with considering social responsibilities in 
individual objective functions. Sen advocates duality of health as a capability and a 
characteristic. Alternative theories, such as extra-welfarism and communitarianism, 
build on Sen’s work. The considerations of justice should target both access to health 
care resources and distribution of health. 
New Institutional Economics provides a complementary theoretical basis to 
neoclassical economics to study efficiency of health production, incentives and 
impact of institutions and policy.  
   Health care provision is strongly regulated and influenced by public institutions 
(organizations and political instruments), whereas neoclassical model is essentially 
institution-free. New Institutional Economics is filling the theoretical gaps and provides 
complementary framework to study incentives and effects of health policy and 
institutions in health care. This can potentially expand our understanding about 
geographical variation and efficiency of different health care systems and, thus, improve 
generalizability of health economic evaluations conducted in different health care 
settings. 
Theoretical foundation for health economic methods in Public Health and policy 
are yet to be elaborated. 
   Cost-benefit analysis is rooted in neoclassical economics; the theoretical foundation of 
cost-effectiveness and cost-utility analysis is less clear. There is no universal agreement 
between economic theories such as non-welfarism, extra-welfarism, communitarianism 
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and others with Public Health paradigm on essential questions to define health policy. 
For instance, there are different views on rationality and preferences in the decision-
making, whether and how individual and population health and welfare should be 
defined and measured, what ethical, equity and social justice considerations should be 
targeted or taken into account while formulating health policy. These and other 
questions merit further elaboration of a common theoretical foundation, which clearly 
require a multidisciplinary approach of Public Health researches and unlikely to be 
developed individually in “established” biomedical and social sciences.    
Generalizability methods are relevant for Public Health research and policy. These 
methods will (1) contribute to better understanding of efficient health care 
provision and (2) increase evidence body for jurisdiction-specific health policy. 
   Assessment of geographical variability contributes to understanding of efficient health 
care provision and aid to formulation of political interventions. Apart from differences 
in economic development across geographic areas, different understandings and 
interpretations of the health policy objectives lead to various institutions, political 
decisions, resource allocations and even empirical indicators measured within different 
systems. Improved generalizability of empirical data and comparison of international 
health economic evidence will help to evaluate efficiency of health care provision in 
different settings.  
   Studying variability and improving generalizability of health economic evidence is 
essential to inform jurisdiction-specific health policy, which, in turn, should improve 
health and reduce inequalities. HTA is not yet fully established in all settings. 
Conducting of health economic evaluations is usually subject to budgetary and time 
constrains. Consequently, available evidence to inform health policy measures is often 
scarce and not always collected in the jurisdiction of interest. Improving of 
generalizability of available health economic evidence for jurisdiction-specific decision-
making will help to save resources dedicated to health care research and formulate 
future research needs.  
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3 Methods to Improve Generalizability of 
Multinational Health Economic 
Evaluations 
 
   In the previous section we outlined theoretical foundations related to Public Health, 
policy and HTA, justified political intervention in health care market and emphasized 
importance of institutional arrangements. Immatureness of normative view and 
theoretical paradigm in Public Health contributes to differences in political agendas, 
instruments and institutions across geographic health care settings. The institutions play 
essential role by setting regulatory environment and influencing incentives and 
efficiency of health care production. This, in turn, may enhance variability in input and 
output parameters between different health care systems, which may not be fully 
explained by differences in absolute level of economic resources available in the 
particular setting. The implication for generalizability of health economic evaluation is 
that the outcome of a specific treatment in economic and even clinical measures may 
not be considered explicitly apart from the health care setting where it has been 
produced. 
   The purpose of this section is to summarize current approaches to address 
heterogeneity and improve generalizability. We conducted targeted review of health 
economic literature and international guidelines. Based on this review, we selected and 
adjusted analytical methods for the case study. This chapter is structured as following. 
We first discuss terminology and describe search strategy applied in literature review. 
We then summarize evidence related to variability factors, requirements and 
recommendations from international health economic guidelines, analytical approaches 
used in decision models and patient-level studies. Finally, we describe generalizability 
methods applied in the patient-level case study. 
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3.1 Terminology and Literature Search Strategy 
   Understanding of the concept and terminology, used in the literature in relation to 
generalizability issues and methods, is required to specify targeted literature review 
strategy. These topics are summarized in the following. 
Terminology 
   There is no universal agreement about generalizability definition in the literature. 
Generalizability has been interchangeably used with other terms and concepts, such as 
transferability, portability, external validity, extrapolation and others (Mason & Mason, 
2006). 
   The term “transferability” is generally used to compare results of health economic 
evaluations across geographic locations (Wilke, 2003; Greiner et al., 2000). Geographic 
“transferability” is of particular interest for health policy in the cases, where cost-
effectiveness data for the specific settings or country is not available. The term 
“extrapolation” is often attributed to the time aspect of the evaluation in e.g. modelling 
of long-term treatment effects. “External validity” is discussed in conjunction with 
“internal validity” of the outcomes generated in randomized clinical trials, where 
treatment efficacy is proved with specific procedures and methods on a selected patient 
population (Evans & Crawford, 2000). “External validity” may be seen in 
epidemiological context as the extent, to which the results of clinical trials are 
applicable to and valid for the everyday medical practice (Baltussen et al., 1999; Coyle 
& Lee, 1998). 
   For the purpose of this thesis, we use broad concept of generalizability suggested by 
Sculpher and colleagues (2004). They define generalizability as  “…the extent to which 
the results of a study, as they apply to a particular patient population and/or a specific 
context, hold true for another population and/or different context “(Sculpher et al., 2004 
p. X). The scope of this definition includes geographical, time and epidemiological 
components. 
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Objectives of literature review 
   We conducted targeted review of the health economic literature and international 
guidelines published between January,1997 – January, 2009. Specifically, review had 
following objectives:  
• To specify variability factors, which affect generalisability of the results of 
economic evaluations across geographic areas and over the time. 
• To identify approaches to address generalisability suggested by the international  
health economic and methodological guidelines. 
• To review essential methods to improve the generalisability of evaluations based 
on decision models. 
• To review essential methods to improve the generalisability of patient-level 
studies. 
Search strategy 
   Collection of the evidence relevant to generalizability aspects was done in targeted 
way as following: 
• Literature published in January, 2004 – January, 2009 was searched in PubMed, 
Google, various health economic sites, ISPOR website and health economic 
conferences.  
• PubMed search was conducted on 4th of March 2007 and 2nd of February 2009 using 
following query terms: (("economics"[TIAB] NOT Medline[SB]) OR 
"economics"[MeSH Terms] OR economic[Text Word]) AND (generalizability[All 
Fields] OR transferability[All Fields] OR generalisability[All Fields]) AND 
English[lang] AND medline[sb] AND "humans"[MeSH Terms]). 
• Literature published between January, 1997 – January, 2004 was retrieved from the 
study of generalizability issue conducted by Sculpher and colleagues from York 
University, commissioned by National Health Service HTA Programme in UK 
(Sculpher et al., 2004). 
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Publications were included based on the following inclusion criteria: 
• Health economic publications in English language. 
• Health economic/methodological/regulatory guidelines.  
• Methodological publications on generalizability or transferability methods. 
• Multinational patient-level studies and health economic evaluations based on 
decision models, which explicitly discussed generalizability and/or transferability 
issues. 
Included literature 
   123 publications and 26 international health economic guidelines were included into 
review. Literature search strategy and included evidence is graphically presented in 
Figure 5. 
Figure 5: Literature Search Strategy 
Source: compiled by the author 
Limitations of the search strategy 
   This review has several limitations. It can not be considered as complete and 
exhaustive due to the fact, that only recent published health economic evaluations in 
English language were retrieved. Only the publications, which explicitly discuss 
Sculpher et al. 
2004 HTA report 
PubMed, 
Google, ISPOR 
123 publications  26 guidelines 
ISPOR/HTA, online 
resource of national 
regulatory bodies 
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2004 
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generalizability or transferability issues were selected and reviewed. All multinational 
studies, which potentially could have applied generalizability techniques without 
referring to generalizability term, may not have been identified and included into the 
review. Additionally, potential generalizability methods outside health economic 
analysis in e.g. epidemiology, education, social and political sciences were out of the 
scope of this literature review. 
 
3.2 Factors Contributing to Between-Country 
Variability  
 
   The need to develop generalizability methods evolved in discussion of observed 
variability in cost-effectiveness outcomes across locations and over the time. A fairly 
extensive literature exists on the range of different factors that could influence 
variability in cost-effectiveness results of different treatments. The detailed overview of 
variability factors is provided by Sculpher and colleagues (Sculpher et al., 2004, chapter 
3). Our literature review of the recent publications published in 2004 – 2009 confirmed 
these findings. The most frequently discussed factors in the health economic literature 
can be divided into patient, disease, health-care system and methodological factors as 
summarized in Table 1 below. 
Table 1: Variability Factors within Health Economic Evaluations 
Group Factors Description  
Demographic 
and clinical 
characteristics 
Demographic (age, gender, race), co-morbidity, risk factors, 
genetics, medical history, life expectancy.  
Patients 
factors Socio-
economic 
characteristics 
Income, lifestyle, educational level, religion, employment, 
migration, traveling, living conditions, nutrition, individual 
preferences for particular levels of health (reflected in utility 
values of health status), acceptance of technology.  
 
  
 62
Group Factors Description  
Clinical 
presentation 
Epidemiology (incidence/prevalence, spread), disease severity 
and progression, mortality, interaction with other conditions 
and co-medications. Disease 
factors 
Clinical 
practice 
Clinical conventions, diagnostics and treatment guidelines, 
applied treatments. 
Health care 
resources 
Level of economic and technological development, social 
security, access to resources, environment, absolute and relative 
prices, regulatory system, organization of delivery system e.g. 
staff, facility, equipment, access to advanced 
technology/treatment, capacity utilization.  
Remuneration 
and incentives 
Types of coverage public/private/mixed, user fees, co-
payments, deductibles, incentives for patients, providers and 
suppliers, methods of remuneration, availability of generics and 
substitutes. 
Health-
care 
system 
factors 
Provider 
characteristics 
Type of facility, specialization of labor, quality of care, 
technical efficiency, capacity utilization, level of competition. 
Study design 
and conduct 
analysis 
Protocol-driven procedures, industry bias, artificial study 
conditions: placebo-controlled, improved treatment compliance, 
not-representative settings, selection of sites, treatment 
comparator, estimation of clinical and economic outcomes, 
costing methods. 
Methodol
ogical 
factors 
Timing 
Timing of economic evaluations, learning effects, technological 
innovation, advancement of technology/practice, development 
and availability of new diagnostics and adjuvant treatment 
options. 
Source: modified from Sculpher and colleagues (2004) and Goeree and colleagues 
(2007). 
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3.2.1 Patients’ Factors 
   Major source of variation in cost-effectiveness is attributed to the patients’ 
characteristics, which could vary within and across jurisdictions and can effect the 
ability to generalize cost-effectiveness results across geographic areas. Patients’ case-
mix is comprised of clinical and wider socio-economic characteristics. 
Clinical patient characteristics  
   These characteristics include age, gender, race, risk factors, co-morbidities, genetic 
factors, life expectancy. For instance, age can have an impact on cost-effectiveness, as it 
is directly associated with susceptibility to severe conditions, such as diabetes and 
myocardial infarction. Severe chronic co-morbidity (e.g. HIV) can affect clinical 
outcomes of the treatment. Combination of clinical factors can affect baseline risk of 
disease and ultimately impact clinical outcomes and economic resource use (Goeree et 
al., 2007). Life expectancy has a direct impact on QALYs gained, especially for the 
treatment of chronic conditions (Welte et al., 2004). Characteristics of the patients vary 
strongly across locations and the difference on this level may affect presentation and 
course of condition, and thus, have effect on outcomes and resource use. Stratification 
of patients into relevant sub-groups is important in health economic evaluations in order 
to inform political decisions about the groups of patients who will mostly benefit from a 
new treatment (NICE, 2008; Raisch et al., 2003; Bryan & Brown, 1998; Ghatnekar et 
al., 2001). 
Socio-economic characteristics  
   Number of non-clinical factors are hypothesized to have effect on resource use and 
costs and vary across locations. In broader terms, income and education could influence 
access to the preventive, diagnostic and treatment options (Tsuchiya et al., 2002; Welte 
et al., 2004; Raisch et al., 2003; Sculpher et al., 2004). Treatment effectiveness for 
several chronic conditions and thus, the results of cost-effectiveness analyses will 
depend critically on patients lifestyle, attitudes, and behavior (e.g. diet, sport exercising, 
smoking and alcohol consumption). Acceptability of new intervention has impact on 
compliance and final outcomes. The level of acceptance may vary with cultural and 
religious preferences for e.g. use of contraception, screening, vaccination and organ 
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transplantation. In addition, compliance may be affected by educational levels and 
cultural factors, which vary across the setting. The implications of non-compliance are 
likely to be reflected in increased resource use and or reduced effectiveness. Finally, 
compliance or adherence to procedures achieved in clinical trial may not be replicated 
in routine practice. Health-related preferences used to calculate QALY in cost-utility 
analysis is another source of between-country variability. Different utility weights used 
for different countries (e.g. EQ5D utility score) will produce different study outcomes 
and may prevent from generalizability to external settings. The underlying factors 
inducing this variation have not yet been extensively studied and need further 
exploration (O’Brien, 1997;  Sculpher et al., 2004).  
 
3.2.2 Disease Factors 
   The second broad category of factors related geographical variability is comprised of 
clinical presentation of the condition and clinical practice of the disease management.  
Clinical presentation 
   There is number of geographical characteristics, that can affect the incidence and 
prevalence of the disease, such as presence of specific genetic factors (e.g. for sickle 
cell anemia), environment (UV light and skin cancer), migration and traveling 
(hepatitis, HIV, tropical diseases) (Welte et al., 2004). Interventions focused on 
prevention are more likely to be cost-effective with higher incidence of a “target” 
disease (Drummond et al., 1997).Variability in patients’ characteristics, cultural and 
environmental differences may affect disease severity or case mix in one country 
compared to another. Similarly, disease progression and spread in the case of infections 
may vary across jurisdictions depending on prevention programmes, environmental 
factors, population density, life-style, treatment acceptance, and notification programs. 
Finally, disease-specific mortality can vary across geographic regions (Reed et al., 
2005; Goodacre & Dixon, 2005). 
Clinical Practice  
   Routine medical practice, diagnostics, treatment guidelines and conventions are 
known to be differently implemented within and across the countries. In part, these 
differences might be attributed to the specific organization of health care provision 
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according to local providers’ structure and characteristics of service delivery. For 
instance, in France specialized medicine is generally provided by community-based 
clinicians, whereas in Great Britain the major part of the services is institutionalized 
within hospitals. Different diagnostic approaches and treatment patterns have effect on 
demand, resource use and relative costs of procedures. This, in turn, will affect supply 
of the health care services and access to new diagnostics and treatments. In addition, 
differences in available treatment alternatives will affect local clinical practice and 
conventions. At a very minimum, variability in clinical practice is reflected in different 
option for comparative and standard treatment, what may produce different cost-
effectiveness outcomes (Sculpher et al., 2004; Mason & Drummond, 1997; Revicki & 
Frank, 1999).  
 
3.2.3 Health Care System Factors 
   Price weights are known to differ between and within countries. Most researchers 
advocate at least replacement of a unit prices, when transferring cost-effectiveness data 
across regions. But it is not just absolute unit prices, that are important. Relative prices 
and other health care system factors can also impact cost-effectiveness or treatment 
decisions. This broad category comprises of health care resources, characteristics of 
incentives and providers, which are related to health care organizations and are known 
to vary across the jurisdictions. 
Health care resources  
   The absolute and relative level of resources available for health care production is 
different across geographic areas. For example, in 2005 USA dedicated 15,3% of its 
GDP to health expenditures comparing to Great Britain with 8.4%, 10.6% in Germany, 
10.0% in Canada and 9.0% in Italy (OECD, 2008). The absolute level of resources 
available for health care funding will effect both clinical practice as well as access and 
dissemination of new diagnostics and treatment alternatives. For instance, cost intensive 
chemotherapy for treatment of lung cancer produces significant health gain but at 
substantial additional costs. Funding of the new drugs in less resourced systems will 
produce higher opportunity costs than in well-resourced systems, since the first will 
need to withdraw more resources dedicated to treatment of all other conditions to 
provide for new resource-intensive therapy. The level of opportunity costs of adopting a 
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new technology may influence political decisions, resulting in rejection of new 
technology in less resourced systems and adoption in well-resourced. This may be 
reflected in different willingness-to-pay thresholds for reimbursement between locations 
on the basis of the essentially the same cost-effectiveness outcomes. As a result, there is 
higher probability, that cost-intensive diagnostics or therapy will become a standard 
treatment in well-resourced system comparing to less resourced counties.  
   Availability of new technology varies across countries. Lower availability (e.g. 
number of computer tomography per capita, number of laparoscopic surgeries) may lead 
to inexperienced use; lower case numbers may have effect on costs estimates. The 
longer distance to technology may effect higher productivity losses associated with 
treatment. The existence of waiting lists as well as different range of licensed health 
care products suggest possible variation in technology access across different countries 
(Welte et al., 2004). 
Remuneration and incentives  
   Health policy and regulations influence relative and absolute prices and set incentives 
for production and consume in health care. Patients’ treatment seeking behavior is 
influenced by health insurance level with respective taxations, co-payments and 
deductibles – the factors known to vary across locations. Also, there are direct bonus 
systems implemented in various health systems to reward health-beneficial behavior. In 
The Netherlands and in Germany the insurance coverage for dental procedures will be 
higher, if the patient undergoes regular dental examination. Prices for the same drugs 
may vary substantially across countries. Price level of drugs is influenced by number of 
instruments implemented by regulators and payers to control rising drug expenditures, 
such as positive/negative lists, generic substitutions, co-payments etc. To some extend, 
the differences in performance of clinical personnel may be explained by incentive 
structure. Remuneration arrangements based on performance of clinical staff  may raise 
sensitivity to the resource use and total costs and result in shorter duration of 
hospitalization (Forsberg et al., 2001). Supplier induced demand, i.e. provision of non-
vital services, is a known phenomenon in health care. Retrospective remuneration for 
performed services may indorse supplier induced demand, whereas prospective 
payments (e.g. based on diagnosis – related groups) may limit it (Welte et al., 2004). 
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Providers 
   There is known variation in providers’ structure and capacity within and between 
geographic areas. Number of beds per capita, lengths of stay in hospital, rates of 
hospitalizations, rates of diagnostic testing, the frequency of clinical follow-ups, and 
drug dosing regimens are all factors known to vary across jurisdictions. For instance, in 
2003 there were 7.59 hospital beds per 1000 population in France, comparing to 8.74 in 
Germany, 3.45 in Spain and 5.82 in Switzerland (WHO, 2009). Other provider 
characteristics relate to experience, education, training, skills, efficiency, as well as 
level of experience with new technology. The skills of clinicians are particularly 
important for invasive interventions, surgery and diagnostic procedures. However, even 
non-invasive procedures can display differences between clinicians. The legal 
obligations of providers may impact clinical decisions. Depending on the disease and 
evidence around treatment effectiveness, patients may be treated less aggressively in 
some countries where the threat of legal litigation is more pronounced. This variability 
may be further enforced by different management of adverse events. These effects are 
difficult to quantify. Finally, the variation in performance of medical personnel can be 
due to different incentives in health-care system (Roberts, 1999; Manca & Willan, 2006; 
Glick et al., 2003; Sculpher & Drummond, 2006a). All these factors can have a 
significant impact on the effectiveness and cost-effectiveness of a program or service. 
 
3.2.4 Methodological Factors 
Study design, conduct and analysis 
   Health economic studies are often conducted along clinical trials. Randomized 
controlled studies facilitate assessment of clinical effects in controlled setting using 
protocolized procedures. Blinding, randomization and standardized procedures improve 
internal validity of the collected evidence. However, strong internal validity might limit 
external validity due to protocol-driven procedures, improved compliance, selection of 
the sites which are not representative for the general population. Also, selected 
comparators might not be available in all settings. As implication, incremental 
effectiveness may not be relevant for the countries, where particular comparators are not 
used.  
  
 68
   Other issues affecting generalizability relate to study perspective and measurement of 
clinical and economic endpoints, which may vary according to different requirements 
for health economic evaluations. The perspective of the study (payer or societal) can 
limit generalizability, if the scope used in the analysis does not meet the requirements of 
the target country. Although, this problem can be usually addressed by disaggregated 
reporting of study results, not all studies adopt broad societal perspective and publish 
results in a disaggregated form. Resource use structure varies between the settings and 
so the estimation within clinical trial setting may not always reflect true costs of 
technology. Calculation of direct costs can be done using per diem costs, market price 
weights, listed fees. The costs may account for overhead and capital costs, which could 
be differently assigned across the clinical institutions even within the same country. 
Similar to direct costs, estimation of indirect costs, such as productivity impairment, can 
be measured in several ways. Hourly rates assigned to missed employed work and lost 
productivity and opportunity costs for unpaid work in household are common 
estimation methods (Taghreed et al., 2003; Welte et al., 2004; Johannesson & Karlsson, 
1997). 
Timing 
   Variability of health economic outcomes over the time has not been extensively 
studied, partially due to the complexity and funding issues for the studies with the long 
follow-up period. In general, majority of the “geographic” factors discussed above, can 
also change over the time. Economic theory suggests that the mean and marginal cost of 
production may fall with increased volume, if the starting level of production is 
sufficiently low. In addition, efficiency may be improved with gaining experience with 
new technology and learning how to optimize production (Ramsay et al., 2001). 
Experience may be associated with both individual knowledge of clinical personnel, i.e. 
technical capabilities to apply complex technologies, and common experience of 
organization with particular instruments, methods and processes (Sculpher et al., 2004). 
The timing of the study may as well impact cost-effectiveness results. Health economic 
study conducted at the early stage of the life-cycle of particular technology may not 
capture the application within routine clinical practice. In addition, clinical practice may 
change over the time when new therapeutic and diagnostic options become available 
(Coyle & Lee, 1998). Another time-dependent parameter relates to diagnostics, standard 
treatment and concomitant therapy, which are likely to change over time and so the 
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cost-effectiveness results against the alternative technologies for general population or it 
sub-groups. For instance, evolution of therapies for rheumatoid arthritis is a recent 
example, where it changed from various combinations of non-steroidal anti-
inflammatory drugs (NSAIDs) and analgesics (pain-relieving drugs) to corticosteroids, 
disease-modifying antirheumatic drugs and biologics, such as anti-TNF. The drugs 
taken as commonly used alternative treatment in early economic evaluations are 
probably no longer relevant in current clinical practice (Sculpher et al., 2004). 
 
3.2.5 Complex Cross-Level Interaction Between Variability Factors 
   Variability is caused by interaction of multiple factors at different levels. Exploring 
the impact of the variability factors discussed above on the outcomes of different 
treatments is essential for the development of generalizability methods. Figure 6 
provides a simplified picture of operating levels within a health care system with 
corresponding variability factors. Some factors may have complex interaction on 
different levels. Thus, the context and the outcomes of intervention should not be 
studied separately.  
   The assessment of macro- and micro-level factors requires additional data collection. 
Some of the factors can be measured directly in the study, e.g. patients age, smoking 
status, education. The association between these factors and treatment effects can be 
then explored in the study analysis. Other high-level factors may not be easily captured, 
e.g. impact of remuneration on treatment pattern and resource utilization. Nevertheless, 
these effects may be central for health policy decision-making and implementation. 
Therefore, the acknowledgement and assessment of the effects of different factors is 
central generalizability question (Murray  et al., 2000). Analysis may not be limited 
only to the evidence which can be easily quantified. Analytical methods should aim to 
accommodate complex interaction while accounting for heterogeneity and uncertainty 
in different levels. Following sections describe approaches suggested by international 
health economic guidelines and published evidence in considering generalizability in 
design, analysis and results of patient-level studies and decision models.  
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Figure 6: Hierarchical Levels within Health Care Systems and Variability Factors 
Source: compiled by the author 
 
3.3 Generalizability Methods Suggested by Health 
Economic Guidelines 
 
   We reviewed 25 health economic guidelines available in English, German or Russian 
languages concerned with HTA evaluation and/or submission for reimbursement to 
national payers and 1 general methodological guideline. The methodological guideline 
to address generalizability (transferability) in health economic evaluations was 
developed by ISPOR tasks force in 2008-2009. The recommendations from national 
guidelines for handling of international evidence and potential methods to improve 
generalizability are summarized in Table 2. 
Macro-level: National healthcare setting 
Meso-level: Providers and clinicians 
Micro-level: Patients 
Patients 
factors 
Healthcare 
systems 
factors  
Disease 
factors 
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Table 2: Recommendations of International Health Economic Guidelines for Handling Generalizability 
Country Title of health economic guidelines Generaliza
bility  
Acceptability of 
international data 
Suggested approaches/methods 
Poland Proposal of Polish Guidelines for Conducting 
Financial Analysis and Their Comparison to Existing 
Guidance on Budget Impact in Other Countries 
(Orlewska & Mierzejewski, 2004) 
Yes Yes; international 
clinical evidence is 
acceptable.  
Systematic review, methods of evidence 
based medicine. 
UK Guide to the single technology appraisal process 
(NICE, 2009) 
Guide to the methods of technology appraisal (NICE, 
2008) 
Yes Yes; clinical data may 
be considered 
generalizable from 
international evidence. 
Decision-analytical framework for the 
evidence synthesis. 
Belgium Pharmaco-Economic Guideline (English version) 
(KCE, 2008) 
Yes Yes Knock-out criteria to assess whether 
data is generalizable to Belgium, 
adjustment to models needed to reflect 
Belgian clinical and resource use 
patterns. 
  
 72 
Country Title of health economic guidelines Generaliza
bility  
Acceptability of 
international data 
Suggested approaches/methods 
Norway Norwegian guidelines for pharmacoeconomic analysis 
in connection with applications for reimbursement 
(Norwegian Medicine Agency, 2005). 
Yes Yes; international 
evidence for clinical 
data may be acceptable, 
health utility and 
economic data from 
outside evidence may 
not be applicable. 
Sensitivity analysis, involvement of 
local experts to evaluate adjustments to 
the country-specific context, 
replacement of abroad resource use with 
Norwegian data. 
Canada Guidelines for the Economic Evaluation of Health 
Technologies: Canada (Canadian Agency for Drugs 
and Technologies in Health, 2006). 
Yes Yes, effectiveness and 
not efficacy is of 
primary interest, 
economic and utility 
data may not be 
generalizable. 
Homogeneity test to evaluate country-
by-treatment interaction, decision 
models, sensitivity analysis, simple 
replacement of clinical and economic 
parameters with country-specific data 
may not be appropriate. 
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Country Title of health economic guidelines Generaliza
bility  
Acceptability of 
international data 
Suggested approaches/methods 
New Zealand Prescription for Pharmacoeconomic Analysis. 
Methods for Cost-Utility Analysis (PHARMAC, 
2007). 
Yes Yes; utility data 
measured by EQ5D 
should be calculated 
using country-specific 
preferences. 
Sensitivity analysis, expert panels for 
validation of resource use and treatment 
patterns. 
Scotland Guidance to Manufacturers for Completion of  New 
Product Assessment Form (Scottish Medicines 
Consortium, 2007). 
Yes Yes; evidence from UK 
will be in general 
accepted. 
 
Systematic appraisal of the evidence, 
meta-analysis and decision modelling 
Sweden Working guidelines for the pharmaceutical 
reimbursement review (The Swedish Pharmaceutical 
Benefits Board, 2008). 
Yes Yes Decision models for evidence synthesis 
of international and country-specific 
data. 
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Country Title of health economic guidelines Generaliza
bility  
Acceptability of 
international data 
Suggested approaches/methods 
France French Guidelines For The Economic Evaluation Of 
Health Care Technologies (Collège des Économistes 
de la Santé, 2004). 
Yes Yes; adaptation for 
French context required, 
international clinical 
data may be used, 
economic data is less 
generalizable. 
Not specified. 
Germany Entwurf einer Methodik für die Bewertung von 
Verhältnissen zwischen Nutzen und Kosten im 
System der deutschen gesetzlichen 
Krankenversicherung (Institut für Qualität und 
Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 
2009). 
Allgemeine Methoden (Institut für Qualität und 
Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 
2008). 
Yes Yes; evidence should 
reflect German health-
care setting. 
Not specified. 
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Country Title of health economic guidelines Generaliza
bility  
Acceptability of 
international data 
Suggested approaches/methods 
The 
Netherlands 
Guidelines for pharmacoeconomic research, updated 
version (College voor zorgverzekeringen Diemen, 
2006). 
Yes Yes; utilities from 
international studies 
may be used. 
Not specified. 
Baltic 
Countries 
Baltic Guideline for Economic Evaluation of 
Pharmaceuticals (Pharmacoeconomic Analysis) 
(Behmane et al., 2002). 
Yes Yes; data should be 
adapted to the country-
specific context. 
Not specified. 
Finland Guideline For Preparing a Health Economic 
Evaluation (Ministry of Social Affairs and Health, 
2003). 
Yes Yes; clinical practice 
and costs should refer to 
Finnish context. 
Not specified. 
Irland Irish Health care Technology Assessment Guidelines 
(IPHA/HSE, 2000). 
Yes Yes Not specified; assumptions made to 
adjust data to Irish context should be 
explained. 
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Country Title of health economic guidelines Generaliza
bility  
Acceptability of 
international data 
Suggested approaches/methods 
Italy Guidelines For Economic Evaluations in Italy: 
Recommendations From The Italian Group Of 
Pharmacoeconomic Studies (Capri et al., 2001). 
 
Yes Yes Not specified. 
Portugal Guidelines For Economic Drug Evaluation Studies 
(Infarmed, 1998). 
 
Yes Yes Not specified. 
US The AMCP Format for Formulary Submissions 
(AMCP, 2005). 
Yes In general yes; the 
manufacturer must 
demonstrate that 
international data is 
applicable for US 
setting. 
 
Not specified. 
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Country Title of health economic guidelines Generaliza
bility  
Acceptability of 
international data 
Suggested approaches/methods 
Austria Guidelines on Health Economic Evaluation (Walter & 
Zehetmayr, 2006). 
Yes Yes; evidence from EU 
countries and 
Switzerland may be 
considered applicable to 
Austrian setting.  
Not specified. 
Hungary Methodological guidelines for conducting economic 
evaluation of healthcare interventions in Hungary: a 
Hungarian proposal for methodology standards 
(Szende et al., 2002). 
 
Yes In general yes, if 
relevance for Hungarian 
setting is demonstrated. 
Sensitivity analysis. 
Russia Branch Standard. The Standardization System in the 
Russian Federation Health Care System Clinico-
Economic Studies. General Provisions (RF Ministry 
of Health, 2002). 
No NA NA 
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Country Title of health economic guidelines Generaliza
bility  
Acceptability of 
international data 
Suggested approaches/methods 
Switzerland Kriterien zur Beurteilung des Nutzens von 
komplementärmedizinischen Methoden (Heusser, 
2001). 
No NA NA 
Denmark The Danish approach to standards for economic 
evaluation methodologies (Alban et al., 1997). 
No NA NA 
Source: International Guidelines, ISPOR “Pharmacoeconomic Guidelines Around the World” database (ISPOR, 2010), compiled by the author. 
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Recommendations of international health economic guidelines 
   Overall, international health economic guidelines differ in their perspectives, 
requirements and recommendations related to generalizability of international evidence 
(Barbieri et al., 2005; Drummond et al., 2009). These differences may be partially 
explained by various roles and objectives pursued by national HTA bodies, as well as 
access and availability of country-specific evidence. The majority of reviewed health 
economic guidelines acknowledge generalizability issues related to the data collected in 
multinational studies and the differences in the clinical and economic parameters 
between and within the countries. Only 3 out of 25 guidelines are not directly referring 
to the generalizability problematic (what does not mean that decision-makers in these 
particular countries will not require this information with submission documents). 
Guidelines differ in scope and extend to which they discuss approaches to handle 
international data. In general, there is tendency to accept clinical evidence to the greater 
extend than the economic data from the abroad settings. The variation of health 
preferences and utility across geographic areas is acknowledged, however, there is no 
common convention about acceptability of health utility data collected outside the 
setting of interest. Majority of guidelines require use of country-level economic data or 
it adaptation to reflect country-specific resource use and costs. However, the 
recommendations about potential approaches and data sources vary across guidelines. 
Selected guidelines reference to the national costs and unit prices. 8 out of 25 guidelines 
make suggestions about the potential methods to improve generalizability. These 
methods are mainly related to systematic evidence appraisal and evidence synthesis by 
use of decision analytical framework. Canadian guidelines suggests homogeneity test to 
check country-by-treatment interaction for the evidence collected in multinational trial.  
Recommendations of ISPOR transferability guideline 
   The methodological guideline to address generalizability (transferability) in health 
economic evaluations was elaborated by ISPOR tasks force in 2008-2009. This 
guideline provides an overview of available analytical tools to improve generalizability 
in patient-level studies and decision models. In essence, while addressing and dealing 
with generalizability in patient-level studies, ISPOR guideline suggests to explore 
heterogeneity by using descriptive statistics, heterogeneity test for qualitative and 
quantitative interactions. Hierarchical models are recommended to account for 
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clustering within sites or countries. The generalizability approaches for decision models 
are largely depending on availability of setting-specific data and the clinical course of 
the condition. Several approaches are discussed, including construction of event-based 
models, application of trial-wide efficacy estimates to the country-specific baseline 
case-mix, synthesis of clinical evidence from randomized-controlled studies through 
meta-analytical approach. The input data for clinical and economic parameters in a 
model can be estimated based on the results from one trial from the target country or on 
a synthesis or meta-analysis of relative treatment effects collected in several clinical 
trials. Adjustment of data collected in international trials to the country-specific baseline 
parameters (case mix) can be supported by regression modelling with baseline data as 
covariates. Extensive deterministic and probabilistic sensitivity analysis is the key tool 
to explore sensitivity of results to different assumptions related to generalizability of the 
data (Drummond et al., 2009). 
 
3.4 Generalizability Methods for Decision Models 
   Decision models and patient-level studies are complementary approaches for the 
standard health economic analysis and for generalizability issue specifically. Decision 
modelling could substantiate cost-effectiveness analysis in the following cases: 
• Patient-level study was not conducted in target county and available (patient-level) 
data may not be fully relevant and applicable for the specific setting.  
• Availability of additional relevant data sources in the target country, e.g. 
observational clinical and economic evidence, registries, HRQoL data, 
epidemiological data on baseline risks, etc.  
• Data collected in patient-level studies do not fully meet the requirements of health 
economic analysis, e.g. insufficient follow-up period, protocol-driven procedures or 
irrelevant treatment comparator for the target country. 
• Available decision model synthesizing evidence from different sources can be 
updated with the respective information from a target country (Sculpher et al., 
2006b; Drummond et al., 2009). 
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   Technically, modelling strategy can include formalized approaches such as decision 
trees, Markov analysis, discrete event simulation and systems dynamics. Practically, the 
choice of the modelling strategy depends on specific aspects of clinical condition, health 
economic impact of a new treatment and, finally, access and availability of the data 
(Brennan & Akehurst, 2000). 
   The major advantage of decision modelling is the facilitation of the data synthesis 
from different sources, in particular for the cases, where clinical studies capture 
incomplete information (Urdahl et al., 2006). Decision models provide the framework to 
apply generalizability methods to construct cost-effectiveness results for the long-term 
therapies, extent results to non-trial locations and to adjust trial results to reflect routine 
practice. The individual aspects are explained in the following sections. 
 
3.4.1 Modelling Long-term Results 
   Decision-models allow simulation of long-term costs and benefits based on data 
collected in short-term clinical studies and assumptions or epidemiological evidence 
about clinical progression and treatment effects. The transition probabilities for Markov 
models can be taken from epidemiological data or observational studies. The economic 
data on costs and resource use can be collected within local costs studies or found in 
existing national registers. 
Generation of long-term results beyond clinical study frame includes: 
• prediction of real-life effectiveness based on short term clinical efficacy 
• estimation of total (life-long) resource use and discounted cost (Brennan & 
Akehurst, 2000). 
   The advantage of combining different type of data could be potentially source for 
error. The absence of randomization in observational data raises concern about selection 
bias. A statistical method to deal with not randomized data - “decomposition 
technique”- has been applied by Shih and colleagues in the context of model for 
treatment of patient with renal disease with epoetin (Shih & Kauf, 1999). 
   Decision models are used for number of chronic conditions. For example, Kobelt and 
colleagues (2003) constructed cost-utility model for interferon treatment of patients with 
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multiple sclerosis (MS). Model synthesized data from different sources, including 
clinical studies and public register for MS progression. Analysis estimated the outcomes 
of treatment over 40 cycles (10 years) based on the data from clinical study for 12 
cycles (3 years). Ordered probit regression was applied to model transition probabilities 
using data from clinical trial. Disease stage was used as dependent variable and age at 
onset of MS, age at start of treatment, time since start of treatment, relapse in the current 
period, and six dummy variables representing the state in the previous period as 
independent variables (Kobelt et al., 2003). 
 
3.4.2 Modelling Location-Specific Results 
   Decision models provide location-specific economic evidence for both study and non-
study settings. Where patient-level data is available, but the targeted country was not 
included into the study, Manca and Willan (2006) suggested to develop an “event-
based” model. Their framework is based on the generalizable aspects of clinical 
condition and patient-level data from the available studies. Country-level estimates can 
be modeled in applying pooled incremental efficacy to the location-specific baseline 
parameters. Application of pooled incremental efficacy (e.g. reduction of pain, adverse 
events) to the baseline parameters in specific countries is a common and feasible 
approach, if there is no evidence to suggest that use of relative efficacy from a specific 
setting or country is more appropriate (Manca & Willan, 2006, Drummond et al., 2009). 
   Caro and colleagues (2000) used similar methodology to set-up a generalized cost-
effectiveness formula distinguishing between the parameters, which could be considered 
as general or country-specific. This approach supported generalization of results from a 
clinical study in cardio-prevention conducted in Scotland to Belgian setting. 
Incremental efficacy was considered generalizable, i.e. applicable to all countries. The 
baseline parameters were taken from country-specific sources. Estimated relative risk 
reduction in Scottish population was applied to Belgian-specific baseline data and costs. 
The cost-effectiveness ratio for Scottish and Belgian setting were not substantially 
different. The authors concluded, that results could be valid for other countries with 
comparable clinical characteristics such as cholesterol level, age and gender (Caro et al., 
1999; 2000; Sculpher et al., 2004). 
  
 83
   Availability and access to country-specific baseline clinical evidence is critical for the 
majority modelling approaches, including the discussed above. Statistical models are 
often used in health economic analysis to estimate future events in selected clinical 
indications, such as fractures in osteoporosis or infarction in cardiovascular indications. 
For example, Framingham cardiovascular risk equations were developed and populated 
with US data. In fact, the logic of this algorithm may be applicable to the other countries 
with the comparable clinical practice and patient population. However, the update with 
country-specific baseline data to reflect local case-mix is always commendable 
(Drummond et al., 2009). 
   For modelling of health economic outcomes when the patient-level data is not 
available and particular country did not participate in the trial, Manca and Willan (2006) 
outline the major issues and reviewed these in a case study conducted by Palmer and 
colleagues (2005) to evaluate cost-effectiveness of glycoprotein IIb/IIIa antagonist in 
treatment of patients with non-ST-elevation acute coronary syndrome. Critical 
analytical and empirical issues included adjustments needed to reflect country-specific 
clinical practice, comparison of the clinical baseline data with country-specific case-
mix, evaluation of the relationship between baseline risk and clinical efficacy of the 
particular therapy and, finally, application of country-specific economic parameters 
(Manca & Willan, 2006; Palmer et al., 2005). The “efficiency” of the analysis requires 
maximum utilization of available evidence under reflection of targeted context. For this 
purpose, decision models offer advantage of combining data from different sources. The 
clinical effectiveness of the treatment (for e.g. calculation of transition probabilities in 
Markov model) can be taken from clinical trial. In the case there are multiple sources 
for the parameters of interest, the data should be pooled using appropriate techniques to 
reflect imprecision of the estimated outcomes and possible heterogeneity. Meta-
analytical techniques have made progress to allow synthesis and handling of different 
types of outcomes from different sources (Drummond et al., 2005).  
   There are several issues with modelling of health economic outcomes for the settings, 
where clinical or economic data is scarce and relies on the outside evidence. First, the 
health production function must be the same as in the study setting, which is rarely the 
case, considering different source of variability discussed above. Second issue is the 
potential source for error while applying non-randomized observational data. Finally, 
economical theory suggests the joint consideration of resource use and costs. Simple 
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application of the country-specific unit costs to external resource use, is not always 
appropriate (Reed et al., 2005; Manca & Willan, 2006). 
 
3.4.3 Modelling “Routine Clinical Practice” Results 
   Clinical trials are often done in the sites, which are specialized on doing clinical 
research. In general, if the decision model is build on the efficacy data from clinical 
trial, the adjustment to routine clinical practice should be considered. 
   Clinical trials are known to raise better treatment compliance, comparing to the 
everyday practice. This issue should be explored in the sensitivity analysis to show the 
impact on the cost-effectiveness ratio.   
   The characteristics of clinical condition and health technology have major 
implications for the design of health economic evaluations. Until now, the majority of 
pivotal clinical studies are being done against placebo to meet regulatory requirements 
for marketing authorization. For many clinical conditions control arm with placebo 
treatment may not be feasible and/or ethical to implement. Models allow to incorporate 
all treatment options with respective sequences to reflect current clinical practice to 
inform policy in a specific setting (Brennan & Akehurst, 2000). The generalizability of 
paclitaxel study by Beard and colleagues (1997) required incorporation of relevant 
standard treatment in UK. The trial was conducted against cisplatin and 
cyclophosphamide, whereas carboplatin was used as standard therapy in UK. The 
results showed improved cost-effectiveness of paclitaxel vs standard UK treatment 
comparing to the control arm used in clinical study (Beard et al., 1997). 
   Baltussen and colleagues (1999) proposed assessment and adaptation of study results 
to reflect routine clinical practice using three-step approach. They evaluated internal and 
external validity of the study outcomes and estimated net impact at system level. The 
assessment of internal validity relied on analysis of study-specific results, which is the 
first step of the proposed approach. In the second step, authors adjusted study-specific 
results in accounting for country-level factors related to medical staff, hospital and 
health care system. This approach involved qualitative assessment, inclusion of 
epidemiological evidence and sensitivity analysis. In the third step, context-specific 
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clinical outcomes and costs were evaluated to estimate net impact of new intervention 
(Baltussen et al., 1999; Sculpher et al., 2004).  
 
3.5 Generalizability Methods for Patient-Level Studies 
   Conduct and analysis of multinational patient-level studies is a complex and lengthy 
process. Generalizability can be improved, if the issue is considered already on study 
design phase, appropriately incorporated in analytical strategy and, finally, published in 
the form useful for external settings. We discuss respective considerations for design, 
analysis and report in the following sections. 
 
3.5.1 Considerations for the Design of Patient-Level Studies 
   Economic evaluations based on patient-level data collected alongside randomized 
controlled clinical studies continue to provide an important source of data for cost-
effectiveness analysis (Drummond et al., 2005). Multinational clinical studies are 
considered as “state of the art” for producing estimates on clinical effectiveness and 
safety. The main motivation for conducting of the studies internationally is the large 
sample size, rapid recruitment and collection of data in wide range of treatment settings 
across different countries. However, interpretation and generalizability of the results 
from international studies is problematic for both clinical and economic outcomes 
(Cook et al., 2003). Additionally to the variability factors discussed in the previous 
sections, economic evaluations within clinical trials are problematic, as sample size of 
clinical studies is often determined to show the differences for clinical and not 
economic end-points and number of patients in different settings is often small and 
imbalanced. In addition, at the early development stage, the resource use in “routine 
practice” for new technology can not be easily reflected within clinical trial. Missing, 
censored or non-existing data is another important issue (Greiner et al., 2000; 
Drummond et al., 2005). Design of clinical studies often introduces protocol-driven 
costs, involves very selective procedure for patient sample recruitment, which may not 
be representative for the general population, and have placebo-arm or comparators not 
reflecting routine clinical practice (Sullivan et al., 2001).  
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   Considering generalizability issue at the study design stage, it is important to create a 
framework, where valid economic patient-level data from the representative population 
can be collected. For the purpose of generalizability, inclusion of study centers would 
be ideally done randomly from the geographic regions for which economic data is 
requested. Inclusion and exclusion criteria for the study patients should avoid selecting 
a specific sub-group not representative for underlying patient population. Important to 
consider, that the average case load can differ across locations. E.g. centers of 
excellence or university clinics often treat patients with advanced disease stage or those 
with severe condition, which may not be the average case for ambulatory practice. In 
this case, it is crucial to collect both patient-level and center-level variables (Drummond 
et al., 2005; Goeree et al., 1999). 
   Comparative treatment should represent standard clinical practice for the jurisdiction, 
for which reimbursement decision will be made. Today, it is rarely the case, that 
standard of care does not exist and placebo control is justifiable for treatment control 
arm. Nevertheless, generalizability could be problematic, if standard treatment differs 
across jurisdictions (Drummond et al., 2005). 
   To generalize results of clinical trials, it is important to reflect routine clinical practice 
and average case-mix of treated population. This is an issue in clinical trials, where 
enrollment criteria exclude part of patient population, which is going to receive 
treatment once technology is licensed. Thus, inclusion criteria should be either “broad”, 
or analysis should be substantiated by additional observational study. Protocol-driven 
costs and utilization could lead to over- or under- estimation of resource use in everyday 
practice (Sullivan et al., 2001). While protocol-driven resource utilization may be 
corrected or subtracted in the analysis, increased compliance in clinical study setting 
may inflate efficacy estimates, which may not replicate effectiveness in routine practice 
(Goodman & Mills, 1999). This issue could be explored in the sensitivity analysis using 
decision model. Observational study design could improve external validity of the 
clinical endpoints and control for protocol driven resource consumption, but may, on the 
other hand, fail to provide clinical evidence with maximum internal validity, as required 
for dug approval purposes (Coyle & Lee, 1998; Tunis et al., 2000).  
   The important advantage of the patient-level studies is the possibility to collect 
resource use and cost data at the early stage before the market approval. It is advisable 
to collect resource utilization in terms of e.g. length of hospitalization, community nurse 
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visits, physiotherapy etc. separately from the price weights of those resources. This 
approach has several advantages. For example, the decision-makers in other 
jurisdictions may need to use local prices to value resource use. Certainly, decision-
makers evaluating analysis based on outside evidence, need to assess, whether the 
clinical procedures and corresponding utilization of resources observed in other 
locations reflect medical practice in their jurisdiction (Drummond et al., 2005; Brown et 
al., 2004). 
 
3.5.2 Methods for the Analysis of Patient-Level Studies 
   Approaches to analyze patient-level data collected in multilocational trials could be 
divided into fully pooled clinical estimates with multi- or one-country costing, fully 
splitted clinical estimates with country-level costing, partially split of clinical and 
economic estimates. Table 3 qualitatively summarizes advantages and disadvantages of 
these methodological approaches (Reed et al., 2005). 
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Table 3: Advantages and Limitations of Analytical Strategies for Patient-Level Studies 
Advantage of analytical 
strategy 
 
Fully pooled, 
multicountry 
costing 
 
Fully pooled, 
one-country 
costing 
Partially 
split, one-
country 
costing 
Fully split, 
one-country 
costing 
Maintain patient-level 
relationship between resource 
use and clinical effect 
Yes 
 
Yes 
 
No 
 
Yes 
Maintain patient-level 
relationship between resource 
use and costs 
Yes No Yes Yes 
Maximize statistical power 
for treatment effect 
Yes Yes No No 
Minimize collection of unit 
costs 
No Yes Yes Yes 
Allows consistent reporting of 
treatment effect 
Yes Yes Yes No 
Source: modified from Reed et al., 2005. 
 
Applying pooled efficacy to resource use with one- or multi-country costing 
   A rather common approach in multinational trials is calculation of the total costs by 
applying unit costs from one country or centre to the pooled resource use collected 
across all countries or centers. Another similar approach is to apply unit costs to 
resource use data collected in each country and relate pooled costs across all countries 
to trial-wide efficacy. The feasibility of this approach requires both clinical efficacy and 
resource use to be fully exchangeable across countries and centers. This assumption 
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may not be universally valid. Economic theory suggests that clinical institutions, similar 
to commercial organizations, will attempt to achieve efficient allocation of available 
resources. Technical efficiency of production function relates to maximum output given 
the mix of constrained input factors. Clinical sites, being cost-sensitive organizations, 
would choose the least cost-input allocation to produce targeted outcomes at the level of 
technical and productive efficiency (Sculpher et al., 2004; Raikuou et al., 2000). In fact, 
it may not be appropriate to apply price weights from outside jurisdictions.  
   The implication of separate analysis of costs and resource use will depend on the 
differences in absolute level of costs and resource use across settings. For instance, 
application of price weights from US or Western European countries to the resource use 
in developing countries will inflate both total and incremental costs between the 
treatment groups. The difference between the costs of new treatment and comparator is 
the numerator of ICER, overestimation of incremental costs will provide incorrect ICER 
(Reed et al., 2005). The resource-mix and health production technology are likely to 
vary across geographical locations and institutions. For example, delivering babies by 
midwives versus family doctors, and care of non severely sick infants in neonatal 
intensive care units versus regular nurseries with intensive nursing, are examples of 
ways of providing a relatively similar service at different costs (Goeree et al., 1999).  
   A fully pooled analysis with multi-country costing preserves the patient-level 
relationship between resource use and clinical efficacy and maximizes statistical power. 
Possible limitation is the need to collect unit costs and make assumption about costing 
methods in different countries. The methodological approach and assumption in costing 
may not be completely transparent and standardized across all participated countries. 
Other limitation relates to possible deterioration of trial-wide difference in resource use 
if applying country-level prices, since countries with higher price weights may affect 
ICER outcomes to greater extend than countries with lower prices. Lastly, the 
application of the pooled results from multinational setting may not be evident and 
easily interpretable for the decision-makers in participating countries (Reed et al., 2005; 
Koopmanschap et al., 2001). 
Fully split analysis in applying country-level costs to country-level efficacy  
   The opposite to the fully pooled analysis is the assumption that the data and results 
from different countries are distinctive and completely not exchangeable. In this case, 
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the analyst applies unit cost to resource use in relation to clinical effectiveness for the 
patient sub-group from a specific country only. This approach may be feasible for large 
countries, like US, Canada and UK, were large-scale national studies are conducted 
routinely. The statistical power and selection bias may be, however, an issue for the 
cases where recruitment in particular countries was slow and the analysis should rely on 
the data from very small patient population (Sculpher et al., 2004; Reed et al., 2005).  
Partial pooling of either efficacy, resource use and costs  
   Partial pooling is probably the most common way of analysis of multinational studies 
and relies on partial aggregation of either economic or clinical data (Li, 2007). For 
example, cost estimation may be limited to the data collected in one country, whereas 
efficacy is estimated from trial-wide patient population. This approach may be 
considered as a compromise between fully pooled and fully split strategy, i.e. between 
statistical power of clinical findings and limited generalizability of economic parameters 
across different countries. Partial pooling allow to maintain the relationship between 
unit costs and resource use, but not between the costs and clinical effectiveness (Reed et 
al., 2005). In fact, in many studies partial exchangeability of absolute and relative 
clinical and economic outcomes can be assumed. The feasibility of combining health 
economic data across the jurisdiction remains an analytical issue (Cook et al., 2003). 
Homogeneity test and several regression-based methods are statistical approaches 
supporting implementation of partial pooling strategy. 
Homogeneity test  
   Cook and colleagues (2003) tested homogeneity of the economic data in the 
Scandinavian Simvastatin Survival Study. As noted before, it is often assumed, that 
relative clinical efficacy of the treatment does not vary between different settings. As a 
result, measures of clinical effect may be aggregated across centres and countries. 
Usually, homogeneity of treatment effect is checked before the clinical data are pooled. 
However, detection of statistically significant difference, i.e. country by treatment 
interactions, is unlikely, partially due to high number of participated sites/countries with 
small number of patients per setting. In addition, absence of country by treatment 
interaction in incremental efficacy does not mean homogeneity of absolute clinical 
outcomes, which are used to estimate cost-effectiveness of new therapy in the 
denominator in the cost-effectiveness ratio.  
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   Homogeneity test by Gail and Simon (1985) is suggested by researches for testing of 
economical outcomes similar to the test for investigation of country-by-treatment 
interaction in clinical endpoints. Treatment outcomes can be measured in terms of 
incremental resource use, incremental costs, cost-effectiveness ratio and net monetary 
benefit. Country-by-treatment interactions can be of qualitative or quantitative nature. 
Qualitative interaction refers to the different “direction” in treatment effect across the 
settings, e.g. new treatment is saving costs in some countries and adding in others. 
Quantitative interaction characterizes differences in the effect’s magnitude. If 
homogeneity of effect’s direction and magnitude is confirmed by the tests, researcher 
may consider to aggregate observations across the settings to maximize statistical power 
and consider trial-wide effect applicable for the decision in individual countries (Cook 
et al., 2003). Nevertheless, the appropriateness of combining the outcomes across the 
countries may be challenged by the unbalanced recruitment and small sample size from 
some countries. The application of this method is demonstrated in the case study and 
described in details in section 3.6. 
Fixed-effect regression models  
   Number of studies employed regression methods to evaluate generalizability of the 
trial-wide cost-effectiveness results to individual countries participating in multinational 
clinical trial. Wilke and colleagues (1998) proposed regression-based method for the 
trial of tirilazad mesylate treatment for subarachnoid hemorrhage for the five highest-
enrolling countries to estimate country-specific incremental costs, while controlling for 
clinical endpoints and country-specific differences in costs for outcome. The method 
assumed that the costs of treatment in multi-country model are determined by 
covariates, such as treatment, clinical outcome, country-by-treatment and country-by-
outcome interaction terms. Although country-specific effects on survival were not 
statistically different, the authors concluded, that generalizability of trial-wide costs to 
the specific countries is not appropriate, as the greatest variation was observed in using 
country-specific resource utilization, unit prices and outcome levels. Thus, country-
specific cost-effectiveness estimates were calculated with trial-wide incremental 
efficacy, but country specific incremental costs (Wilke et al., 1998; Wilke, 2003). 
   Rutten-Van Molken and colleagues (1998) used ordinary least-squares regression to 
explore heterogeneity in the cost in the cost-effectiveness analysis of two asthma 
  
 92
treatments in the study conducted in six European countries. Country-specific unit costs 
were applied to resource use of country-level patients subgroups. Regression analysis 
was conducted using log transformed total costs as dependent variable and country, 
treatment, age and duration of condition as covariates. Analysis showed no evidence for 
statistically significant difference in cost between the treatment arms, but significant 
variation in costs across the countries. Patients from Italy had significantly lower costs, 
comparing to other countries, whereas patients from Switzerland had the highest costs. 
This heterogeneity was partially explained by variations in costing approaches and 
uncertainty about the data sources. The authors emphasized, that pooling of costs may 
not be informative and suggested splitted reporting of resource use and costs, instead of 
total costs only (Rutten van Molken et al., 1998; Sculpher et al., 2004). 
   Coyle and Drummond (2001) applied one-way ANOVA in economic analysis of 
radiotherapy in cancer treatment to explain heterogeneity in radiotherapy and relevant 
inpatient costs between and within treatment centers. Variability in costs may arise on 
patient- and center- levels. Regression analysis was used to identify statistically 
significant difference in costs between the treatment centers and specific parameters 
(covariates) which could explain this variation. Identifying the predictors allows to 
improve the generalizability of the study findings beyond the study settings to e.g. 
hospitals with the same level of covariates. Analysis revealed significant heterogeneity 
in costs across the centers. Major part of variation in radiotherapy costs was explained 
by differences in price weights. The significant differences in inpatient costs were 
partially attributed to variation in costs for ward’s accommodation. Finally, patient-level 
covariates explained differences in costs between two treatments (Coyle and 
Drummond, 2001; Sculpher et al., 2004). 
Hierarchical regression models  
   Several authors suggested using hierarchical regression-models to handle multilevel 
data in cost-effectiveness analysis (Rice & Jones, 1997; Manca et al., 2005, Sculpher et 
al., 2004; Drummond et al., 2005, Duncan et al., 1998). Observations in multinational 
studies may be considered as “clustered” within locations, geographical areas or clinical 
institutions. Stochastic cost-effectiveness analysis, however, relies on independence of 
the events within centres, countries or geographic regions. Thus, the application of e.g. 
ordinary least square regression does not formally allow hierarchical (clustered) nature 
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of the data and will produce inefficient parameter estimates. Hierarchical modelling can 
be used for clustered data to calculate (1) correct estimates of the trial-wide incremental 
cost-effectiveness with respective standard errors and confidence or credibility intervals, 
and (2) country-level estimates of incremental cost-effectiveness for either informing 
decisions based on study results or for further analysis as input in decision models. The 
estimation of the statistical models can be done with frequentist’s maximum likelihood 
or Bayesian shrinkage estimation procedures. The caveat of the use of hierarchical 
models is the assumption, that selection of the sites in the study is random, which is 
rarely the case (Sculpher et al., 2004; Manca et al., 2005). The detailed discussion and 
application of this method is demonstrated in the case study and described in details in 
section 3.6. 
Value of perfect information analysis to guide further research 
   Obviously, generalizability of health economic evaluations is always subject to 
uncertainty associated with input parameters and results. Decision models allow to 
synthesize available evidence to establish cost-effectiveness of a new intervention to the 
general population or it sub-groups and explicitly account for uncertainty associated 
with estimated parameters. The decision-makers will face inevitable question about the 
likelihood to make wrong decision based on the current uncertain evidence.  
   Several advanced statistical methods are being developed in this field. Value of 
perfect information analysis is a new approach rooted in decision theory. It aimed to 
support decision about the need for additional studies by assessment of the probability 
and the costs of making the wrong decision on the basis of current evidence. The 
intervention should be reimbursed based on available data at a give time-point. 
Nevertheless, the quantification of the degree of uncertainty provides decision-makers 
and researches with the valuable information. It can help to determine future research 
needs, priorities and optimize research design (Claxton et al., 2002; Drummond et al., 
2005). 
3.5.3 Appraisal Methods for Reported Evidence 
   Extensive number of publications exist on the assessment and appraising of existing 
economic evaluations. Several authors suggested various criteria or checklists, which 
can be used for the assessment of published evidence for the decision-making in 
particular country (Boulenger et al., 2005; Urdahl et al., 2006; Spath et al., 1999; Welte 
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et al., 2004). The short list for quick assessment is provided by Drummond and 
colleagues (2005) in Figure 7. Overall, the authors agree that the essential prerequisite 
for the utilization or generalizability of “external” data is the solid internal validity of 
the evaluations and availability of the detailed information on effectiveness, costs and 
resource use.  
Figure 7: Checklist for Assessment of the Generalizability of Published Studies 
1. Are study sites representative of the jurisdiction(s) for which data are required? 
2. Are study sites (centers) randomly selected? 
3. Can data on center characteristics be collected (e.g., bed occupancy levels)? 
4. Does the trial include a high proportion of the normal clinical caseload? 
5. Does the comparator therapy represent current practice in the settings concerned? 
6. Is a wide range of user perspectives represented in the study? 
7. Are prices (unit costs) being collected separately from resource use data? 
8. Is a widely used generic instrument being used for quality of life measurement? 
9. Can regression-based techniques be used to obtain center-specific measures of cost-
effectiveness? 
Source: modified from Drummond et al., 2005. 
 
3.6 Methods Applied In Patient-Level Case Study 
   Selection of analytic strategy to explore variability and improve generalizability 
depends on several factors. The essential factor is the availability of the patient-level 
data. For the patient-level studies, two methods were suggested by the literature: 
homogeneity test and hierarchical modelling. First method is deemed to detect 
heterogeneity in the incremental effects and the second to calculate country-level 
estimates.  
   Our case study is based on secondary analysis of patient-level data collected in 
clinical phase III study comparing efficacy of two antibiotics in treatment of 
community-acquired pneumonia (CAP). The detailed description of study design and 
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dataset is provided in section 4. This section presents methods applied to improve 
generalizability of clinical and economic results. We applied the selected 
generalizability methods on the following endpoints: 
• Mean and incremental effectiveness. 
Mean effectiveness is measured by proportion of cured patients in the treatment and 
comparator arms. Incremental effectiveness is the difference between treatment and 
comparator arms. Positive incremental effectiveness means that treatment is more 
efficacious than comparator. 
• Mean and incremental costs. 
The costs outcomes are measured similarly to the effectiveness. Positive incremental 
cost suggests that treatment is more expensive than the comparator therapy. 
• Mean and incremental length of stay (LOS) in the hospital. 
Hospitalization is the major resource use in treatment of CAP. More broadly, in-patient 
care contributes substantially to the overall costs in health care sector. The between-
country heterogeneity and impact of the new therapy on LOS is therefore of particular 
interest and is being evaluated. 
   Details on homogeneity test and hierarchical models applied in the case study to the 
above endpoints are described below. 
 
3.6.1 Homogeneity Test  
   The test was suggested by Cook and colleagues in analysis of multinational health 
economic study to explore homogeneity of the effect in different settings (Cook et al., 
2003). The test evaluates, whether the relevant clinical or economic effect differs by 
country and treatment. The treatment effect kD with the variance 
2
ks  for countries k=1 
to K can be an estimate for difference in clinical response between treatment and 
comparator arms, difference in length of hospitalization, difference in costs, incremental 
net monetary benefit (INMB). The between-country heterogeneity can be of qualitative 
or quantitative nature. Qualitative interaction refers to the differences in the effect 
direction, whereas quantitative interaction refers to the effect size or magnitude. If there 
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is no evidence of heterogeneity and sample size was sufficient to detect economically 
meaningful differences in effectiveness and costs, then the aggregated trial-wide 
estimates are considered valid for all participated countries. If the method indicates 
heterogeneity, the trial-wide estimates may not be informative for the decision-making 
in individual countries (Cook et al., 2003; Gail & Simon, 1985). 
Test for qualitative interactions  
   Qualitative interaction refers to the heterogeneity where the treatment effect (e.g. 
difference in clinical effectiveness, resource use, costs, net monetary benefits) is 
positive in some countries and negative in the others. Finding of qualitative interaction 
suggests that e.g. treatment is more efficacious in some countries, whereas comparator 
is more efficacious in the others, or new therapy has positive NMB in some countries 
and negative in the others. 
   In the case study, we test the null hypothesis that there is no country-by-treatment 
interaction, i.e. the treatment effect is either greater than 0 or less than 0 for all countries 
as following: 
1) 0≥Δ kE  in all countries. Incremental effectiveness SkTkk TOCTOCE −=Δ  , 
measured as difference in treatment response, is greater in the treatment arm comparing 
to the standard therapy.  
2) 0≤Δ kC  in all countries. The treatment is cost saving comparing to standard 
treatment in all countries, i.e. incremental cost SkTkk CCC −=Δ , measured as difference 
between mean total costs for treatment and  comparative therapy, is non-positive for all 
countries. 
3) 0≥kINMB  in all countries. Incremental monetary benefit calculated as 
ECINMB Δ−Δ= λ , is non-negative in all countries. 
4) 0≥− TkSk LOSLOS in all countries. The mean length of stay for the patients 
receiving comparative therapy is longer than for those getting new treatment. 
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The test statistic is computed as following: 
∑ =− = Kk kk SDQ 1 22 )/(  for 0≥kD  
∑ =+ = Kk kk SDQ 1 22 )/(  for 0<kD  
The likelihood ratio test is expressed by: 
α2),min( CQQQ >= −+  
Critical values are reported in Gail and Simon (1985). 
The calculation of the power of the test for qualitative interactions is suggested by Pan 
and Wolfe (1997) as following: 
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Where [ ]Φ  is the standard normal cumulative distribution function and αz is the α  
percentile of the standard normal distribution for 
[ ])1/(1)1(1 −−−= kαα . 
Test for quantitative interactions  
   This test evaluates homogeneity of treatment effect’s magnitude across different 
settings. The null hypothesis for the treatment effects (as formulated for qualitative 
homogeneity test) is that the effect’s magnitude is equal in all countries. 
Test statistic is computed as following: 
∑ = −= Kk kk SDDH 1 22 /)(  
[ ] [ ]∑∑ === Kk kKk kk ssDD 1 21 2 /1//  
   Test statistics H is compared with critical values of the chi-square distribution with 
K−1 degrees of freedom. Heterogeneity is indicated by large values of H, where 
treatment effect in individual countries departs substantially from trail-wide estimate. 
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3.6.2 Hierarchical Modelling 
   Various research areas in social science are evaluating associations between 
individual factors and environmental context. This question is important for Public 
Health research where several studies explored relationship between contextual impact 
and individual health status (Rice & Jones 1997; Duncan et al., 1998; Britton, 1990).  
   Variations between different countries and sites in clinical and economic parameters 
in the health economic study can be associated with both clinical characteristics of the 
patients in the setting ("compositional" effects), as well as the factors of the 
environment where treatment is provided ("contextual" effects), as illustrated in the 
Figure 8. The outcomes under study may be affected by processes operating at more 
than one "level": patient-, centre-, health care system- levels. To understand and 
quantify contextual and compositional impact on cost-effectiveness outcomes, all 
relevant levels need to be incorporated into analysis and considered simultaneously 
(Duncan et al., 1998). 
Figure 8: Contextual and Compositional Levels in Clinical Study Setting 
Source: compiled by the author 
Traditional methods for analysis of contextual and compositional effects 
   Traditional regression analysis have limitations in analyzing contextual and 
compositional levels together. Standard regression models, estimated with ordinary 
least-square approach, allow for one-level analysis, e.g. aggregated (contextual) level or 
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individual (compositional) level. The issue with aggregated analysis is known under the 
term of “ecological fallacy”, where uncovered macro-level inferences may not reflect 
lower level associations. The disadvantage of conducting analysis at a lower level is 
potential “atomistic fallacy” caused by neglecting of environmental impact where the 
treatment and health outcomes are being produced (clinical trial site, in-patient 
institution, country) (Alker, 1969). Clustering imposes the similarity or dependency of 
observations coming from the same higher-level unit, what will produce inefficient 
estimates and lead to inflation of type I error, e.g. finding differences and associations in 
the cases where these may not exist (Skinner et al., 1989; Snijders & Bosker, 1999).  
   ANCOVA analysis allows to accommodate hierarchy in introducing additional 
“fixed”-effect as proxy for different sites or countries. For example, the analysis over 50 
settings (clinical hospitals) with different intercept and slope terms for each would result 
in 100 parameters. This, in turn, possess serious requirements for the sample size to 
assure the reliability and robustness of the estimates. Thus, ANCOVA has limited 
capability to maximize efficiency in the analysis of  small dataset. Another limitation of 
the “fixed”-effect approach is the fact that the inferences are valid explicitly for studied 
sample and context, but not necessarily to general population, what is of main interest in 
Public Health research. Instead, hierarchical models make inferences for the underlying 
population, from which the studied sample was randomly drawn. Overall, hierarchical 
modelling overcome the issues related to aggregated and disaggregated analysis and aid 
to fully explore the context and improve generalizability of the estimated parameters 
(Duncan et al., 1998). 
Application of hierarchical models for clustered data  
   Hierarchical models are fairly recent statistic development. Different termini are used 
in the literature to describe this methodology: multilevel models (Goldstein, 1995), 
random coefficient models (Longford, 1993) and hierarchical models (Bryk & 
Raudenbush, 1992). In this work we use the term "hierarchical models". Hierarchical 
models are applied in various research areas of social and natural sciences, such as 
education, geography, epidemiology, public health and others (Wu, 1995; Duncan et al., 
1996; 1998; Britton, 1990; Carey, 2000; Bryk & Raudenbush, 1992; Paterson & 
Goldstein, 1992; Carr-Hill et al., 1996; Goldstein, 1995; Leyland & Boddy, 1997; Davis 
& Gribben, 1995). 
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   Health economic data from multinational trials falls naturally under hierarchical or 
clustered structure, where the patients are “nested” within the jurisdictions they are 
treated, e.g. trial sites, hospitals, countries. Most recent health economic literature has 
extended simple regression approach with the application of hierarchical models to 
economic data (i.e. costs, effectiveness, incremental net benefit and incremental cost-
effectiveness ratio) derived from multinational trials (Rice & Jones, 1997; Manca et al., 
2005; Grieve et al., 2005; 2007; Pinto et al., 2005; Willan & Kowgier, 2007; Willan et 
al., 2005; Manca et al., 2007; Thompson et al., 2010). Hierarchical modelling is 
appropriate analytical framework to address generalizability. It goes beyond indication 
of heterogeneity with homogeneity test and allows for estimation of trial-wide and 
country-level cost-effectiveness parameters and adjustment for patient- and country-
level covariates (Drummond et al., 2009). 
Assumption made in hierarchical models 
   By using hierarchical models following assumptions are made:  
• Random grouping.  
For levels above the lowest level units, e.g. patient-level for clinical or health economic 
studies, the groups are assumed to be random sample from underlying population. This 
means that clinical study sites are assumed to be selected randomly from all clinical 
institutions (DiPrete & Forristal, 1994; Hox & Kreft, 1994). 
• Exchangeability.  
The important assumption of hierarchical models is the “exchangeability” of the 
parameters of interest, which are drawn from a common distribution. This assumption 
implies, that there are no a priori reasons to believe that estimates are relatively high or 
relatively low in a particular jurisdiction. Obviously, this assumption relates to the 
above requirements of random grouping. 
• Independent blocks.  
Hierarchical modelling allows for “clustering” of individual observations within higher-
level unit, however the clusters, formed by the subject variables, are assumed to be 
independent.  
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• Adequate sample size.  
There is no simple rule of thumb for calculation of sufficient sample size. The number 
of units on both contextual and compositional levels should be tentatively higher if the 
relationship between different parameters is not strongly pronounced (Goldstein, 1995; 
Garson, 2009; Spiegelhalter et al., 2002). 
Model formulation in the case study 
   For our case study we adopted the model’s formulation proposed by Nixon and 
Thompson (2005) and Willan and Kowgier (2007) as summarize below. 
jiE ~ ),( jiji EEDist σφ and jiC ~ ),( jiji CCDist σφ  where jiE  and jiC  are the observed 
effectiveness and costs with respective mean and standard deviation values for patient i  
in treatment arm j  from country [ ]Mk :1∈ .  
   Bivariate hierarchical model for country-by-treatment interaction for mean cost and 
effectiveness is specified respectively: 
∑
=
++=
M
k
jikEkEkEE zjjji
1
)( δγμφ        
φC ji = μC j + (γCk + δCk j)z jik
k=1
M∑ +β j (E ji −φEji)      
where jikz  is an indication function for patient i  in the treatment arm j  from country k . 
The model assumes that effectiveness may influence costs, through non-zero parameter 
jβ , however, there is no opposite effect of costs influencing effectiveness. This is a 
plausible assumption for the fully protocolized clinical study, where expenditures for 
the trial are fully covered by pharmaceutical company (this assumption may not be valid 
while analyzing observational data).  
   For each country there are corresponding regression coefficients CkCkEkEk δγδγ ,,, , 
which assumed to be random-effects with mean zero drawn from bivariate normal 
distribution. The trial-wide treatment effectiveness is 01 EEe μμ −=Δ  and cost 
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01 CCC μμ −=Δ ; the country-level treatment and cost effects are Eke δ+Δ  and CkC δ+Δ  
respectively. 
   Covariates ijx  are incorporated as following to account for covariate interaction with 
treatment: 
jiEE
M
k
jikEkEkEE xjzjjji )()(
1
ωθδγμφ ++++= ∑
=
   
jiCCEjijij
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ωθφβδγμφ ++−+++= ∑
=
  
   Here, the regression coefficients θ  and ω are respective direct and interaction effects 
on costs and effectiveness. The positive interaction effect increases mean incremental 
cost or effectiveness by ω per unit of covariate. Continues covariates ijx  are centered 
around the trial-wide mean. 
   Effectiveness is a Bernoulli parameter and is restricted between 0 and 1 as following: 
jijijijiEji ττταφ +−−= )1),,min(max(   
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Cost data is modelled using gamma distribution with probability density function: 
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   The gamma distribution allows mean cost to be modeled as linear function of the 
treatment, covariate and country effects. The shape parameter is unique for each 
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country, namely: ∑ == Mk kjikji z1 *ρρ  (Nixon&Thompson, 2005; Willan&Kowgier, 2007).  
. 
Variance component model  
   Model for the cost variable could be presented as following: 
CikCkCC eujjik ++= μφ         
Where 
jikC
φ  is the cost for the ith patient receiving either treatment or comparator in the 
country k; 
jC
μ  is the intercept, i.e. the average cost from pooling all the observations in 
the dataset; Cku  is the random term applying to the patients from country k; Cike  is 
another random term applying to ith patient within the country k. 
   The model has two random components, namely Cike  and Cku  with zero means and 
respective variance 2uσ  and 2eσ , the variance components, which can be used to 
calculate intraclass correlation coefficient (ICC) as following: 
22
2
eu
uICC σσ
σ
+=          
   The value of  ICC ranges between 0 and 1 and indicates the fraction of total variance 
that can be attributed to between-country variation (Manca et al., 2005). 
Shrinkage estimation  
   Country-level estimates (slope and intercept) are facilitated through shrinkage 
estimation. The random term Cku  is a latent variable and is derived in the parameter 
estimation process. The raw residual of variance component model can be calculated as  
ijkijk CCijk
r φφ ˆ−=          
where 
ijkC
φ - observed cost of ith patients from country k and 
ijkC
φˆ is estimated cost . 
The raw residual kr of the country kth is calculated as the mean of ijkr over all patients in 
the country. Shrinkage estimation of the country-specific residuals is calculated as 
following: 
  
 104
[ ] kkeu ujk rnu ×+= )/(ˆ 22
2
σσ
σ
      
   The multiplier kr  ranges between 0 and 1 so that the estimated residual cannot exceed  
the raw residual for a specific country. This multiplier is referred to as the “shrinkage 
factor”, which will be noticeably less than one, when 2eσ is large relatively to 2uσ , or 
when kn is small or both. In either case we have relatively little information about the 
particular country, where the outcomes are very variable or there are just few patients, 
and raw residuals are “shrunk” toward the overall mean. The countries with small 
sample size and/or unreliable estimates are “borrowing information” from the other 
countries with less uncertainty in their estimates. Shrinkage estimation can be 
considered as compromise between fully pooled and fully splitted approach, trial-wide 
mean and the country-level estimates (Goldstein, 1999; Manca et al., 2005; Willan et 
al., 2005). 
Estimation of hierarchical models  
   Hierarchical models can be estimated in different ways. Widely used method is 
maximum likelihood, which rely on assumption of normally distributed random 
coefficients of the model and requires large dataset. Another commonly used option is 
estimation via generalized least squares or an iterative version of it, which will provide 
same results as maximum likelihood, if random effects are normally distributed. Latest 
development of computational options allowed for full Bayesian analysis with 
employment of Markov Chain Monte Carlo (MCMC) methods using Gibbs sampling, 
which are applied to estimate our case study models using the software WinBUGS 
(Goldstein, 1999; Manca et al., 2005). The main differences between traditional and 
Bayesian approaches are outlined in the next section. 
Bayesian analysis 
   Traditional “frequentist” estimation with maximum likelihood and Bayesian analysis 
as implemented in WinBUGS software with MCMC procedure, are distinctive in their 
underlying basis. In this section, we discuss only selected aspects about the 
understanding of parameters, distribution and inference. The important difference 
between Bayesian and frequentist approaches is that Bayesians refer to the model 
parameters as randomly distributed unknown values with some probability distribution. 
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In contrast, frequentists understand parameter values as unknown, but fixed without 
probability. The difference in understanding of the nature of the parameters is translated 
into distinctive interpretation of probability. Bayesian statistic refers to probability as a 
“degree of belief”, whereas frequentist statistics rely on relative frequency, e.g  many 
repeating observations (e.g. “throwing the dice” many times). The distinctions between 
understanding of parameters and probability are reflected in different approaches to 
inference. P-value is essential for frequentist analysis and describes conditional 
probability to observe more extreme values provided the studied hypothesis is true P(Y 
≥ c | H0 is true). Bayesian analysis focus on validation of conditional probability based 
on known evidence and observed data. Conditional probability P(H1 is true | Y) 
describes probability of the event provided available evidence, knowledge or opinions. 
Posterior probability adjusts our “degree of belief” into particular event given the old 
evidence updated with new information.  
   Formal expression of Bayes’ theorem is the following:  
P(η | Y) ∞ P(Y | η) P(η), where η represents the model parameters, Y the observed data, 
P(η | Y) the posterior density function. 
   The posterior density function contains probability of different value sets for η given 
the observed data and is basis for Bayesian statistical inference. It is proportional to the 
product of the likelihood of the data given the model parameter P(Y | η) and the 
marginal density for η, P(η). Prior density function P( η) is informed by available 
evidence or prior knowledge. As the point estimate for η in WinBUGS, we may take the 
mode (analogous to the maximum likelihood), the mean or the median of this density. 
The interval of  2.5th and the 97.5th percentile of the posterior density provides 95% 
credibility intervals. Credibility intervals are corresponding to “frequentist” confidence 
intervals in the large datasets (van der Berg et al., 2006; Fryback et al., 2001; 
Spiegelhalter et al., 1996). 
Advantages of Bayesian approach for the case study analysis 
   One advantage of application Bayesian MCMC for parameter estimates in our case 
study is that it calculates outcomes in an appropriate form for estimation of cost-
effectiveness acceptability curves (Fenwick et al., 2004). Cost-effectiveness 
acceptability curves provide the probability that the intervention is cost-effective as a 
function of willingness-to-pay of the decision maker. This data can be estimated from 
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the posterior distribution of incremental net monetary benefit (Manca et al., 2005). The 
other advantage of MCMC is it particular application to small samples. Maximum 
likelihood estimation rests on assumption that studied sample size is sufficiently large. 
Using MCMC in small samples directly accounts for uncertainty around the values of 
the random parameters and provides the exact measures of this uncertainty with 
respective credibility intervals (Goldstein, 1999). 
 
3.7 Summary of Chapter 3 
   This section provided overview of methods to improve generalizability used in 
published health economic evaluations and international guidelines, and presented the 
methodology used in patient-level case study. 
Generalizability of health economic evaluations is recognized issue in health 
economic literature and international guidelines.  
   Review of health economic guidelines and published health economic studies 
indicates that the issues is acknowledged by academics, industry and international 
decision-makers. Understanding of variability and improving generalizability of health 
economic evidence is supporting efficient resource allocation in research and informed 
decision-making in policy.  
Various clinical and wider non-clinical variability factors are potential sources of 
between-country heterogeneity. 
   Number of publications describes patient, disease, health care system and 
methodological factors, which may contribute to differences in cost-effectiveness results 
across locations and over the time. Several methods are proposed to deal with variability 
and to improve generalizability in patient-level studies and decision models.  
Decision modelling is complementary analytical “vehicle” to the patient-level 
studies to improve generalizability, as it facilitates synthesis of data from different 
sources.  
   Decision models provide the framework to apply generalizability methods to construct 
cost-effectiveness results for the long-term therapies, simulate results for the non-trial 
locations and adjust trial results to reflect routine clinical practice. Models facilitate 
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calculation of setting-specific cost-effectiveness, also for the cases, where the relative 
treatment effect is not available from the particular setting. Generalizability of input 
parameters collected in other locations is subject to uncertainty, which can be 
appropriately reflected and tested within sensitivity analysis in decision modelling 
framework. 
Patient-level studies should address generalizability at study design, analysis and 
report phases. Homogeneity test and regression methods are suggested for data 
analysis. 
   In the patient-level studies, the generalizability issue is to be considered at the study 
design stage in order to minimize artificial research bias. Several statistical tools, such 
as homogeneity tests and regression based methods, were applied in the analysis of the 
selected multinational studies. Further development of hierarchical regression methods 
is anticipated avenue for future research on generalizability methods. The appraisal 
methods and checklists are available to assess relevance of published evidence for 
decision-making in a specific setting.  
Only few studies considered generalizability in the analysis. This topic should be 
addressed in future research.  
   The application of the generalizability techniques in the decision modelling and 
patient-level studies could have different implications for analysis and results across 
clinical indications and therapies. Available methods were developed and/or applied in 
particular studies in specific clinical indications. Further research needed to test these 
methods in other clinical “environment” in the different patient-level studies.  
Homogeneity test and hierarchical models are applied in the case study to improve 
generalizability of the outcomes collected in multinational setting. 
   Case study is based on secondary analysis of the patient-level data collected in 
multinational context to compare efficacy of two antibiotic treatments. We selected 
homogeneity test and hierarchical models to explore between-country variability and 
potential improvement of generalizability within and beyond study setting. 
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4 Case Study 
 
   In previous sections we reviewed theoretical foundations of health economic methods 
and practical recommendations and implementation of different approaches to address 
generalizability issue in international guidelines and health economic literature. 
Following chapter will demonstrate application of selected generalizability methods in 
the secondary analysis of the multinational patient-level study. We first provide 
motivation and objectives of the case study, followed by description of dataset and case 
study results.  
4.1 Case Study Objectives 
Purpose of research and case study objectives 
   The purpose of the thesis is to explore the methods to improve generalizability of 
health economic evaluations and can be specified in the terms of two following research 
objectives: 
1) To identify methods to explore heterogeneity and to improve generalizability applied 
in published health economic evaluations conducted in multinational settings.  
2) To apply selected methods to the patient-level data in a case study to investigate 
between-country variability of cost-effectiveness parameters, heterogeneity factors 
explaining between-country heterogeneity and to calculate country-level and trial-wide 
cost-effectiveness estimates. 
   We addressed the first objective in the literature review, described in the previous 
section. Homogeneity test and hierarchical models are recommended by recent health 
economic literature as tools to explore variability and to improve generalizability. The 
need to gain more inside about using these methods for health economic analysis in 
different indications, treatment patterns and settings has been acknowledged. To address 
the second research objective, we apply selected methods in the case study, based on 
secondary analysis of a multinational study to investigate efficacy and safety of 
sequential intravenous/oral moxifloxacin (the treatment) in comparison to sequential 
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intravenous/oral co-amoxiclav (the comparator) with or without clarithromycin in the 
treatment of patients with community-acquired pneumonia.  
   Analytical approach for the case study could be essentially described by the following 
steps: (1) assessment of between-country variability, (2) quantification of major 
heterogeneity factors, (3) estimation of country-level and trial-wide parameters and (4) 
based on heterogeneity factors and country-level estimates, assessment of feasibility to 
generalize results to non-study settings. In detail, the case study research objectives are 
specified in Table 4. 
Table 4: Research Objectives of the Case Study 
Nr Objectives Methods 
1 To provide crude mean and incremental costs and 
effectiveness estimates based on trial-wide and country-
level patient data analysis. 
Descriptive statistics 
2 To provide crude analysis of patient-level and country-
level heterogeneity factors, which are likely to have effect 
on costs and effectiveness estimates. 
Descriptive statistics 
3 To assess qualitative country-by-treatment interaction in 
incremental costs, effectiveness, resource use and NMB. 
Qualitative homogeneity 
test 
4 To assess quantitative country-by-treatment interaction in 
incremental costs, effectiveness, resource use and NMB. 
Quantitative 
homogeneity test 
5 To determine degree of within-country clustering. Variance component 
model ICC 
 
6 To calculate trial-wide and country-level estimates of the 
incremental cost and effectiveness using patient-level data 
while accounting for within country clustering. 
 
Hierarchical models for 
cost-effectiveness 
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Nr Objectives Methods 
7 To calculate trial-wide and country-level estimates of the 
incremental cost and effectiveness using patient-level data 
while accounting for within country clustering and 
controlling for patient-level and country-level covariates. 
Hierarchical models for 
cost-effectiveness with 
covariates 
8 To explore and assess model fit after country- and patient- 
level covariates adjustment.  
Hierarchical models 
with and without 
covariate 
9 To assess covariates effects on mean and incremental 
costs and effectiveness estimates and possibility to 
generalize results of  the study to non-study settings on 
hand of explored covariates (external generalizability). 
Hierarchical models 
with covariates 
10 To calculate cost-effectiveness acceptability curves based 
on estimates from models without and with covariates.  
Hierarchical models 
with and without 
covariate 
11 To calculate trial-wide and country-level estimates of the 
incremental LOS using patient-level data and accounting 
for within country clustering. 
Hierarchical models for 
LOS 
12 To calculate trial-wide and country-level estimates of 
LOS using patient-level data and accounting for within 
country clustering while controlling for patient-level and 
country-level covariates. 
 
Hierarchical models for 
LOS with covariates 
13 To explore and assess model fit after country- and patient- 
level covariates adjustment.  
Hierarchical models for 
LOS with and without 
covariates 
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Nr Objectives Methods 
14 To assess covariates effects on mean and incremental 
LOS estimates and possibility to generalize results of  the 
study to non-study settings on hand of explored covariates 
(external generalizability). 
Hierarchical models for 
LOS with covariates 
 
   The case study research is of explorative nature and is not deemed for primarily cost-
effectiveness analysis. Thus, no a priori hypothesis are formulated, if not otherwise 
specified.  
 
4.2 Dataset 
4.2.1 Data Sources and Management 
   Case study is based on a secondary analysis of a multinational, prospective, 
randomised, open study to investigate the efficacy and safety of sequential 
intravenous/oral moxifloxacin (the treatment) in comparison to sequential 
intravenous/oral co-amoxiclav (the comparator) with or without clarithromycin in the 
treatment of patients with community-acquired pneumonia requiring initial parenteral 
treatment (BSP study report, 2000). The study and all clinical work were conducted in 
accordance with Good Clinical Practice for Trials on Medicinal Products in the 
European Community (EMEA, 2002). Local and Central Ethic Votum were obtained 
before the start of the study as well as patient’s informed consent to participate in this 
clinical trial. The results of primarily analysis are published elsewhere (Finch et al., 
2002; Drummond et al., 2003).  
   Patient-level clinical database, report and unit costs for UK, Spain, Germany and 
France for secondary analysis for application of generalizability methods were received 
from Bayer Schering Pharma. Data management, collection of unit costs for 
Switzerland, country-level covariates and complete analysis was performed by the 
author. Resource use valuation and costing was performed in Eclipse JAVA application. 
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Calculation of total costs and resource utilization was done by the author and may 
deviate from results of primary analysis.  
   Descriptive statistics and calculation of ICC have been performed with Stata software 
package version 9 (StataCorp, 2005). Descriptive analysis (frequencies, means, and 
standard deviations) was done to examine the demographics and baseline characteristics 
of the subjects. Explorative bivariate inferential statistics was performed in form of t-
test for continuous variables and chi2 test for binary or categorical variables. The a 
priori level of significance was 0.05 for all statistical tests. All tests were two-tailed 
unless otherwise specified. Calculation of ICC was performed by fitting the variance 
component model using loneway procedure in Stata without covariates. 
   Estimation of hierarchical models was facilitated by Markov Chain Monte Carlo using 
WinBUGS software. WinBUGS code was adapted from the model by Willan and 
Kowgier (2007) and is given in the appendix. If not otherwise specified, the posterior 
mean estimates and 95% credibility intervals were obtained from MCMC estimation 
running 2 chains for minimum 50,000 iterations following a burn-in period of a 
minimum 20,000 iterations. WinBUG’s Gelman-Rubin diagnostics was used to validate 
convergence (Spiegelhalter et al., 2003). 
   Incremental cost and effectiveness were estimated using 3 hierarchical models: model 
1 (HM1) without covariates, model 2 (HM2) with complete set of country- and patient-
level covariates, model 3 (HM3) with the patient-level covariates only. Analogue to 
incremental cost and effectiveness models, we estimated incremental LOS using 3 
hierarchical models: model 4 (HM4) without covariates, model 5 (HM5) with complete 
set of country- and patient-level covariates, model 6 (HM6) with the patient-level 
covariates only. Crude or “naïve” estimates are calculated using country-specific data 
sub-samples.  
   Bivariate correlation for continuous covariates was done to check for extreme 
multicollinearity. Results are provided in appendix. Notably, some degree of 
collinearity could be tolerated, since the continuous covariates are centered around trial-
wide means. However, no evidence for strong linear correlation between the covariates 
could be found. 
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4.2.2 Indication 
   Community-acquired pneumonia is an infectious disease acquired in social and 
community places other than clinical or long-term care institutions. The morbidity and 
mortality associated with CAP is high. In Germany, approximately 350,000 to 500,000 
cases of CAP are reported each year (Ewig et al., 2002), while over 700,000 patients per 
year are affected in France (Mark, 2008). Study conducted in US estimated incidence as 
of 5.6 million cases per year, of those ca. 20 % required inpatient care (Niederman et 
al., 1998; 2001). In UK, about 50,000 CAP patients annually required hospitalization 
(British Thoracic Society, 1993). Mortality for inpatient population is 2-21% and 
increases to over 50% for the severe CAP patients (Marrie, 1998; Bartlett & Mundy, 
1995). 
   In approximately 30 to 60% of CAP patients diagnostic tests fail to identify the 
targeted pathogen, therefore the empiric approach to the CAP therapy is needed. 
Guidelines developed by the British and American Thoracic Societies in 1993 
recommend that empiric therapy for CAP to provide coverage against Streptococcus 
pneumoniae, the most common cause of CAP (British Thoracic Society, 1993; 
American Thoracic Society, 1993). 
   The economic impact of CAP on the health care systems is high because of associated 
effects, such as excess of hospitalization for certain underlying conditions, heart failure 
and long-standing deterioration of health. Burden of illness study conducted in UK 
estimated direct health care costs at approximately 441 GBP million per year in 1992-
1993. Inpatient care contributed to major proportion of the total annual cost. The mean 
costs of outpatient clinical case was ca. 100 GBP, whereas inpatient management 
required 1700-5100 GBP (Guest & Morris, 1997).  
   A recent study from Spain analyzed information from the national surveillance 
hospital data during two-years period.  Study concluded that CAP accounted for 53,000 
hospitalizations with cost to the Spanish health care system of approximately 140 
million USD per year (Monge et al., 2001). 
   In the US, the annual CAP costs were estimated around 8.4 billion USD. 
Approximately half of the total costs was paid for hospital services. The mean duration 
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of hospitalization varied between  5.8 days for those under 65 years of age and 7.8 days 
for older patients (Niederman et al., 1998). 
   Antibiotics account for a small portion of the total costs of CAP treatment. Given the 
differential for hospital versus outpatient treatment in most countries, treatments, that 
reduce the length of hospitalization, may result in significant cost-savings for the health 
care system. This concept has been confirmed in several economic studies in which 
CAP treatments, that resulted in shorter lengths of stay, created cost-savings without 
affecting patient outcomes (Palmer et al., 2000; Dresser et al., 2001; Coughlin et al., 
2003). 
 
4.2.3 Clinical Study Design 
   The clinical study was a multinational, multicentral, randomized, open label, phase III 
study designed to examine the safety and efficacy of sequential intravenous (IV)/oral 
(PO) moxifloxacin (the treatment) compared to a standard regimen of sequential IV/PO 
co-amoxiclav with or without clarithromycin (IV or PO) (the comparator) in the 
treatment of CAP in adult patients requiring initial parenteral therapy. Collection and 
assessment of resource use data was a secondary objective of this clinical study. The 
study started in February 1999 and completed in May 2000, enrolling a total of 628 
patients. Patients were screened and randomized at 65 centers from 10 countries: 
Germany (19% of patients), Greece (16%), Israel (13%), South Africa (12%), and 
France (10%), followed by the United Kingdom (9%), Switzerland (8%), Spain (7%), 
Belgium (4%), and Russia (2%). 
   Clinical characteristics of the patient population enrolled into the study included the 
following: 
• Patients aged 18 years or above. 
• Patients requiring initial parenteral treatment whose clinical condition suggested that 
they would require at least 3 days of intravenous therapy. 
• Patients who were willing and able to provide written informed consent. 
• A diagnosis of CAP was to be confirmed on an out-patient basis or within 48 hours 
after hospital admission. 
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• Signs and symptoms of pneumonia (patients were to have evidence of categories, 
A,B and C): 
A. Fever (core temperature > 38.5C and/or oral temperature > 38C) and/or 
leucocytosis (WBC > 10000/mcl) and/or left shift (>=15% band forms). 
B. One or more of the following characteristics: productive cough, purulent 
sputum, dyspnoea or tachypnoea (>20 breaths/minute), rigors/chills, pleuritic chest pain, 
auscultation findings consistent with pulmonary consolidation. 
C. Radiological evidence of an infiltrate consistent with pneumonia. 
 
   Disease severity was stratified as following: 
Stratum 1: The status of mild to moderate community-acquired pneumonia was 
assigned to patients not eligible for stratum 2.  
Stratum 2: Severe community-acquired pneumonia: presence of at least one of the 
following conditions: 
• Respiratory rate >30 breaths/minute 
• Hypoxaemia with PO2 <8 kPa (60 mmHg) 
• Requirement for mechanical ventilation 
• Chest radiograph showing bilateral involvement or involvement of multiple lobes 
• Diastolic blood pressure <=60 mmHg 
• Requirement for vasopressors for more than 4 hours 
   Patients received either treatment or comparator intravenously for a minimum of 3 
days. At any time after this, following assessment by the investigator, the patient could 
be switched to oral therapy.  Treatment was to last for a minimum of 7 days, and for a 
maximum of 14 days (Finch et al., 2002; BSP study report, 2000). 
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4.2.4 Patient Population 
   622 patients (99.0%) of the 628 patients enrolled were correctly randomised and 
received at least one dose of study medication, hence they were eligible for the 
intention-to-treat population (ITT). 301 patients were in the treatment group and 321 
patients were in the comparator group. 6 patients were excluded from the ITT analysis: 
1 patient was excluded due to a randomisation error, 4 patients were excluded since they 
received no study medication and 1 patient was excluded due to previous enrolment in 
the study. 
   Following numbers of patients were observed in each race class for the ITT 
population: 
 “Caucasian”   507 patients (81.5%) 
 “Black”   48 patients (7.7%) 
 “Asian”   3 patients (0.5%) 
 “Other”   1 patient (0.2%) 
 “Not documented ”   63 patients  (10.1%)  
   In France local regulations prohibit the documentation of race. Similar profile is being 
observed within the two treatment groups. The baseline comparability of the treatment 
groups is presented in Table 5. 
Table 5: Baseline Parameters of Treatment Groups 
Mean ± standard deviation or frequencies Variable, categories 
Treatment Comparator Total 
p-value 
Sex Male 193 (64.1%) 207 (64.5%) 400 (64.3%) 0.92 
  Female 108 (35.9%) 114 (35.5%) 222 (35.7%)   
Mild/Mod 143 (47.5%) 158 (49.2%) 301 (48.4%) 0.67 Disease 
severity 
Severe 158 (52.5%) 163 (50.8%) 321 (51.6%)   
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Age (years) (55.2 ± 20.6) (55.9 ± 19.6) (55.6 ± 20.1) 0.65 
Weight (kg) (72.2 ± 15.6) (72.4 ± 17.1) (72.3 ± 16.4) 0.85 
Temperature (°C) (38.7 ± 0.9) (38.8 ± 1.0) (38.8 ± 1.0) 0.46 
Respiration rate (bpm) (24.4 ± 7.0) (25 ± 7.1) (24.7 ± 7.1) 0.22 
Hospitalisation  No 148 (49.2%) 156 (48.6%) 304 (48.9%) 
pre-therapy Yes 153 (50.8%) 165 (51.4%) 318 (51.1%) 
0.89 
No 217 (72.1%) 229 (71.3%) 446 (71.7%) Pre-existing broncho-pulmonary 
disease 
Yes 84 (27.9%) 92 (28.7%) 176 (28.3%) 
0.84 
Smoking Never 123 (40.9%) 122 (38.0%) 245 (39.4%)   
History  Passive 1 (0.3%) 3 (0.9%) 4 (0.6%)   
  Previous 91 (30.2%) 92 (28.7%) 183 (29.4%)   
  Smoker 86 (28.6%) 104 (32.4%) 190 (30.5%)   
Abstinent 156 (51.8%) 159 (49.5%) 315 (50.6%) 0.41 
Light 110 (36.5%) 116 (36.1%) 226 (36.3%)   
Moderate 29 (9.6%) 31 (9.7%) 60 (9.6%)   
Heavy 6 (2.0%) 14 (4.4%) 20 (3.2%)   
Alcohol 
consumption 
  
  
  
No data   1 (0.3%) 1 (0.2%)   
None 20 (6.6%) 26 (8.1%) 46 (7.4%) 0.89 
Mild 82 (27.2%) 90 (28.0%) 172 (27.7%)   
Moderate 151 (50.2%) 149 (46.4%) 300 (48.2%)   
Severe 48 (15.9%) 56 (17.4%) 104 (16.7%)   
Cough  
  
  
  
  
Present 1 (0.3%) 1 (0.3%) 2 (0.3%) 
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None 57 (18.9%) 53 (16.5%) 110 (17.7%) 0.7 
Mild 87 (28.9%) 87 (27.1%) 174 (28.0%)   
Moderate 95 (31.6%) 112 (34.9%) 207 (33.3%)   
Severe 62 (20.6%) 69 (21.5%) 131 (21.1%)   
Dyspnoea  
Present   1 (0.3%) 1 (0.2%)   
 
   Of the 622 patients valid for the intention-to-treat population 400 (64.3%) were male 
(193 and 207 in the treatment and comparator treatment groups respectively) and 222 
(35.7%) were female (108 and 114 in the treatment and comparator treatment groups 
respectively). Of the 622 intention-to-treat patients 301 patients (48.4%) (143 and 158 
in the treatment and comparator treatment groups respectively) had mild to moderate 
CAP and 321 (51.6%) of the ITT patients had severe CAP (158 and 163 in the treatment 
and comparator treatment groups respectively). Three hundred and eighteen of the 622 
ITT patients (51.1%) were hospitalized pre-therapy (153 (50.8%) and 165 (51.4%) in 
the treatment and comparator treatment groups respectively).  There was no statistically 
significant difference between treatment groups in relation to the incidences of 
hospitalization, p=0.8859. The majority of patients had coexisting medical histories, 258 
(85.7%) and 282 (87.9%) in the treatment and comparator treatment groups 
respectively. The most frequently observed conditions related to the endocrine, 
nutritional, metabolic and immunity system (69 (22.9%) and 87 (27.1%) in the 
treatment and comparator treatment groups respectively), circulatory system (135 
(44.9% and 132 (41.1%) in the treatment and comparator groups respectively) and 
respiratory system (124 (41.2%) and 129 (40.2%) in the treatment and comparator 
treatment groups respectively). 84 (27.9%) and 92 (28.7%) of the treatment and 
comparator treatment groups respectively had coexisting broncho-pulmonary disease 
giving a total of 176 (28.3%). 451 patients were febrile at the start of the study 
(temperature >= 38.5 C) (215 (71.4%) and 236 (73.5%) in the treatment and comparator 
groups respectively). Overall, the two treatment groups were well comparable with 
regard to demographic and baseline characteristics (findings verified with BSP study 
report, 2000). 
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4.2.5 Estimation of Effectiveness Outcome 
   Patients enrolled in the study were followed until 21 to 28 days after the last study 
drug intake. The maximum time period to the test of cure (TOC) visit of 21 days (i.e. 14 
days maximum treatment followed by 7 days follow-up) was selected for the economic 
evaluation time frame since it corresponded to the primary clinical efficacy measure 
(i.e. clinical assessment at TOC visit). 
   Efficacy endpoints were defined as following: 
• Clinical cure: Resolution of clinical symptomathology related to the infection 
without requirement of further antibacterial therapy.  
• Clinical failure: Death due to CAP, failure or partial response to the study drug 
treatment, requiring a modification or extension of antibacterial therapy. 
• Indeterminate: Patients in whom a clinical assessment was not possible to 
determine (e.g. due to early withdrawal from the study because of adverse 
events, protocol violation, withdrawn consent, etc.). 
   The overall treatment effectiveness measure was the proportion of patients cured 
based on the primary efficacy parameter: the clinical response to study drug at the TOC 
visit (i.e. 5 to 7 days post-treatment) (Finch et al., 2002). The most conservative 
approach was used to estimate clinical effectiveness, considering all patients with the 
outcome of indeterminate or missing as clinical failures. 
 
4.2.6 Estimation of Resource Use and Costs  
   The economic analysis was conducted from the perspective of the health care 
providers: the mandatory German Sickness Funds (Gesetzliche Krankenkassen 
Versicherung (GKV)), the French public health insurance sector, the Spanish National 
Health System, the UK National Health Service (NHS) and Swiss Statutory Health 
Insurance. The timeframe of economic evaluation are years 1999 - 2001. It was 
assumed that all patients in the study would have been eligible for coverage under each 
of these public health insurance plans. Health economic analysis from societal 
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perspective was not performed due to unavailability of data for indirect costs. In 
following we outline organization of health care in respective countries in 1999-2001 
and summarize costing approach for individual resource use. 
Description of health care systems in UK, Spain, Germany, France and 
Switzerland 
   In Germany, health care is funded by membership of sickness funds. The health care 
system requires that all working people have health insurance provided by the 
mandatory sickness funds (GKV), with membership fees divided equally between 
employer and employee. The GKV covers a wide range of health care services 
including hospitalizations, inpatient procedures, rehabilitation, and medications, with 
respective patient co-payments associated with each health care service.  
   The French health care system is primarily funded by national sickness insurance 
funds, which are part of the social security system. The insurance funds are financed by 
compulsory payroll contributions of employers and employees. National insurance 
provides for a wide range of outpatient and hospital services, pharmaceutical therapies 
and other essential care needs. Approximately 75% of health expenditures are accounted 
for by the insurance funds, with the remainder covered by the central government, 
patient co-payments, and Mutual Insurance Funds, which provide private supplemental 
insurance coverage.  
   The Spanish National Health System is financed out of general taxation. Coverage is 
almost universal for citizens of Spain and includes extensive list of services and care to 
all citizens regardless of personal wealth. Benefits include general medical care at 
doctors’ offices and patients’ homes, outpatient and inpatient care including all medical 
and surgical specialties in acute care, prescription medications with patient co-payments 
of up to 40% for those received out of hospital, and complementary benefits such as 
prostheses, orthopedic products, and wheelchairs. Individuals may chose to have 
membership in an alternative, employment-linked insurance program, and also have the 
option of purchasing additional private insurance. 
   The NHS in the UK is financed out of general taxation, employers and employees via 
the National Insurance Scheme. All UK citizens are provided coverage for inpatient 
care, outpatient care, and medications. In addition, is it possible to buy private health 
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care insurance which is fully paid by the insured or which can be provided (as a benefit) 
by employers to employees, in which case the employer bears all costs. 
   Swiss health care is funded by a system of public-private statutory health insurance, 
where country's 26 cantons (regions) and more than 3000 communes (municipalities) 
have substantial power with regard to financing and management of the health care 
system. Individual cantons act as the main financers for around 80% of hospitals within 
the public sector. Health care spending is financed primarily by the Statutory Health 
Insurance system (SHI) and supplementary private insurance. SHI system generates 
around 40% of total health expenditure. Around 35% of the population purchases 
voluntary supplementary health care insurance in addition to the statutory insurance 
system for dental, travel, and other items not covered via the statutory system's basic 
basket of services. Procedures related to treatment of acute conditions, such as CAP, 
would be covered by statutory service to a large extend (IHS Global Insight, 2008; 
Drummond et al., 2003; BSP study report, 2000; WHO European Centre for Health 
Policy, 2008). 
Estimation of CAP-related resource use and cost 
   Resources were valued using 1999-2001 unit costs and reimbursement rules from 
Germany, France, Spain, UK and Switzerland to determine CAP-related cost to each 
country’s health care system. Unit costs for Germany, France, UK and Switzerland were 
collected in German Deutsche Marks (DM), French Francs (FF), British Pounds and 
Swiss Francs (SFr) and total costs for each resource component were converted into 
EUR using the conversion rates of 1 DM = 0.5113 EUR, 1 FF = 0.1524 EUR, 1GBP = 
1.5674 EUR and 1SFr = 0.657 EUR (Bank of Canada, 2008). Unit costs for Spain were 
collected in EUR. Exchange rates were used, since they more accurately reflect what a 
domestic buyer has to pay for a product or service within the country. The valuation of 
costs with purchasing power parity for West European Countries would not have major 
impact on estimates due to very small variation in coefficients between the countries 
(Musgrove & Fox–Rushby, 2006; OECD, 2009).  
   The CAP-related cost included study medication, hospitalizations, concomitant and 
follow-up CAP-related medications, radiological procedures, and therapeutic adjuncts 
over the 21-day evaluation time frame. Protocol-related costs associated with study 
visits were not included into the total cost estimation. From clinical perspective, both 
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evaluation timeframe as well as study procedures are considered representative for 
general medical practice for CAP treatment with antibiotics. Economic analysis was 
integrated part of the research objective and protocol-driven utilization and sufficient 
observation timeframe were considered during the study design phase (Drummond et 
al., 2003; BSP study report, 2000). Following section summarize major aspects of 
costing approach, detailed unit costs and data sources are provided in attachment. 
Estimation of the study medication costs  
   Utilization of study medication was determined for each patient based on the 
compliance record within the case report form where the day, time, and route of each 
dose were recorded. The number of days of study medication use was determined 
considering all days within the 21-day evaluation time frame upon which at least one 
dose of study medication was received. The cost per patient was determined by 
multiplying the actual number of doses received by the cost per dose. Although the cost 
of medications received in hospital are likely to differ from those received out of 
hospital due to contract negotiations between hospitals and suppliers, this information is 
not publicly available and would be highly variable between the hospitals. Therefore, 
the public price of study medications was assumed for all doses received both in 
hospital and following hospital discharge. Only doses received out of hospital were 
subjected to local reimbursement rules.  
   For comparator medications in Germany, a weighted cost was assumed for the oral 
forms of co-amoxiclav and clarithromycin based on the current market share of brand 
and generic name products. For co-amoxiclav IV, the price of branded product was 
assumed. For the study medication received out of hospital, a patient co-payment of 
4.60 EUR per package was subtracted to obtain the cost to the German health care 
system.  
   For the French analysis, the costs of branded products were used for the IV and PO 
forms of co-amoxiclav and clarithromycin. A reimbursement rate of 65% was applied to 
all doses received out of hospital to represent the cost to the public health insurance 
funds.  
   For the comparator medications in Spain, a weighted cost was assumed based on the 
current market share of brand and generic name products. For all medications received 
out of hospital, patients pay 40% of the cost with the exception of specific groups for 
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which there are no out-of-pocket payments. These groups include the retired (age 65 
and over), the handicapped, invalids, and people who have suffered occupational 
accidents. Although it was not possible to identify the proportion of study patients who 
were handicapped, invalid, or had suffered occupational accidents, the proportion of 
study patients under the age of 65 years was determined and a weighted reimbursement 
rate of 76% was calculated. Hence, for all doses of study medications received out of 
hospital, a reimbursement rate of 76% was applied to obtain the cost to the Spanish 
health care system.  
   For the UK analysis for all comparator medications, a weighted cost was assumed 
based on the current market share of brand and generic name products with the prices 
obtained from official sources: the Drug Tariff and the British National Formulary. 
These two sources also list prices for generic medications. Prescription pharmaceuticals 
are not subject to value added tax. For medications dispensed in the community, 100% 
reimbursement was assumed. In practice, this assumption is not strictly true because 
non-exempt patients pay a co-payment of 9.72 EUR per prescription item. However, it 
was not practicable to identify the proportion of non-exempt patients in the study and 
normal UK practice in economic evaluations is to assume 100% reimbursement. In 
hospital, the true acquisition prices of medications are not known as listed prices are 
subject to discounts negotiated either with the wholesaler or the manufacturer. It was 
therefore assumed that the published basic NHS prices prevailed in hospital.  
   For Swiss analysis, costs of the medication to the health insurance were reduced by 
10% co-pay. Hospital prices of the drugs are most likely to be different from the public 
prices. Suppliers have a special interest that their drugs are prescribed in hospital since 
this is generally the first location where drugs are prescribed. Due to confidentiality of 
the price negotiations, hospital prices for medications are generally not publicly 
available. Thus, public price of the pharmaceuticals is assumed for in-patient care (HIS 
Global Insight, 2008; BSP study report, 2000; WHO European Centre for Health Policy, 
2008). 
Estimation of hospitalization duration and costs 
   The number of days of hospitalization by ward type within the 21-day time frame was 
determined for each patient based on the number of days between the admission and 
discharge dates recorded in the case report form (CRF). Any readmissions within the 
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evaluation time frame were also included in the total. The cost of hospitalization was 
determined for each patient by multiplying a daily cost of hospitalization by the number 
of days spent in each ward. Separate per diems were obtained for stays in an  intensive 
care unit (ICU) and in a general ward. All wards that were not identified as ICU in the 
CRF were assumed to have the same cost as the general ward since costs were not 
available for all ward types listed. Hospitalization costs included resources such as 
treatments received in hospital, medical procedures, laboratory tests, physician services, 
nursing care, board and lodging.  
   The costs obtained in Germany represented the average cost for all admissions, and a 
patient co-payment of 8.69 EUR per day was subtracted from the per diem for the first 
14 days (PKV, 1999/2000).  
   The costs obtained in France were based on weighted average per diem costs for 
appropriate diagnostic related groups in the public and private not-for-profit sectors, and 
a direct payment made by the patient to the hospital of 8.38 EUR per day was not 
included in the daily cost of hospitalization to the French health care sector (PMSI, 
2000).  
   The costs obtained in Spain represented the average cost for CAP  and related 
conditions from a variety of sources including literature estimates and hospitals 
(SOIKOS, 2001).  
   For the UK, fees for hospitalization were determined using the NHS Reference Costs 
2001 database, which consists of costs obtained from the NHS hospitals. The per diem 
values used in the study represented the average cost for bronchopneumonia patients 
treated in NHS trust hospital (NHS Reference costs, 2001/2002).  
   In Switzerland, basic general ward and ICU per diem cost were taken based on 
Taxordnung for Kanton St. Gallen (Taxordnung, 2002).  
   Since the hospitalization costs obtained from each country were fully allocated and 
included the cost of medications, in our analysis we removed the proportion of the total 
per diem represented by antibiotics. We included patient-specific study medication 
costs, which vary between treatment groups and may have impact on cost-effectiveness 
results.  
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   Estimation of total hospital costs and cross-country comparison is challenging due to 
different remuneration systems (DRG, per diem, capitation reimbursement contracts) 
employed in each country. In addition, there is variation due to local contracts between 
hospitals and e.g. municipal administrations. Thus, the costs of the comparable clinical 
cases may widely vary within and across countries. In the case study we calculated total 
costs assuming per diem remuneration in all countries assuming same unit costs for all 
hospital in the same country. This estimation may not truly reflect the actual costs per 
clinical case. However and since the assumption was consistent across all hospitals and 
countries, this imprecision should not have major implication for studying 
generalizability methods.  
Costs for concomitant medications  
   Out-patient use of CAP-related concomitant and post-therapy antimicrobials and other 
CAP-related concomitant medications was determined for each patient within the 21-
day evaluation time frame based on the start and stop dates recorded in the CRF. Only 
medications relevant to the direct treatment of CAP, as judged by a clinician, were 
included in the analysis. This included antimicrobials prescribed for pneumonia as well 
as other medications prescribed for the following indications: cough and congestion, 
dyspnea, fever, hypotension, pain, tachypnea, tachycardia, short ventricular tachycardia, 
bradycardia, pulmonary insufficiency, respiratory distress or insufficiency, cardiogenic 
shock (in case of septic shock), cardiac failure, respiratory acidosis, renal insufficiency 
related to CAP, electrolyte substitution, hyperkalemia, hypokalemia, dehydration, low 
magnesium, low phosphate, sepsis, and septic shock (BSP study report, 2000). Public 
prices for all CAP-related medications reimbursed by the German, French, Spanish, 
Swiss and UK health care systems were obtained from the following sources. For 
Germany, the source was the Rote Liste® (2001); for France: Vidal-Semp (2001); for 
Spain: Vademecum International (2001) and Portalfarma (2001); for Switzerland: 
Documed (2001) and for the UK: British National Formulary (2001) and NHS Drug 
Tariff (2001). Unit prices for the daily dosages consumed were multiplied by the 
durations of use within the time frame to obtain the cost for each medication. 
Appropriate reimbursement rates were applied to each medication cost to determine the 
cost from each health care perspective. Medications received in hospital were not 
valued separately as the hospitalization costs obtained were fully allocated and included 
medication costs.  
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Costs for out-patient radiological procedures  
   The number of out-patient, non-protocol driven radiological procedures conducted for 
the treatment of CAP was determined for each patient within the evaluation time frame. 
Relevant procedures reported by patients included chest X-ray and chest CT scan (Finch 
et al., 2002). The cost of each procedure was obtained from each country.  
   For Germany, the source was Gebührenordnung für Ärzte (GOA, 2000); for France: 
National Fee Schedule (NGAP, 2001) and  l'Union des Caisses Nationales de Sécurité 
Sociale (TIPS, 2001); for Spain: Base de datos de costes sanitarios (SOIKOS, 2001); for 
Switzerland: Tarmed (2002) and for the UK: NHS Drug Tariff (2001). 
   After applying the appropriate reimbursement rules, the cost was multiplied by the 
number of procedures completed to determine the cost of this component to each health 
care system. Inpatient radiological procedures were not valued separately since the cost 
of these services was included in the average daily hospitalization cost. 
Costs for out-patient therapeutic adjuncts  
   The number of days on which therapeutic adjuncts were received on an out-patient 
basis for the treatment of CAP was determined for each patient within the evaluation 
time frame. Procedures relevant to the analysis included aerosol breathing therapy, chest 
physiotherapy, inhalation therapy, nasal c-pap, and oxygen received via face mask or 
nasal cannula. For adjuncts received by a physiotherapist, it was necessary to estimate 
the number of treatments that would be received per week since only the start and stop 
dates for the entire treatment period were recorded on the CRFs. It was estimated by a 
clinician that, on average, patients would receive five 20- to 30- minute sessions per 
week. The cost of each adjunct (including professional time and supplies, where 
appropriate and available) was obtained from each country.  
   For Germany, the source was Physiotherapy offices in Northrhein-Westphalia (2001); 
for France: National Fee Schedule (NGAP, 2001) and Tarif Interministériel des 
Prestations Sanitaires (TIPS, 2001); for Spain: Base de datos de costes sanitarios 
(SOIKOS, 2001); for Switzerland: Physioswiss (2001); and for the UK: NHS Drug 
Tariff (2001) and Personal Social Services Research Unit (2001). 
   After applying the appropriate reimbursement rules, the cost was multiplied by the 
number of days of adjuncts received to determine the cost of this component to each 
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health care system. Inpatient therapeutic adjuncts were not valued separately since the 
cost of these services was included in the average daily hospitalization cost. Further 
details on unit costs estimates are listed in appendix.  
 
4.2.7 Advantages of the Dataset for Studying Generalizability 
Methods 
   This dataset offers several advantages for studying between-country variability and 
application of generalizability methods.  
• Heterogeneous multinational setting. 
Clinical and economic evidence was collected in standardized way as directed in 
common clinical protocol across 10 countries, which represent various settings with 
different clinical and socio-economic environment.  
• Acute condition with internationally defined diagnostic procedure. 
Community acquired pneumonia is an acute condition which may be considered as to 
limited extend exposed and influenced by the factors unobserved in clinical trial setting. 
The analysis of chronic conditions may be more challenging as the patients may get 
different diagnosis and treatment during the disease course, what may not be captured 
and studied within the clinical study timeframe.   
• Hospitalization is major resource use. 
In-hospital stay is the main cost-driving resource use for all health care settings. 
Inconsistency in costing methodology may introduce additional “technical” variability 
to the economic parameters. In fact, collection of unit costs for all 10 countries is 
resource intensive and difficult due to unavailability of unit costs data in some 
countries. Thus it is feasible to apply generalizability methods directly to resource use 
parameters such as length of hospitalization. 
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4.3 Results 
   This section provides results of the case study analysis per objective as defined in 
section 4.1. The results are presented as following. We first provide the summary of 
crude estimates for effectiveness, costs, LOS and covariates, followed by results of 
between-country qualitative and quantitative heterogeneity test. We then present results 
of hierarchical modelling for costs and effectiveness for 5 countries and LOS for the 
complete dataset of 10 countries. Finally, we present effects of country and patient-level 
covariates and discuss potential for external generalizability. 
 
4.3.1 Crude Country-Level Estimates 
Objective 1: Estimation of crude mean and incremental costs and effectiveness 
based on trial-wide and country-level data analysis. 
   Table 6, Table 7 and Table 8 present crude or “naïve” cost, effectiveness and LOS 
estimates calculated using country-level and trial-wide sub-groups. Cost estimates were 
calculated for 5 countries with available country-specific unit costs. Major resource 
utilization – hospitalization – and effectiveness data are calculated for all participating 
countries. Histograms for costs and LOS are provided to visually check distributional 
properties and skewness of the outcomes. 
   Recruitment of patients in different countries was unbalanced resulting in the smallest 
patient sample in Russia (12 patients) and the largest in Germany (118 patients) (Table 
7). Small country-level samples do not allow for robust resource use and cost-
effectiveness analysis in all participating countries using the patient data from these 
respective countries only.  
   Brief inspection of country-level data for incremental costs, net monetary benefit, 
effectiveness and LOS in Table 6, Table 7 and Table 8 indicate potential between-
country heterogeneity. New treatment is cost saving in Germany, UK, France and 
Switzerland, but not in Spain. The magnitude of cost saving is strongly pronounced in 
France (-1191.84 EUR) and UK (-979.16 EUR), to a smaller extent in Switzerland (-
219.90 EUR), whereas the data for Spain suggests the comparator is cost saving over 
the treatment (80.40 EUR). As shown on histograms (Figure 9), cost data are skewed to 
the right. Similar data shape can be observed for data distribution on treatment- and 
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country- levels as shown on the diagrams in appendix. Not-normal distributions was 
confirmed by significant Shapiro-Wilk test (p< 0.001). This fact is relevant for the 
regression analysis. Nevertheless, arithmetic mean and t-test are robust to violation of 
the normality assumption and could be considered informative for the country-level 
analysis. 
   Similarly to the costs, there are differences across the countries in mean and 
incremental effectiveness (Table 7). Mean country-level effectiveness varies from 0.58 
in Belgium to 0.92 in Greece in treatment arm and from 0.62 in Switzerland to 0.86 in 
Spain in comparator arm. Treatment is more efficacious in Germany, Spain, UK, 
France, Greece, Israel and Russia, but has no pronounced difference or comparator is 
more efficacious in South Africa, Belgium and Switzerland.  
   Both mean and incremental LOS (Table 8) show potential differences between the 
countries with the longest mean LOS in Russia (12.60 days) and shortest in South 
Africa (4.03 days) in treatment arm and longest in Germany (12.68 days) and shortest in 
South Africa (4.20 days) in comparator arm respectively. Similar to the cost, LOS data 
are also skewed to the right as shown on histograms (Figure 10). Histograms on data 
distribution per treatment arm are provided in appendix.  
   Overall, country-level analysis indicates potential between-country differences in 
incremental effectiveness, costs and LOS, which could be attributed to either patient-
level (compositional) characteristics or underlying country-specific (contextual) factors.
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Table 6: Summary Data for Costs and Incremental Net Monetary Benefit 
Country 
N 
Treat 
N 
Comp N total C Treat SD Treat C Comp SD Comp 
Diff Treat-
Comp 95% CI  Ttest 
INMB 
(1000) 
DE 56 62 118 2476.25 1182.54 3033.07 1249.56 -556.82 -1001.65 -111.99 0.02 673.75
ES 22 21 43 2562.89 2036.24 2482.49 2344.68 80.40 -1270.21 1431.01 0.91 -73.91
UK 29 30 59 1683.74 903.65 2662.90 2251.43 -979.16 -1879.37 -78.95 0.03 1139.16
FR 30 34 64 5133.37 4520.42 6325.22 5814.00 -1191.84 -3820.03 1436.34 0.37 1260.84
CH 23 26 49 3088.41 1502.12 3308.31 2330.80 -219.90 -1363.60 923.80 0.70 213.21
5 CNTR 160 173 333 2930.73 2551.08 3590.42 3350.40 -659.69 -1305.51 -13.87 0.05 743.87
Note: Costs are calculated in EUR, N denotes number of patients, C - cost of treatment, INMB – incremental net monetary benefit 
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Table 7: Summary Data for Effectiveness: Proportion of Cured Patients in Treatment and Comparator Arms 
Country N Treat N Comp N total E Treat SD E Comp SD Total SD Diff 95% CI P chi2 
DE 56 62 118 0.88 0.33 0.76 0.43 0.81 0.39 0.12 -0.020 0.254 0.10
ES 22 21 43 0.86 0.35 0.86 0.36 0.86 0.35 0.01 -0.201 0.213 0.95
UK 29 30 59 0.79 0.41 0.63 0.49 0.71 0.46 0.16 -0.067 0.386 0.18
FR 30 34 64 0.83 0.38 0.76 0.43 0.80 0.41 0.07 -0.127 0.263 0.50
CH 23 26 49 0.61 0.50 0.62 0.50 0.61 0.50 -0.01 -0.280 0.267 0.96
BE 12 11 23 0.58 0.52 0.64 0.51 0.61 0.50 -0.05 -0.451 0.345 0.79
GR 50 50 100 0.92 0.27 0.84 0.37 0.88 0.33 0.08 -0.046 0.206 0.220
IL 39 40 79 0.77 0.43 0.73 0.45 0.75 0.44 0.04 -0.147 0.236 0.650
RU 5 7 12 0.80 0.45 0.71 0.49 0.75 0.45 0.09 -0.399 0.570 0.740
ZA 35 40 75 0.80 0.41 0.80 0.41 0.80 0.40 0.00 -0.182 0.182 1.000
5 CNTR 160 173 333 0.81 0.39 0.73 0.45 0.77 0.42 0.08 -0.006 0.170 0.07
10 CNTR 301 321 622 0.81 0.39 0.75 0.43 0.78 0.41 0.06 -0.001 0.128 0.06
  
 132 
Table 8: Summary Data for Hospitalization (LOS) 
CNTR N Treat N Comp N total LOS Treat SD Treat LOS Comp SD Comp Total SD Diff 95% CI  P ttest 
DE 56 62 118 10.73 5.55 12.68 4.88 11.75 5.28 -1.94 -3.85 0.04 0.05 
ES 22 21 43 7.41 5.07 7.38 5.48 7.39 5.21 0.03 -3.22 3.28 0.97 
UK 29 30 59 6.10 3.63 8.63 4.82 7.39 4.43 -2.53 -4.76 0.30 0.03 
FR 30 34 64 8.87 6.64 10.65 6.71 9.81 6.68 -1.78 -5.12 1.56 0.29 
CH 23 26 49 9.61 4.46 9.35 5.41 9.46 4.94 0.26 -2.61 3.13 0.85 
BE 12 11 23 7.67 4.64 9.36 4.03 8.48 4.64 1.70 -2.35 5.75 0.39 
GR 50 50 100 6.84 4.00 7.50 4.07 7.17 4.03 -0.66 -2.26 0.94 0.41 
IL 39 40 79 5.95 4.68 5.00 2.60 5.47 3.78 0.95 0.74 2.64 0.27 
RU 5 7 12 12.60 6.42 8.29 5.94 10.08 6.26 4.31 3.69 12.32 0.26 
ZA 35 40 75 4.03 2.58 4.20 2.50 4.12 2.53 -0.17 -1.34 1.00 0.77 
5 CNTR 160 173 333 8.93 5.49 10.43 5.70 9.71 5.64 -1.51 -2.72 -0.30 0.02 
10 CNTR 301 321 622 7.63 5.19 8.43 5.37 8.05 5.29 -0.81 -1.64 0.03 0.06 
Note: LOS are calculated in days
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Figure 9: Cost Histogram for Treatment and Comparator Arms Combined 
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Figure 10: LOS Histogram for Treatment and Comparator Arms Combined 
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Objective 2: Crude analysis of patient-level and country-level covariates 
(heterogeneity factors) which are likely to have effect on mean and incremental 
costs, resource use and effectiveness outcomes 
   Patient-level and country-level covariates were selected based on the conclusions of 
the literature review of generalizability methods (section 3) and selected health 
economic studies in CAP indication (Fine et al., 1990; 1993; 1997; 2000; Battleman et 
al., 2002; McCormick et al., 1999; Woodhead et al., 2004; Ruiz et al., 1999; Janssens, 
2005; Lave et al., 1999). 
   Following patient-level covariates were hypothesized to have effect on resource use 
and costs: 
• demographic characteristic: patients age 
• clinical characteristic: severity of CAP condition at hospital admission 
• health-related behavior: mean number of cigarettes smoked per day. 
Respectively, following country-level covariates were thought to have effect on 
resource use and costs: 
• characteristics related to national health-care resources: total health expenditure as 
% of gross domestic product (GDP) and number of hospital beds per 100 000 
inhabitants 
• characteristic related to clinical presentation of disease on national level: bacteria 
resistance to antibiotic treatment.  
   Summary statistics on patient- and country-level covariates is presented in Table 9, 
Table 10, Table 11 and Table 12. Patient-level covariates were collected during the 
study course. Health expenditures as % of GDP and number of hospital beds per 100 
000 for individual countries were extracted from WHO HFA database (WHO, 2009). 
Measurement and quantification of antibiotic resistance on country-level appeared to be 
a complex issue (Low, 2004). On hand of EARRS (2006) report we have dichotomized 
countries with high and low level of antibiotic resistance (level of covariate 1 and 0 
respectively). 
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   Results show variability in country-level characteristics. The highest total health 
expenditures as proportion of GDP are observed in Switzerland (10.5%) followed by 
Germany (10.3%) and France (9.7%) in contrast to Russia (2.8%) with lowest total 
health expenditure. Even greater difference can be seen in number of hospital beds per 
100 000 population with highest hospital capacity in Russia (1085 beds/100 000 
inhabitants) and lowest in Spain (377.6 beds/100 000 inhabitants). Overall, examination 
of selected country-level characteristics suggests substantial differences between the 
settings as measured by selected parameters. Thus, further analysis should deem to 
explore and quantify association between the country-level characteristics, mean and 
incremental costs and resource use for treatment of CAP in the particular settings.  
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Table 9: Summary Statistics for Patient- and Country-Level Covariates 
Variable Description Source DE ES UK FR CH BE GR  IL  RU ZA  
Patient-level covariates 
CX2 
Severity of CAP condition, 1=severe 
CAP, 0=mild CAP data base 0.43 0.70 0.37 0.48 0.73 0.39 0.40 0.49 0.33 0.79 
CX4 Mean patient's age data base 58.6 60.3 53.4 60.8 67.4 48.3 57.3 56.1 35.6 40.6 
CY3 Mean number of cig/day data base 5.8 4.3 3.3 5.8 7.4 8.4 7.6 6.0 12.6 3.1 
Country-level covariates 
CX3 
Antibiotics resistance, 1=high 
resistant, 0=low  
EARSS, 
2006 0 1 0 1 0 1 1 1 1 0 
CY1 
Total health expenditure as % of 
gross domestic product (GDP), 1999 
WHO, 
2009 10.3 7.3 7.1 9.7 10.5 8.6 7.8 8.2 2.8 7.2 (*) 
CY2 
Number of hospital beds per 100000 
population in 1999 
WHO, 
2009 919.6 377.6 416.4 828.7 660.8 559.2 472.4 612.0 1085.0 480.0(*)
Note: *WHO data not is not available. Information extracted from published sources: United Nations (2008), van Walbeek (2002) 
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   Descriptive statistics for patient-level covariates - severity of CAP, age and smoking  - 
is provided in Table 10, Table 11 and Table 12. As expected in randomized design 
study, there is no substantial difference in proportion of patients with severe CAP 
between treatment (0.53) and comparator arm (0.51) in the pooled set over 10 countries. 
However, the proportion of patients with severe CAP varies from 0.20 in Russia to 0.86 
in South Africa and 0.30 in UK to 0.73 in South Africa in treatment and comparator 
arms respectively. The relative difference between the arms varies from 0.15 in UK to -
0.30 in Belgium. There is no indication for statistically significant difference within the 
countries between treatment and comparator arms. However, the absolute and 
insignificant between-country differences may impact mean and incremental resource 
use and cost. This association is investigated in multivariate analysis. 
Table 10: Descriptive Statistics on Proportion of Patients with Severe CAP at Admission 
Country 
N 
Pat 
CAP 
Treat SD 
CAP 
Comp SD Total SD Diff 95% CI 
Ch2 p 
value 
DE 118 0.45 0.50 0.42 0.50 0.43 0.47 0.03 -0.15 0.21 0.77
ES 43 0.68 0.48 0.71 0.46 0.70 0.47 -0.03 -0.31 0.24 0.82
UK 59 0.45 0.51 0.30 0.47 0.37 0.49 0.15 -0.1 0.39 0.24
FR 64 0.47 0.51 0.50 0.51 0.48 0.50 -0.03 -0.28 0.21 0.79
CH 49 0.78 0.42 0.69 0.47 0.73 0.45 0.09 -0.15 0.34 0.48
BE 23 0.25 0.45 0.55 0.52 0.39 0.50 -0.30 -0.68 0.09 0.15
GR 100 0.40 0.50 0.40 0.50 0.40 0.49 0.00 -0.19 0.19 1.00
IL 79 0.49 0.51 0.50 0.51 0.49 0.50 -0.01 -0.23 0.21 0.91
RU 12 0.20 0.45 0.43 0.54 0.33 0.49 -0.23 -0.74 0.27 0.41
ZA 75 0.86 0.36 0.73 0.45 0.79 0.41 0.13 -0.05 0.31 0.16
5CNTR 333 0.53 0.50 0.49 0.50 0.51 0.50 0.04 -0.07 0.15 0.47
10CNTR 622 0.53 0.50 0.51 0.50 0.52 0.50 0.02 -0.06 0.1 0.67
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   Similar to severity of CAP condition, and owing to randomized study design, there is 
no substantial difference in mean patients’ age between treatment (55.21 SD 20.51) and 
comparator arm (55.94 SD 19.59) in the trial-wide set. However, mean age varies from 
33.00 years to 68.61 years and 37.43 years and 66.23 years in Russia and Switzerland in 
treatment and comparator arms respectively. There is no indication for significant 
difference in mean patient age between treatment and comparator arms per country and 
trial-wide. However, ANOVA analysis (normality assumption confirmed by Shapiro-
Wilk test) indicates significant p<0.001 between-country difference in mean age for 
both 5 countries and 10 countries sets. 
Table 11: Descriptive Statistics for Patients’ Age at Admission 
Country 
N 
Pat Treat SD Comp SD Total SD Diff 95% CI 
p 
value 
DE 118 56.73 17.69 60.19 17.44 58.55 17.57 3.46 -2.95 9.87 0.28
ES 43 59.91 17.53 60.76 15.05 60.33 16.18 0.85 -9.23 10.93 0.87
UK 59 54.14 22.60 52.60 20.99 53.36 21.62 -1.54 -12.90 9.83 0.79
FR 64 55.43 22.46 65.50 15.95 60.78 19.78 10.07 0.42 19.72 0.04
CH 49 68.61 16.36 66.23 14.74 67.35 15.40 -2.38 -11.31 6.56 0.60
BE 23 50.75 16.31 45.64 21.88 48.30 18.91 -5.11 -21.75 11.53 0.53
GR 100 56.52 23.27 58.02 19.38 57.27 21.32 1.50 -7.00 10.00 0.73
IL 79 56.72 19.74 55.50 19.34 56.10 19.42 -1.22 -9.97 7.54 0.78
RU 12 33.00 10.27 37.43 14.94 35.58 12.60 4.43 -12.89 21.75 0.58
ZA 75 42.83 17.20 38.45 16.20 40.49 16.71 -4.38 -12.07 3.31 0.26
5CNTR 333 58.16 19.73 60.90 17.59 59.58 18.67 2.73 -1.29 6.76 0.18
10CNTR 622 55.21 20.51 55.94 19.59 55.57 20.03 0.74 -2.42 3.90 0.65
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   There is insignificant difference in mean number of cigarettes smoked per day 
between treatment (5.36) and comparator arm (6.23). Mean number cigarettes varies 
from 2.89 in UK to 12.00 in Russia and 2.90 in Spain and 13.00 in Russia in treatment 
and comparator arms respectively.  
   In early simulations with hierarchical models we considered to use smoking 
consumption data as country-level covariates. Number of cigarettes smoked per person 
per day may not be directly considered as contextual effect. However, indirectly, mean 
average consumption per person can reflect country-level contextual factors, such as 
social acceptance of smoking, effect of political/financial incentives against smoking, 
etc. Table 13 presents descriptive summary of cigarettes consumption calculated using 
study dataset and data extracted from WHO-HFA database. There is only small 
deviation between mean number of cigarettes smoked per person/day in study dataset 
(5.81) and WHO data (5.14). However, country-level statistics shows substantial 
differences between country-level study data set and WHO data for Germany, Spain, 
France, Belgium and Russia. This example indicates potential problematic of collecting 
country-level covariates outside the study and applying these to small patient samples 
selectively recruited into the study. In fact, mean parameter values reported on higher 
country-level may not be valid for the population included in the study. 
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Table 12: Descriptive Statistics for Mean Daily Cigarette Consume 
Country Nr Pat Treat SD Comp SD Total SD Diff 95% CI p value 
DE 118 5.45 11.05 6.27 11.40 5.88 11.20 0.83 -3.28 4.93 0.69
ES 43 5.50 10.02 2.90 9.55 4.33 9.76 -2.60 -8.62 3.44 0.39
UK 59 2.89 6.98 3.67 7.54 3.29 7.21 0.77 -3.02 4.56 0.69
FR 64 6.50 10.76 5.15 7.93 5.78 9.31 -1.35 -6.04 3.33 0.57
CH 49 7.39 17.64 7.38 11.55 7.39 14.56 -0.01 -8.48 8.47 0.99
BE 23 7.67 14.49 9.18 15.85 8.39 14.83 1.52 -11.64 14.67 0.81
GR 100 5.54 10.26 9.70 14.86 7.62 12.88 4.16 -0.91 9.23 0.11
IL 79 5.18 11.42 6.75 11.47 5.97 11.40 1.57 -3.56 6.70 0.54
RU 12 12.00 10.96 13.00 14.60 12.58 12.65 1.00 -16.30 18.30 0.90
ZA 75 3.06 5.70 3.18 6.36 3.12 6.02 0.12 -2.68 2.91 0.93
5CNTR 333 5.36 10.00 5.47 11.41 5.42 10.68 -0.11 -2.42 2.20 0.93
10CNTR 622 5.36 10.83 6.23 11.19 5.81 11.01 0.88 -0.86 2.61 0.32
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Table 13: Comparison of Smoking Consumption Based on Study Set and WHO Data 
Country Nr Pat 
Study mean 
cig consume 
patient/day SD 
WHO 
cig/person/year 
2000 
WHO 
person/day 
Diff Study-
WHO 
DE 118 5.88 11.20 1553.15 4.26 1.62
ES 43 4.33 9.76 2464.44 6.75 -2.42
UK 59 3.29 7.21 1123.39 3.08 0.21
FR 64 5.78 9.31 1303.29 3.57 2.21
CH 49 7.39 14.56 2336.36 6.40 0.99
BE 23 8.39 14.83 1532.50 4.20 4.19
GR 100 7.62 12.88 2953.80 8.09 -0.47
IL 79 5.97 11.40 2161.00 5.92 0.05
RU 12 12.58 12.65 2411.14 6.61 5.97
ZA 75 3.12 6.02 933.00 2.56 0.56
5CNTR 333 5.42 10.68 1756.13 4.81 0.61
10CNTR 622 5.81 11.01 1877.21 5.14 0.67
Note: * WHO consumption for Israel is based on 2003 data, all other countries on 2000 
Source: Study database and WHO, 2009 
4.3.2 Test of Between-Country Heterogeneity 
Objective 3: Assessment of qualitative country-by-treatment interaction in 
incremental costs, effectiveness, resource use and INMB. 
   The results of qualitative homogeneity including test statistic and test power are 
summarized in Table 14. The results of qualitative homogeneity test suggest absence of 
country-by-treatment interactions in incremental effectiveness, length of stay, costs and 
INMB. That indicates, essentially, that the effect’s direction appears to be homogeneous 
in all countries, i.e. new treatment is more efficacious, saves hospitalization time and 
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costs. However, the test power for incremental effectiveness, cost, INMB and LOS (5 
countries) is low. Particularly low test power is seen for incremental costs and INMB 
(0.41 and 0.51 respectively), where the variability of estimates is high, and thus, the 
heterogeneity may remain undetected. 
Table 14: Results of Qualitative Homogeneity Test 
Test Statistic 
Incremental effect Q+ Q- 
Critical 
Value Power 
Effectiveness 5 CNTR 5.3 0 4.96 0.58 
Costs 5 CNTR 0.01 10.4 4.96 0.41 
NMB 5 CNTR 11.62 0.01 4.96 0.51 
LOS 5 CNTR 1.53 2.84 4.96 0.68 
LOS 10 CNTR 5.94 6.52 10.99 0.96 
 
Objective 4: Assessment of quantitative country-by-treatment interaction in 
incremental costs, effectiveness, resource use and NMB. 
   Test for quantitative interactions, similar to the results of the test for qualitative 
interaction, suggests absence of between-country heterogeneity for incremental 
effectiveness, costs and INMB with p-values of 0.80, 0.70 and 0.67 respectively (see 
Table 15). However, the results for incremental length of hospitalization indicate 
significant quantitative between-country heterogeneity, suggesting significant difference 
in the magnitude to which the treatment reduces length of hospitalization in different 
countries. 
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Table 15: Results of Quantitative Homogeneity Test 
Country 
Incremental 
Efficacy 
Incremental 
Costs  
INMB 
(1000) 
Incremental 
LOS 
5CNTR 
Incremental 
LOS 
10CNTR 
DE 0.12 -556.82 673.75 -1.95 -1.95
ES 0.01 80.40 -73.91 0.03 0.03
UK 0.16 -979.16 1351.61 -2.53 -2.53
FR 0.07 -1191.84 1047.79 -1.78 -1.78
CH -0.01 -219.90 213.21 0.26 0.26
Test stat H 1.67 2.20 2.37 0.21 0.60
P value 0.80 0.70 0.67 0.00 0.00
 
   Overall, the tests indicated homogeneity of effect’s direction and magnitude. 
However, due to modest test power for qualitative interactions and significant between-
country heterogeneity stated by the test for quantitative interactions in incremental LOS, 
potential between-country heterogeneity can not be completely ruled out. Hence, it 
remains unclear, to which extend could trial-wide cost, effectiveness and resource use 
estimates be considered informative for the decision making in individual countries.  
 
4.3.3 Country-level Cost-Effectiveness Estimates While Accounting 
for Data Hierarchy and Heterogeneity 
Objective 5: Determination of degree of within-country clustering 
   Intraclass correlation coefficient was calculated to explore degree of clustering within 
the countries in LOS and costs estimates. Variance component models were fitted in 
STATA using “loneway” procedure. The results are summarized in Table 16. 
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Table 16: Estimation of ICC for Economic Parameters Cost and LOS 
Setting Nr patients Parameter ICC 95% CI 
5 CNTR 333 Cost 0.203 0.000 0.452 
5 CNTR 333 LOS 0.111 0.000 0.272 
10 CNTR 622 LOS 0.228 0.038 0.418 
 
   Intraclass correlation is measuring the strength of nesting (or clustering), e.g. the 
extent to which observations depend on higher-level variable, which is country in our 
case study. Higher value of ICC suggests the use of hierarchical modelling instead of 
conventional regression techniques. Regression without accounting for hierarchical 
structure may provide misleading outcomes of significance test due to lack of 
independence of the error terms (Garson, 2009). The presented results suggest the 
evidence for clustering within the countries for the parameters costs and LOS. The 
results in Table 16 are indicative. Summary of the components of variance is 
appropriate for the normally distributed data, but is problematic for skewed distributions 
where within-group measure is based on skewed data, but not the between-group 
measure. Thus, direct interpretation of ICC for given dataset is not feasible. 
Objective 6: Calculation of trial-wide and country-level estimates for the 
incremental cost and effectiveness using patient-level data while accounting for 
within country clustering. 
   The results of incremental effectiveness and costs for 5 countries estimated with 
hierarchical model 1 without covariates are reported in Table 17. Trial – wide estimates 
for incremental effectiveness is 0.081 CR -0.007 – 0.169 and incremental costs -555.50 
CR -945.00 - -160.10 suggesting that new treatment is more efficacious and less costly. 
This result is consistent with country-level estimates for all countries. The country-level 
incremental cost and effectiveness estimates are shrunk towards trial-wide results. For 
each country k there are four regression coefficients estimated with the model: 
CkCkEkEk δγδγ ,,,  where CkEk δδ , are random effects for incremental costs and 
effectiveness drawn from bivariate normal distribution. The random effects are re-
centered so that weighted sum is zero and are interpreted as country-level effect of trial-
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wide main and interaction effects; extend of shrinkage depends on estimated precision 
within each country and true heterogeneity between the countries.  
Table 17: Results of Hierarchical Model 1 without Covariates 
Node Setting  Mean  SD  MC error 2.50% Median 97.50%
Trial-wide -555.50 199.10 1.31 -945.00 -556.80 -160.10
Germany -564.00 212.00 1.16 -983.50 -563.40 -147.60
Spain -328.70 432.10 4.59 -1094.00 -367.10 622.40
UK -826.60 303.90 2.99 -1477.00 -807.10 -279.50
France -547.90 542.50 5.82 -1650.00 -558.90 608.90
Incremental 
costs Switzerland -417.50 398.10 3.29 -1159.00 -441.50 444.70
Trial-wide 0.081 0.045 0.000 -0.007 0.081 0.169
Germany 0.095 0.052 0.000 -0.005 0.093 0.200
Spain 0.083 0.058 0.000 -0.034 0.083 0.197
UK 0.079 0.057 0.000 -0.039 0.079 0.189
France 0.081 0.055 0.000 -0.032 0.081 0.188
Incremental 
effectiveness Switzerland 0.049 0.072 0.001 -0.126 0.058 0.166
Note: Incremental costs are calculated in EUR, incremental effectiveness is calculated as difference in 
proportion of cured patients. 
Objective 7: Calculation of trial-wide and country-level estimates of the 
incremental cost and effectiveness using patient-level data while accounting for 
within country clustering and incorporating patient-level and country-level 
covariates. 
   The results of incremental effectiveness and costs for 5 countries estimated by 
hierarchical model 2 with complete set of country-level and patient-level covariates and 
model 3 with patient-level covariates only are reported in Table 18 and Table 19. 
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   Trial –wide estimates for incremental effectiveness as calculated with model 2 are 
0.073 CR -0.015 – 0.161 and incremental costs -475.10 CR -869.00 - -81.84 suggesting 
that new treatment is more efficacious and less costly. These results are consistent with 
incremental effectiveness and costs estimates in individual countries.  
   The trial-wide results of model 3, 0.073 CR -0.015 – 0.160 for incremental 
effectiveness and -472.30 CR -839.00 - -100.50 for incremental costs, do not 
substantially depart from the results of model 2 and are consistent across all countries. 
   Inclusion of patient-level covariate “age” produced small differences on the 
effectiveness estimates in models 2 and 3 comparing to model 1 (data not shown here). 
The preliminary simulations showed that covariates other than “age” showed negligible 
effect on incremental effectiveness and were therefore not included into final 
effectiveness equations in model 1-3. 
Table 18: Results of Hierarchical Model 2 with Patient-Level and Country-Level Covariates 
Node Setting  Mean  SD  MC error 0.025 Median 0.975
Trial-wide  -475.10 199.40 2.16 -869.00 -474.90 -81.84
Germany -443.50 427.30 16.38 -1292.00 -458.20 498.30
Spain -186.60 674.80 23.41 -1452.00 -251.40 1335.00
UK -755.10 586.30 22.32 -2129.00 -694.70 314.80
France -510.20 634.30 12.47 -1868.00 -503.50 805.90
Incremental 
costs Switzerland -421.40 395.20 5.47 -1203.00 -430.30 397.00
Trial-wide 0.073 0.045 0.000 -0.015 0.073 0.161
Germany 0.085 0.051 0.000 -0.013 0.085 0.188
Spain 0.073 0.057 0.000 -0.043 0.074 0.183
UK 0.070 0.056 0.000 -0.043 0.071 0.177
France 0.071 0.055 0.000 -0.040 0.072 0.176
Incremental 
effectiveness Switzerland 0.050 0.065 0.001 -0.101 0.056 0.160
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Table 19: Results of Hierarchical Model 3 with Patient-Level Covariates 
Node Setting  Mean  SD 
 MC 
error 0.025 Median 0.975
Trial-wide  -472.30 187.90 1.53 -839.00 -473.70 -100.50
Germany -481.20 198.20 1.41 -874.40 -480.10 -92.07
Spain -232.70 405.30 6.00 -939.70 -270.80 672.00
UK -663.10 296.10 3.96 -1293.00 -646.10 -124.20
France -481.10 500.70 7.05 -1529.00 -481.20 563.20
Incremental 
costs Switzerland -420.00 350.50 3.76 -1100.00 -431.00 318.50
Trial-wide 0.073 0.045 0.000 -0.015 0.073 0.160
Germany 0.085 0.051 0.000 -0.014 0.084 0.187
Spain 0.073 0.057 0.000 -0.042 0.073 0.183
UK 0.070 0.056 0.000 -0.043 0.071 0.178
France 0.071 0.055 0.000 -0.040 0.072 0.177
Incremental 
effectiveness Switzerland 0.049 0.066 0.001 -0.105 0.055 0.160
 
Objective 8: Overall comparison and assessment of DIC across the models with 
and without covariates adjustment  
   Table 21 provides overview of the results calculated by models 1 – 3 and descriptive 
statistics. Figure 11 provides graphical presentation of incremental costs obtained with 
hierarchical models and descriptive statistics. 
   Comparing results obtained with descriptive statistic and hierarchical modelling, we 
observe the largest between-country variation in incremental costs and effectiveness in 
descriptive statistics estimates. Country-level estimates in hierarchical models are 
shrunk toward trial-wide results, what represents a “compromise” between aggregated 
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(trial-wide) or disaggregated (country-level) analysis. The disaggregated analysis 
(descriptive statistics) may provide more extreme results due to the fact that some 
countries (e.g. Spain) have fewer patients. Modelling of cost with gamma distribution 
allows for better data representation and accounting for the small amount of patients 
producing very high costs. This explains why incremental costs for France are smaller 
(in absolute amount) if calculated with hierarchical models comparing to descriptive 
statistics. 
   The deviance information criteria (DIC) was calculated to indicate and compare data 
fit across different models (Spiegelhalter et al., 2002). Model with lower DIC is 
generally regarded as improvement of data fit whereas difference in 5-10 points is 
considered as substantial improvement (The BUGS Project, 2010). DIC for model 1 is 
6216.82, model 2 and 3 maintained better data fit confirmed by a smaller DIC of 
6188.36. Comparing the results of model 2 and model 3, we state, that model 3 provides 
gain in precision of the mean incremental costs estimates as showed by narrower 
credibility intervals while maintaining the same DIC as the model 2. 
Table 20: Deviance Information Criteria (DIC) for Hierarchical Models 1-3 
Model HM 1 no covariates HM 2 all covariates HM 3 pat-level covariates 
DIC Costs 5858.01 5830.20 5830.20 
DIC Efficacy 358.82 358.16 358.16 
DIC total 6216.82 6188.36 6188.36 
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Table 21: Results of Incremental Cost and Effectiveness Estimated with Hierarchical Models 1-3 and Descriptive Statistics 
    HM1: 5 CNTR HM2: 5 CNTR ALL COV HM3: 5 CNTR PAT COV DESCR STAT 
    Mean CR 2.5 CR 97.5 Mean CR 2.5 CR 97.5 Mean CR 2.5 CR 97.5 Mean CR 2.5 CR 97.5 
Germany -564.00 -983.50 -147.60 -443.50 -1292.00 498.30 -481.20 -874.40 -92.07 -556.82 -1001.65 -111.99
Spain -328.70 -1094.00 622.40 -186.60 -1452.00 1335.00 -232.70 -939.70 672.00 80.40 -1270.21 1431.01
UK -826.60 -1477.00 -279.50 -755.10 -2129.00 314.80 -663.10 -1293.00 -124.20 -979.16 -1879.37 -78.95
France -547.90 -1650.00 608.90 -510.20 -1868.00 805.90 -481.10 -1529.00 563.20 -1191.84 -3820.03 1436.34
Switzerland -417.50 -1159.00 444.70 -421.40 -1203.00 397.00 -420.00 -1100.00 318.50 -219.90 -1363.60 923.80
I
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
 
Trial-wide -555.50 -945.00 -160.10 -475.10 -869.00 -81.84 -472.30 -839.00 -100.50 -659.69 -1305.51 -13.87
Germany 0.095 -0.005 0.200 0.085 -0.013 0.188 0.085 -0.014 0.187 0.117 -0.020 0.254
Spain 0.083 -0.034 0.197 0.073 -0.043 0.183 0.073 -0.042 0.183 0.006 -0.201 0.213
UK 0.079 -0.039 0.189 0.070 -0.043 0.177 0.070 -0.043 0.178 0.160 -0.067 0.386
France 0.081 -0.032 0.188 0.071 -0.040 0.176 0.071 -0.040 0.177 0.069 -0.127 0.263
Switzerland 0.049 -0.126 0.166 0.050 -0.101 0.160 0.049 -0.105 0.160 -0.007 -0.280 0.267
I
n
c
r
e
m
e
n
t
a
l
 
e
f
f
e
c
t
i
v
e
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e
s
s
 
Trial-wide 0.081 -0.007 0.169 0.073 -0.015 0.161 0.073 -0.015 0.160 0.080 -0.006 0.170
DIC total 6216.82     6188.36     6188.36     NA     
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Figure 11: Incremental Cost Estimated with Hierarchical Models and Descriptive Statistics 
-3000.0
-2500.0
-2000.0
-1500.0
-1000.0
-500.0
0.0
500.0
1000.0
1500.0
2000.0
Germany Spain UK France Sw itzerland Trial-w ide
 
Note: Incremental costs (Y axis) are calculated in EUR
HM1 HM2 HM3 descr 
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4.3.4 Cost-Effectiveness Acceptability Curves 
Objective 9: Construction of cost-effectiveness acceptability curves based on 
estimates from models without and with covariates. 
   The INMB is defined as ECINMB Δ−Δ= λ , where lambda is willingness to pay of a 
payor for a unit of effectiveness. Figure 12, Figure 13, Figure 14 and Figure 15 display 
cost-effectiveness acceptability curves, i.e. the probability that new therapy is cost 
effective as a function of lambda (Fenwick et al., 2004). Formally, there will be no 
difference in decision using the different estimates of hierarchical models 1 to 3, since 
the probability that new treatment is cost-effective remain above 0.5 at any willingness-
to pay value in all countries. However, the ability to calculate country-level estimates by 
borrowing information from the other countries is a clear advantage and allow for 
flexible decision making using country-specific results and willingness-to pay 
thresholds. 
 
Figure 12: Cost Effectiveness Acceptability Curves (CEAC) Based on Descriptive Statistics 
Crude trial-wide and country-level results
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Note: Y axis reflect probability of the therapy to be cost-effective at different willingness-to-pay values 
denoted in EUR (X axis). 
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Figure 13: Cost Effectiveness Acceptability Curves (CEAC) Based on HM 1 Without Covariates 
HM1 (without covariates): Trial-wide and contry-level results
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Figure 14: Cost Effectiveness Acceptability Curves (CEAC) Based on HM 2 With Patient- and 
Country-Level Covariates 
HM2 (country- and patient-level covariates): Trial-wide and 
country-level results 
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Figure 15: Cost Effectiveness Acceptability Curves (CEAC) Based on HM 3 With Patient-Level 
Covariates 
HM3 (patient-level covariates): Trial-wide and country-level results 
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4.3.5 Country-level LOS Estimates While Accounting for Data 
Hierarchy and Heterogeneity 
Objective 10: Calculation of trial-wide and country-level estimates of the 
incremental LOS using patient-level data and accounting for within country 
clustering. 
   The results of HM 4 in Table 22 suggest considerable variation of incremental LOS 
between 10 countries. Trial-wide estimate shows reduction in LOS for the patients 
receiving treatment comparing to standard therapy (-0.56 CR -1.35 – 0.29). This result 
is not consistent with country-level estimates in all countries: in Switzerland, Israel, 
Russia and Greece incremental LOS is in favor of comparator. The estimates for Russia 
(7.96 CR -1.97 – 28.75) are considerably different from other countries and trial-wide 
results. Also, there is a high uncertainty around the estimate reflected in wide credibility 
intervals. Small sample size of Russian sub-group (12 patients in both arms) does not 
allow for robust sub-group analysis, therefore the high difference between treatment and 
comparator arm just by chance can not be ruled out. Owing to small sample size and 
high uncertainty of the estimate, the results from Russia do not have major impact on 
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trial-wide estimates (confirmed in model simulation without Russian patients; results 
are not presented here).  
Table 22: Results of Hierarchical Model 4 for Incremental LOS without Covariates 
Setting  Mean  SD  MC error 2.50% Median 97.50%
Trial-wide -0.56 0.43 0.01 -1.35 -0.57 0.29
Germany -1.70 1.80 0.02 -5.21 -1.71 1.93
Spain -1.39 1.62 0.02 -4.57 -1.41 1.85
UK -1.32 1.02 0.01 -3.30 -1.32 0.69
France -0.88 0.73 0.01 -2.32 -0.88 0.56
Switzerland 0.09 1.44 0.02 -2.70 0.06 3.00
Belgium -2.29 0.99 0.01 -4.27 -2.28 -0.36
Greece 0.51 0.73 0.01 -0.92 0.51 1.96
Israel 0.74 1.58 0.02 -2.28 0.67 4.00
Russia 7.96 10.06 0.23 -1.97 6.00 28.75
South Africa -0.25 0.51 0.01 -1.25 -0.25 0.74
Objective 11: Calculation of trial-wide and country-level estimates of incremental 
LOS using patient-level data and accounting for within country clustering while 
controlling for patient-level and country-level covariates. 
   Similar to the cost-effectiveness analysis with HM 2, we included full set of country- 
and patient-level covariates in HM 5. Trial-wide estimate of incremental LOS suggest 
shorter hospitalization for the patients receiving treatment (-0.65 CR -1.40 – 0.13, see 
Table 23). Again, similar to results of HM 4, there is considerable variation in country-
level estimates: in Spain, UK, France, Belgium, Greece and South Africa patients in the 
treatment arm spent less time in the hospitals, whereas in Germany, Switzerland, Israel 
and Russia the patients receiving comparator have no substantial difference or shorter 
LOS. Inclusion of covariates considerably increased uncertainty of the estimates as 
reflected in wide credibility intervals in HM 5. 
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Table 23: Results of Hierarchical Model 5 with Patient- and Country-Level Covariates 
Setting  Mean  SD  MC error 2.50% Median 97.50%
Trial-wide -0.65 0.39 0.00 -1.40 -0.66 0.13
Germany -0.10 25.47 0.60 -50.09 -0.38 47.71
Spain -0.73 21.05 0.50 -40.43 -0.61 40.17
UK -2.51 19.68 0.46 -40.29 -2.82 35.16
France -1.20 17.97 0.42 -35.61 -0.94 33.55
Switzerland 0.27 14.33 0.33 -29.38 1.33 26.95
Belgium -1.26 6.82 0.16 -13.99 -1.33 12.34
Greece -1.21 13.38 0.32 -25.92 -1.14 25.07
Israel 0.20 4.97 0.11 -8.87 -0.05 10.55
Russia 6.55 47.56 1.10 -86.76 7.56 98.05
South Africa -1.28 15.51 0.37 -30.94 -1.32 28.44
   HM 6 is calculated using patient-level covariates only. Trial-wide estimate of 
incremental LOS suggest shorter LOS for the patients receiving treatment (-1.24 CR-
2.20 –  -0.25, see Table 24). Similar to results of HM 4 and HM 5, there is variation of 
country-level estimates: in Germany, Spain, UK, France, Belgium, Greece, Switzerland 
and South Africa patients in treatment arm spent less time in the hospitals, whereas in 
Israel and Russia the patients on comparator have shorter LOS. The precision of the 
country-level estimates is improved comparing the credibility intervals in HM5. 
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Table 24: Results of Hierarchical Model 6 with Patient-Level Covariates 
Setting  Mean  SD  MC error 2.50% Median 97.50%
Trial-wide -1.24 0.50 0.00 -2.20 -1.25 -0.25
Germany -1.46 0.95 0.01 -3.32 -1.46 0.39
Spain -0.55 1.33 0.01 -3.14 -0.55 2.10
UK -2.79 0.84 0.01 -4.47 -2.79 -1.13
France -1.62 1.45 0.01 -4.46 -1.63 1.29
Switzerland -0.51 1.45 0.01 -3.30 -0.54 2.44
Belgium -1.47 1.51 0.01 -4.44 -1.48 1.57
Greece -1.03 0.63 0.00 -2.27 -1.02 0.18
Israel 0.10 0.79 0.00 -1.47 0.10 1.66
Russia 7.52 8.69 0.07 -1.86 5.76 27.50
South Africa -1.57 0.70 0.01 -2.93 -1.58 -0.18
 
Objectives 12: Overall Comparison and Assessment of model fit after country- and 
patient- level covariates adjustment. 
   Table 26 provides the overview of the results as calculated by HMs 4 – 6 and 
descriptive statistics. Table 25 summarizes results for DIC for models 4-6. Figure 16 
and Figure 17 provide visual presentation of incremental LOS obtained with 
hierarchical models and descriptive statistics. 
   Data fit of the models is measured by DIC. Model with lower DIC and change in 
amount of 5-10 points is regarded as improvement of data fit (Spiegelhalter et al., 2002; 
The BUGs Project, 2010). DIC for HM 4 is 3434.6, HMs 5 and 6 maintained better data 
fit confirmed by a lower DIC of 3354.34 and 3353.99 respectively. Comparing HM 5 
and HM 6, we state, that HM 6 provides better precision of the mean incremental costs 
estimates as showed by narrower credibility intervals.  
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   Comparison of results obtained with descriptive statistic and hierarchical models 
indicates that different methods may lead to different country-level conclusions. For 
instance, in Spain, Switzerland, Belgium, Israel, Russia and South Africa the mean 
descriptive values suggest that new treatment has either no substantial effect on LOS or 
even prolongs LOS comparing to standard treatment. Mean incremental LOS, as 
calculated by HM 6, suggest that in all the above countries but Russia and Israel new 
treatment reduces LOS. Country-level results calculated with hierarchical models 4-6 
are shrunk toward the trial-wide results. Inclusion of patient-level and country-level 
covariates has an impact on both mean and incremental trial-wide and country-level 
LOS estimates. Similar to HM2, inclusion of country-level covariates into HM 5 
increased uncertainty of the estimates as reflected in wider credibility intervals. Results 
for Russian setting suggest some unique features which could not be fully explored due 
to limited sample size. The patient from this setting appeared to be substantially 
younger (35.58, SD 12.60) than trial average (55.57, SD 20.03); were heavy smokers 
(12.58, SD 12.56) comparing to the trial-wide (5.81, SD 11.01), but had less patients 
with severe CAP (0.33, SD 0.49, trial-wide: 0.52, SD 0.50). In this case, trial-wide 
results as calculated by hierarchical model may be considered for the country-level 
decision-making, since country-level estimates may be susceptible for bias due to small 
sample size.   
Table 25: Deviance Information Criteria (DIC) for Hierarchical Models 4-6 
Model 
HM 4 without 
covariates 
HM 5 all 
covariates 
HM 6 pat-level 
covariates 
DIC 3434.62 3354.34 3353.99 
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Table 26: Results of Incremental LOS Estimated with Hierarchical Models 4-6 and Descriptive Statistics 
HM4: 10 CNTR LOS HM5: 10 CNTR LOS ALL COV HM6: 10 CNTR PAT COV DESCR STAT Incremental 
LOS mean CR 2.5 CR 97.5 mean CR 2.5 CR 97.5 mean CR 2.5 CR 97.5 mean CR 2.5 CR 97.5 
Germany -1.70 -5.21 1.93 -0.10 -50.09 47.71 -1.46 -3.32 0.39 -1.94 -3.85 0.04
Spain -1.39 -4.57 1.85 -0.73 -40.43 40.17 -0.55 -3.14 2.10 0.03 -3.22 3.28
UK -1.32 -3.30 0.69 -2.51 -40.29 35.16 -2.79 -4.47 -1.13 -2.53 -4.76 0.30
France -0.88 -2.32 0.56 -1.20 -35.61 33.55 -1.62 -4.46 1.29 -1.78 -5.12 1.56
Switzerland 0.09 -2.70 3.00 0.27 -29.38 26.95 -0.51 -3.30 2.44 0.26 -2.61 3.13
Belgium -2.29 -4.27 -0.36 -1.26 -13.99 12.34 -1.47 -4.44 1.57 1.70 -2.35 5.75
Greece 0.51 -0.92 1.96 -1.21 -25.92 25.07 -1.03 -2.27 0.18 -0.66 -2.26 0.94
Israel 0.74 -2.28 3.97 0.20 -8.87 10.55 0.10 -1.47 1.66 0.95 0.74 2.64
Russia 7.96 -1.97 28.75 6.55 -86.76 98.05 7.52 -1.86 27.50 4.31 3.69 12.32
South Africa -0.25 -1.25 0.74 -1.28 -30.94 28.44 -1.57 -2.93 -0.18 -0.17 -1.34 1.00
Trial-wide -0.56 -1.35 0.29 -0.65 -33.75 32.47 -1.24 -2.20 -0.25 -0.81 -1.64 0.03
DIC 3434.62     3354.34     3353.99     NA     
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Figure 16: Results of Incremental LOS Estimated with Hierarchical Models 4-6 and Crude Estimates (high definition) 
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Note: Incremental LOS is expressed in days (Y axis) 
HM4 HM5 HM6 descr 
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Figure 17: Results of Incremental LOS Estimated with Hierarchical Models 4-6 and Crude Estimates (low definition) 
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4.3.6 Use of Covariates for External Generalizability 
Objective 13: Assessment of covariates effects on mean and incremental costs and 
effectiveness estimates and possibility to generalize results of the study to non-
study settings on hand of explored covariates (external generalizability). 
   Table 21 summarizes results of hierarchical models 1 – 3 and crude estimates; the 
covariates coefficients from models 2 and 3 are presented in Table 27 and Table 28 
respectively. Effect of a covariate is splitted into direct effect on mean and interaction 
effect on incremental costs and LOS. Covariates coefficients have partial effect on the 
outcome of interest, meaning that increase of covariate in one unit will increase 
outcome of interest for an amount of coefficient holding all other parameters constant. 
Positive interaction effect increases mean difference in costs or effectiveness by a 
regression coefficient for a unit of covariate above the trial-wide average. For example, 
mean incremental cost are increased by 4.67 per year of age above the trial-wide mean 
age. In the case mean incremental effect is negative – therapy costs of treatment are 
lower than the costs of comparator – incremental costs will be lower in absolute value.  
   As mentioned above, inclusion of covariates improved data fit measured by reduced 
DIC when comparing models 1, 2 and 3. We have gain in precision of estimates 
reflected in narrower credibility intervals for estimates in model 3 comparing to model 
2. 
   Trial-wide incremental cost are negative as estimated by hierarchical models and 
descriptive statistics: -555.50 (95 CR -945.00 – -160.10) for HM 1, -475.10 (95 CR -
869.00 –  -81.84) for HM 2, -472.30 (95 CR -839.00 – -100.00) for HM 3 and -659.69 
(CI -1305.51 –  -13.78) based on crude estimate. Incremental costs in models 2 and 3 
are clearly affected by inclusion of covariates. Overall, country-level covariates (GDP- 
total health expenditures as proportion of GDP, HOSP – number of hospital beds per 
100 000 inhabitants, RES – antibiotics resistance) had small impact on incremental 
costs. This evidence suggests that it might be difficult to identify “right” contextual 
(country-level) covariate with sufficiently strong causal association with parameters of 
interest in order to predict incremental effect of the therapy based on country-level 
parameters alone. However, patient-level covariates (AGE – patient’s age at admission, 
SMOK – mean number of cigarettes smoked per day, CAP – severity of CAP condition 
at the hospital admission) showed different picture. Covariates age, number of cigarettes 
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smoked per day and severity of the condition at the hospital admission have effect on 
mean costs. Patients’ age and severity have positive effect on incremental costs, 
whereas effect of age is more pronounced than the effect of severity of the condition. 
Smoking had small negative effect on incremental costs. 
Table 27: Covariates Coefficients from Hierarchical Model 2 
  Coefficient Mean CR 2.5 CR 97.5 
CAP omegaCX2 1.47 -18.00 21.01 
RES omegaCX3 -0.07 -19.57 19.50 
AGE omegaCX4 4.51 -7.44 16.23 
GDP omegaCY1 0.05 -19.55 19.72 
HOSP omegaCY2 -0.26 -4.52 3.50 
SMOK omegaCY3 -0.34 -15.43 15.28 
Interaction 
effect AGE omegaEX4 0.00 0.00 0.00 
CAP  thetaCX2 2.43 -17.10 21.85 
RES thetaCX3 0.10 -19.47 19.76 
AGE thetaCX4 18.16 8.09 28.32 
GDP thetaCY1 0.07 -19.64 19.67 
HOSP thetaCY2 1.76 -7.25 9.37 
SMOK thetaCY3 12.76 -0.20 25.85 
Direct 
effect  AGE thetaEX4 0.00 -0.01 0.00 
Note: Patient-level covariates CAP denotes severity of condition at baseline, AGE – patients’ age; SMOK 
– mean number of cig/day; country-level covariates RES denotes antibiotics resistance, GDP – total 
health expenditure in % of GDP, HOSP – number of hospital beds per 100 000.  
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Table 28: Covariates Coefficients from Hierarchical Model 3 
  Coefficient Mean CR 2.5 CR 97.5 
CAP omegaCX2 1.45 -17.83 20.82 
AGE omegaCX4 4.67 -7.03 16.46 
SMOK omegaCY3 -0.22 -15.49 15.44 
Interaction 
effect AGE omegaEX4 0.00 0.00 0.00 
CAP  thetaCX2 2.45 -16.79 21.90 
AGE thetaCX4 18.23 8.15 28.24 
SMOK thetaCY3 12.80 -0.13 25.95 
Direct effect  AGE thetaEX4 0.00 -0.01 0.00 
 
Objectives 14: Assessment of covariates effects on mean and incremental LOS 
estimates and possibility to generalize results of the study to non-study settings on 
hand of explored covariates (external generalizability). 
   Covariates coefficients calculated in models 5 and 6 are summarized in Table 29 and 
Table 30. 
   Inclusion of covariate improved data fit when comparing DIC of model 4 (3434.62) 
with DIC of models 5 and 6 (3354.34 and 3353.99 respectively). Estimated trial-wide 
incremental LOS is comparable between hierarchical models and crude estimate: -0.56 
(95 CR -1.35 – 0.29) for HM 4, -0.65 (95 Cr -33.75 – 32.47) for HM 5, -1.24 (95 CR -
2.20 –  -0.25) for HM 6 and -0.81 (CI -1.64 – 0.03) based on crude estimate. 
Incremental LOS in models 5 and 6 are clearly affected by inclusion of covariates. 
   Inclusion of country-level covariates (GDP- total health expenditures as proportion of 
GDP, HOSP – number of hospital beds per 100 000 inhabitants, RES – antibiotic 
resistance) introduced high uncertainty into parameters’ estimation, what is reflected in 
both credibility intervals of covariates coefficients and incremental LOS results in HM 
5. Covariate GDP and resistance have small direct effect on mean LOS. In contrast, 
number of hospital beds per 100 000 inhabitants have pronounced direct effect, 
  164
suggesting that in countries with number of hospital beds higher than trial-average, the 
length of hospitalization is longer. The interaction effects suggest very small impact of 
country-level covariates on the LOS as well as high uncertainty of estimates, as 
reflected by wide credibility intervals. In general, wide credibility intervals are 
reflecting lack of information to quantify association of country-level parameters and 
incremental LOS partially attributed to a limited sample size. 
   After removing of country-level covariates, we have gained precision of estimates 
reflected in narrower credibility intervals for Germany, Spain, Switzerland, Israel and 
Russia for estimates in HM 6 comparing to models 4 and 5. 
   Similar to HM 2 and 3, direct and interaction effects of patient-level covariates are 
more precisely estimated comparing to country-level coefficients (narrower credibility 
intervals). 
Table 29: Covariates Coefficients from Hierarchical Model 5 
  Coefficient Mean CR 2.5 CR 97.5 
CAP omegaCX2 0.90 -0.19 2.00 
RES omegaCX3 1.01 -10.63 13.00 
AGE omegaCX4 0.00 -0.03 0.03 
GDP omegaCY1 -0.74 -19.68 18.09 
HOSP omegaCY2 -0.86 -18.29 16.28 
Interaction 
effect SMOK omegaCY3 -0.03 -0.08 0.03 
CAP  thetaCX2 0.93 0.17 1.69 
RES thetaCX3 -0.27 -3.60 3.09 
AGE thetaCX4 0.06 0.04 0.09 
GDP thetaCY1 0.86 -8.13 8.95 
HOSP thetaCY2 6.71 -0.73 13.89 
Direct effect  SMOK thetaCY3 0.04 0.00 0.08 
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Table 30: Covariates Coefficients from Hierarchical Model 6 
  Coefficient Mean CR 2.5 CR 97.5 
CAP omegaCX2 0.89 -0.21 1.98 
AGE omegaCX4 0.00 -0.03 0.03 
Interaction 
effect SMOK omegaCY3 -0.03 -0.08 0.03 
CAP  thetaCX2 0.95 0.18 1.70 
AGE thetaCX4 0.06 0.04 0.09 
Direct effect  SMOK thetaCY3 0.04 0.00 0.08 
 
   The effect of covariates on mean and incremental estimates is similar in HM 2 and 3 
and HM 5 and 6: country-level covariates have effect on mean costs and LOS, but small 
und uncertain impact on incremental estimates. In the countries with the parameters 
above the trial average - GDP expenditures, hospitals beds per capita, or with higher 
antibiotic resistance - mean average costs will tend to be higher. Analysis of full dataset 
with 10 countries showed that in particular number of hospital beds per capita is 
associated with increased mean LOS in the countries with hospital capacity above trial- 
average. Patient-level covariates have effect on both mean and incremental estimates. In 
absolute terms the incremental difference between elderly patients and patient with 
severe CAP is diminishing in both incremental costs and LOS analysis; for the smokers 
the incremental effect will increase with amount of cigarettes smoked.  
   These findings resonate with clinical evidence about CAP indication and treatment 
drug. Treatment has targeted activity against Streptococcus pneumoniae (including 
multi-drug resistant strains), Haemophilus influenzae, Moraxella catarrhalis, 
Mycoplasma pneumoniae, and Chlamydia pneumoniae. In vitro studies have 
demonstrated that treatment achieves drug concentrations at least three times higher in 
lung tissues than the older compounds: fluoroquinolones, levofloxacin or ciprofloxacin 
(Mandell et al., 2004). Clinical studies have demonstrated that treatment monotherapy is 
as effective (Katz et al., 2004; File et al., 2001; File, 2003) or more effective (Finch et 
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al., 2002; Drummond et al., 2003) than comparator combination regimens, usually 
containing a β-lactam and/or macrolide. Treatment (IV, 400 mg) followed by p.o. (400 
mg) for 7-14 days had superior clinical success rates (93% vs 85%) and superior 
bacterial eradication (94% vs 82%), and treatment-treated patients were afebrile in a 
shorter time (by day 2, 59% vs 47%) than comparator-treated patients (IV co-
amoxiclav, 1.2 g t.i.d., followed by p.o. co-amoxiclav, 625 mg, t.i.d., with or without 
IV/p.o. clarithromycin, 500 mg b.i.d. for 7-14 days) in 628 adult patients with CAP 
requiring initial parenteral therapy (Finch et al., 2002). A faster IV to oral switch 
therapy by day 5 was observed for patients receiving treatment than comparator in 
severe CAP (n = 376) (Lode et al., 2003). Thus, clinically proven safety and tolerability 
profile of the treatment drug supports our findings on cost and LOS savings comparing 
to the standard therapy in general population.  However, the incremental difference is 
smaller for elder and severe CAP patients. The evidence suggests that elder patients 
with CAP are at higher mortality and re-admission risk. Severely sick and /or elder 
patients recover more slowly due to existing co-morbidities (Garcia-Ondonez et al., 
2001). Thus, treatment outcomes and decision about the discharge (and thus savings of 
LOS and overall costs) may not rely on the efficacy of the therapy alone, but rather by 
the patient’s overall functional status, need for care and rehabilitation and destination of 
discharge (e.g. nursing home or family care). 
   Interesting finding about potentially increased incremental difference in LOS and 
costs for smokers finds supporting evidence in the published literature. Smoking effects 
multiple immune mechanisms in lungs in a complex way. The exact mechanism of 
action is not yet well understood (Robbins et al., 2006). Hand and colleagues (1985) 
investigated antibiotics uptake in smokers. Their findings suggest that lipid soluble 
antibiotics achieved high concentration in the pulmonary alveolar macrophages cells in 
contrast to poorly uptake of lipid insoluble antibiotics (Hand et al., 1985). In fact, 
treatment is a fluoroquinolone and is lipid-soluble; the comparator is a B-lactam and has 
low solubility in lipids. Certainly, relationship between smoking and immune response 
is very complex and differ across the age group and co-morbidity status. Thus, the effect 
of new therapy in smokers and potential savings merit further investigation in larger 
settings.  
  167
4.4 Summary of Chapter 4 
   This section comprises the results of the case study. Mean and incremental costs and 
effectiveness were estimated for UK, France, Germany, Spain and Switzerland using 
crude country-level sub-samples and hierarchical models with and without covariates. 
Mean and incremental duration of hospitalization was estimated for the full 10-country 
set (UK, France, Germany, Spain, Switzerland, Israel, Russia, Belgium, South Africa 
and Greece) using crude country-level sub-samples and hierarchical models with and 
without covariates. Between-country heterogeneity was explored by using qualitative 
and quantitative homogeneity test. 
Descriptive statistics using country-level sub-groups indicated potential between-
country heterogeneity. 
   New treatment is cost saving in Germany, UK, France and Switzerland, but not in 
Spain. The magnitude of cost saving is strongly pronounced in France and UK, less so 
in Switzerland, whereas the data for Spain suggests the comparator is cost saving over 
the treatment. With regard to incremental effectiveness, treatment is more efficacious in 
Germany, Spain, UK, France, Greece, Israel and Russia, but has no pronounced 
difference or comparator is more efficacious in South Africa, Belgium and Switzerland. 
Similarly, duration of hospitalization is shorter under treatment in Germany, UK, 
France, Greece and South Africa and longer in Spain, Switzerland, Belgium and Israel. 
Overall, country-level results indicate potential between-country heterogeneity. 
Homogeneity test is not conclusive for decision about between-country 
heterogeneity. 
   Results of qualitative homogeneity tests suggest absence of country-by-treatment 
interactions in incremental effectiveness, length of stay, costs and INMB. That indicates 
essentially, that the effect’s direction appears to be homogeneous in all countries, i.e. 
new treatment is more efficacious, saves hospitalization time and costs. However, test 
power for incremental effectiveness, cost, INMB and LOS (5 countries) parameters is 
low. Particularly low test power is seen for incremental costs and INMB, where the 
variability of estimates is high, and thus, the heterogeneity may remain undetected. 
   Test for quantitative interactions, similar to the results of the test for qualitative 
interaction, suggests absence of between-country heterogeneity for incremental 
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effectiveness, costs and INMB. However, the results for incremental LOS indicate 
significant quantitative between-country heterogeneity, suggesting significant difference 
in the magnitude to which the treatment reduces length of hospitalization in different 
countries. 
   Overall, it remains unclear, to which extend could trial-wide cost, effectiveness and 
resource use estimates be considered informative for the decision making in individual 
countries.  
Hierarchical models are used as compromise between country-level and trial-wide 
analysis for the calculation of trial-wide and country-level estimates. Inclusion of 
covariates improves model fit. 
   Mean and incremental costs and effectiveness were calculated using bivariate 
hierarchical models for effectiveness distributed with Bernoulli and costs with gamma 
distributions to account for nesting of the data within individual countries and right-
skewness of the costs distribution.  
   Patient-level covariates (age at admission, severity of CAP condition at admission and 
mean number of cigarettes smoked per day) and country level covariates (total health 
expenditures as proportion of GDP, number of hospital beds per 100 000 inhabitants, 
antibiotic resistance) covariates improved data fit in hierarchical models with costs and 
LOS comparing to the hierarchical models without covariates as confirmed by lower 
DIC. 
Country-level covariates have limited predictive ability for incremental effects to 
generalize case-study results beyond the setting of participating countries. 
   Country-level covariates had very small impact on incremental costs estimates. 
Patient-level covariates (age, number of cigarettes smoked per day and severity of the 
condition at the hospital admission) have effect on mean costs. Patients’ age and 
severity have positive effect on incremental costs, whereas effect of age is more 
pronounced than the effect of severity of the condition.  
   Similar to costs estimation, covariate GDP and resistance have very small direct effect 
on mean LOS. In contrast, number of hospital beds per 100 000 inhabitants have 
pronounced direct effect, suggesting that in countries with number of hospital beds 
higher than trial-average, the length of hospitalization is longer. The interaction effects 
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suggests very small impact of country-level covariates on the LOS as well as high 
uncertainty of estimates, as reflected by wide credibility intervals. Severity of condition 
at admission, measured at patient-level, had direct and interaction effect on LOS. Thus, 
patients with severe condition were more likely to stay in the hospital longer. Positive 
interaction effect suggests that incremental difference between treatment and 
comparator will be smaller for the patients with severe condition. In general, it may be 
difficult to predict incremental costs and effectiveness based on explicit consideration of 
macro country-level parameters only. 
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5 Discussion  
 
Summary of thesis objectives and major findings  
   Between-country variability in clinical and economic parameters in health economic 
studies is broadly acknowledged in the literature. However, assessment and 
quantification of heterogeneity and it implication for generalizability of cost-
effectiveness estimates has not been extensively investigated.  
   In this work we explored approaches to improve generalizability of multinational 
patient-level studies by addressing two main objectives: 
1) Review of published methods used in multinational health economic studies to 
explore heterogeneity and to improve generalizability.  
2) Application of selected methods to the multinational patient-level dataset in a case 
study to evaluate between-country variability in cost, resource use and effectiveness 
parameters, to identify potential covariates explaining between-country heterogeneity 
and to calculate country-level and trial-wide cost, effectiveness and resource use 
estimates. 
   First objective was addressed by conducting a targeted review of health economic 
literature and health economic guidelines. Essential findings of the literature review are 
the following:  
• Between-country variability in cost-effectiveness and resource use estimates 
could be attributed to wide geographical differences in patient-level and country-
level (or setting-level) parameters. 
• Studying of between-country variability is not yet established part of health 
economic analysis. It is recognized, however, that the estimates based on the 
aggregated analysis (e.g. trial-wide resource use) may not be appropriate for the 
country-level decision making in all participating countries. 
  171
• Homogeneity test and hierarchical modelling emerged as analytical strategies to 
address heterogeneity and appropriate handling of hierarchical data for 
calculation of trial-wide and country-level parameters.  
Second objective was attained by a case study, which illustrated application of 
homogeneity test and hierarchical models. The major results are the following: 
• Qualitative homogeneity test suggested no evidence for between country 
heterogeneity in incremental clinical and economic effects. Quantitative 
homogeneity test revealed between-country heterogeneity in incremental length 
of hospitalization. 
• Limited test power for qualitative interactions and potential quantitative 
heterogeneity does not suggest concordant evidence for between-country 
homogeneity and hence feasibility of pooling data across participated countries.  
• Trial-wide and country-level estimates of incremental effectiveness, costs and 
LOS were calculated by using bivariate hierarchical models with and without 
covariates. Hierarchical modelling accounts for clustered data within individual 
countries as well as allow for using appropriate not-normal distribution for the 
parameters of interest.  
• Using of covariates substantially improved model fit. Patient-level covariates 
had effect on mean and incremental cost and LOS. Country-level covariates had 
limited effect on incremental economic estimates. The generalizability of the 
study findings beyond the study setting may not be feasible by explicit 
considerations of country-level covariates alone. 
Relevance of the thesis research subject to Public Health realm 
   Health economic studies, being part of HTA, are vehicles to collect clinical and 
economic evidence to inform health political decision-making. Facing the technological 
revolution and emerging of new expensive technologies, efficient allocation of limited 
resources is essential to maintain access to health technologies and to provide health 
care services to the broad population. The “invisible hand” of the competitive market 
will not necessarily allocate limited resources to get maximum health gain. Free market 
failure is caused by asymmetric information, uncertainties and externalities. Inefficiency 
of health care market should be corrected by governmental institutions and policy. In 
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order to improve health care system performance (and not to do more harm than good, 
since competitive market incentives are applicable for many health care sectors), 
political decision-making should be based on good evidence. In the framework of HTA 
the evidence about the impact of new technology is collected and evaluated from the 
broad societal perspective. The aim of HTA is to inform decision makers and to 
promote rational use of health care services. Economic analysis of new technology is 
one of the aspects of HTA. Evidence on economic impact of technologies (on costs and 
outcomes) is limited and is often available from international studies only. Development 
of generalizability methods will be beneficial for both health policy and research for 
two main reasons: 
1) Generalizability methods will improve data utilization from available sources 
and conducted economic evaluations and provide local tailored evidence for the 
decision-making in particular setting.  
2) Assessment of between-country heterogeneity will contribute to cross-country 
comparison, understanding the factors inducing the differences between the 
settings and indicate the more efficient way of health provision and production.  
Theoretical considerations for studying between-country heterogeneity and 
generalizability 
   Discussion about between-country differences in mean and incremental resource use 
and cost is mainly driven by empirical considerations in differences of health-care 
inputs (e.g. proportion of GDP spent on health care, number of hospital beds per capita 
etc.) and outputs (mortality, morbidity, resource use). The empirical approach alone 
may fail to uncover the whole complexity of the relationship between different clinical 
and wider socio-economic factors operating at various levels (patient-, formulary-, 
regional-, country-levels) and influencing mean and incremental clinical and economic 
outcomes. Thus, normative theoretical considerations are important to provide guidance 
for empirical analysis.  
   In this thesis we outlined major economic theories related to health policy and 
empirical research and linked these to Public Health realm. Welfare economic theory 
advocates political intervention and regulation of health care market. In fact, health care 
production is strongly influenced by health policy, institutions and setting in which they 
are operating. From the theoretical perspective New Institutional Economics provides a 
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conceptual and theoretical basis for studying policy, interrelationship between 
institutions, incentives and efficiency in health care markets. New Institutional 
Economics, being at it infancy stage, is yet to be broadly applied in studying of 
efficiency and incentives of different institutions and political interventions and thus, 
expand our understanding of contextual effects on health care. Exploring of the 
contextual effect will enable researches to account for between-country heterogeneity 
and factor this into quantitative models to improve generalizability of multinational 
health economic studies. 
Exploring heterogeneity in patient-level studies using homogeneity test 
   Homogeneity test has been suggested to detect between-country heterogeneity in 
effect’s direction (qualitative interaction) and magnitude (quantitative interaction). In 
the absence of qualitative interaction in the effect direction, pooled estimates are 
considered applicable for the decision-making in individual countries participated in the 
trial (Cook et al., 2003). 
   Homogeneity test can be easily implemented and could be routinely used as part of 
health economic analysis. However, the conclusions about the absence of heterogeneity 
may not be drawn based on the results of the test alone due to the following limitations: 
• Low test power may not allow to detect qualitative interaction in economic 
parameters, when it actually exists.  
• Impossibility to formally explore and account for factors inducing heterogeneity. 
It is possible, however, to group countries with no evidence for treatment-by-
country interaction. 
• Unclear extend to which the trial-wide results, in absence of qualitative 
interactions, should be considered applicable for the decision-making in 
individual countries. Using pooled estimates for all participating countries would 
imply the high degree of similarity between geographical settings, what could be 
unrealistic and difficult to prove.  
   In addition, it has been argued, that statistical significance is not primarily relevant in 
health economic analysis (Claxton, 1999). In fact, in many cases it might be plausible to 
assume between-country heterogeneity and handle analysis with appropriate methods, 
such as hierarchical modelling. 
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Calculation of trial-wide and country-level estimates using hierarchical models 
(internal generalizability) 
   Evolving health economic literature demonstrated application of hierarchical 
modelling for calculation of setting-specific estimates using patient-level data collected 
in multinational trials (Rice & Jones, 1997; Manca et al., 2005; Grieve et al. 2005; 
2007; Pinto et al., 2005; Willan & Kowgier, 2007; Manca et al., 2007). 
   Hierarchical models provide a flexible framework to address the generalizability of 
the estimates across and possibly beyond the study jurisdictions. It allows calculation of 
country-level resource use, costs and cost-effectiveness by a mean of the shrinkage 
estimation - a weighted average of country-level and trial-wide (pooled) data. 
Hierarchical analysis takes into account between- and within settings variability and 
thus allows for correct reflection of uncertainty around parameter estimates. Moreover, 
it is possible to apply appropriate not-normal distribution for clinical and economic 
data. Finally, hierarchical modelling can be used to explore the extent, to which results 
are influenced by compositional and contextual effects and could be applicable beyond 
the study setting. 
   In the case study, we calculated trial-wide and country-level incremental costs and 
effectiveness estimates using bivariate hierarchical model framework proposed by 
Nixon and Thompson (2005) and Willan and Kowgier (2007). There are two important 
advantages of bivariate approach: (1) possibility to model costs and effectiveness 
separately with appropriate not-normal distributions and (2) include different set of 
covariates as necessary into costs and effectiveness equations. In our case study we used 
gamma distribution for costs and Bernoulli for effectiveness estimation and evaluated 
impact of patient-level and country-level covariates on cost, but not on clinical 
effectiveness. Clinical effect of the studied drugs was assumed not to be severely 
influenced by covariates, since pivotal clinical studies are highly controlled 
“experiments” designed to evaluate efficacy with the minimal risks to patients’ health.  
This means that maximum efforts are applied to restore and preserve health, but 
probably at different costs for different therapies. This assumption may not be valid for 
routine clinical practice, where both effectiveness and costs may be influenced by 
covariates.  
  175
   Important prerequisites for hierarchical analysis relates to “exchangeability” of data 
and sufficient sample size. 
   “Exchangeability” is a crucial assumption for hierarchical analysis and implies that 
selection of sites and countries participating in the study was carried out randomly and 
those are representative for the general population, for which the inference is being 
made. This should be valid for each country and site included into the study. This 
assumption may not be appropriate for any dataset and specific study design. Different 
populations may be considered as distinctive, rather than exchangeable, and should be 
treated with appropriate methodology e.g. using fixed effect model. Here, the shrinkage 
estimation procedure may not be appropriate. Exchangeability assumption should be 
considered at the study design stage in specification of patients’ and centers’ inclusion 
criteria. As noted by Duncan and colleagues (1998), this assumption is critical, and, 
similarly to all statistical techniques, hierarchical models are only as good as the data 
they fit (Duncan et al., 1998). 
   The second prerequisite relates to the sample sizes. Precise estimation of between- and 
within-level variation requires sufficient number if units at contextual and 
compositional levels. Efficient data collection may be achieved by multistage sampling 
design. Considerations about the optimal sample size are difficult outside the context of 
specific research question. Hierarchical models are broadly applied in analysis of school 
performance, where sampling considerations have been discussed. For example, Bryk 
and Raudenbush recommended sample of 60 students from 160 schools for reliable 
estimation of school-level random effects, whereas other researchers indicated that 
smaller group sample and size could be sufficient for specific research questions 
(Duncan et al. 1998; Bryk & Raudenbush, 1992; Paterson & Goldstein, 1992). 
Nonetheless, this data requirements may not be feasible for rare clinical conditions or, 
due to limited funding, many health economic studies will not be able to fulfill these 
prerequisites, particularly with regards to the number of countries.  
   The estimation of the hierarchical models may face technical issues in the cases where 
the number of higher-level settings is insufficient. As Draper (1995) emphasized, 
broadly used maximum likelihood estimation is implying large sample size. For the 
cases with small sample of high-level settings, maximum likelihood procedure may 
provide biased variance estimates and too narrow confidence intervals. The possible 
way to overcome this problem is to use a fully Bayesian approach (Goldstein, 1995; 
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Draper, 1995; Gilks et al., 1996; Duncan et al., 1998). This method is implemented in 
WinBUGS and was used for the model estimation in our case study.  
Adjusting for patient- or country-level differences: Hierarchical modelling with 
covariates (internal generalizability)  
   Effects of patient- and country-level covariates on economic parameters in 
hierarchical models are not yet broadly explored in health economic literature 
(Drummond et al., 2009). Inclusion of covariates into costs and effectiveness equations 
in hierarchical models can optimize analysis as following: 
• Increase precision of the costs and effectiveness estimates.  
• Allow for possible case-mix differences in baseline characteristics 
between treatment and control groups across different countries.  
• Adjust for differences in covariates to conform with “exchangeability” 
assumption in hierarchical models.  
• Identify the extent, to which covariate influence incremental costs and 
effectiveness estimates.  
   Our case study confirmed that inclusion of covariates into the models improved model 
fit and reduced uncertainty of the estimates as confirmed by narrower credibility 
intervals of the respective estimates. 
   Randomization of patients to different treatment arms should minimize imbalance 
between treatment and comparator groups in risk and other important parameters; 
nevertheless, it is appropriate to adjust for covariates to allow for any differences by 
chance between the groups (Nixon & Thompson, 2005). In addition, controlling for 
difference in the important clinical parameters between the countries is not secured by 
randomization procedure. In our case study we adjusted for differences in patients’ age, 
smoking and severity of condition, which showed impact on mean and incremental 
costs estimates. It means, that variability in resource consumptions and incremental 
effect of the therapy is partially attributed to differences in patients age, smoking and 
severity of condition.  
   Important assumption of hierarchical models is the “exchangeability” of the 
parameters of interest, since these are drawn from a common distribution (Spiegelhalter 
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et al., 2002). It implies, that there are no a priori reasons to believe, that estimates are 
relatively high or relatively low in a particular jurisdiction. This assumption might be 
critical for multinational trials conducted in countries at different stage of economic 
development and with different health care coverage. Cost analysis (hierarchical models 
1-3) was based on the data from patients coming from Western European countries and 
treated in all countries using common study protocol. Analysis of LOS (hierarchical 
models 4-6) used data collected in countries with different level of social security and 
economic developments, where adjustment of covariates was particularly important. 
   Inclusion of covariates into analysis allows both to identify “predictors” and to 
conduct the test for interactions between the groups. In our case study all patient-level 
covariates showed effect on mean costs and LOS; the covariates “age” (patients age at 
admission) and “CAP” (severity of condition at admission) showed positive effect on 
incremental costs and covariate CAP showed effect on incremental LOS.  
   In the analysis, country-level covariates showed only small effect on incremental cost 
and LOS estimates. These findings may indicate true absence of the relationship 
between country-level parameters and incremental costs and LOS. However, it can not 
be completely ruled out, that our analysis failed to reveal the association between 
contextual factors due to the following reasons:  
• selection bias and controlled phase 3 environment 
• ambiguous quantification of covariates  
• clustering on the site-level 
• assumed linear relationship between the covariates and dependent variables  
• measurement scale and extend of dissimilarity. 
   Inclusion of only few patients in individual countries could lead to a selection bias in 
country-level samples. For example, the patients from Switzerland were significantly 
elder than trial-average. As the result, country-level patient sample in the study may not 
be entirely representative for the country general patient population, and so country-
level covariates will fail to explain variability. In our case we attempted to include 
smoking status as country-level covariate based on WHO data as mean number of 
cigarettes smoked per person per year (Table 13). As a country-level covariate, smoking 
  178
had no effect on mean and incremental costs. We then used smoking as a patient-level 
covariate measured by mean number of smoked cigarettes per day. By ranking the 
countries based on cigarette consume, there were no overlap based on these two 
calculation options (WHO data for mean consume of cigarettes per person per year and 
study data of mean number of cigarettes consumed per day), implying either potential 
selection bias of the patients into the study or substantial difference in tobacco consume 
in patients with CAP and general population. 
   Quantification of the covariates may be problematic. In the case study we included 
antibiotic resistance as a country-level covariate. As mentioned earlier, the measurement 
and quantification of the antibiotic resistance is not unanimous and universally agreed 
due to clinical complexity of the issue and difficulty to measure this parameter in 
several countries by the same methodology (EARSS, 2006). Thus, it is possible that 
incorrect or imprecise assessment of covariates is the reason for it failure to explain 
variability. 
   In the case study we assumed two-level hierarchy: the patients were clustered within 
the countries and selected covariates from respective patient- and country-levels. 
However, it is well possible, that three-level hierarchical model would be more 
appropriated, namely: patients nested within trial sites and trial sites nested within the 
countries. The within-country variation in costs and effectiveness outcomes is well 
acknowledged in the health economic literature (Cook et al., 2004; Birch & Gafni, 
2003). Site-level parameters, e.g. community or teaching university hospital, hospital 
size, financing structure and others, may have substantial effect on mean and 
incremental costs and effectiveness. In our case study it was not feasible to conduct 
three-level hierarchical model with site-level due to small sample size in many centers.   
   In the case study we modeled the effect of covariates as linear and additive, e.g. a 
covariate was adding a certain amount to mean and incremental cost or resource use. 
Covariates may have non-linear effect on the outcomes variable by e.g. multiplying 
costs by a certain factor. This option should be investigated in the future simulations.  
   Finally, covariates can be measured on different scale types, e.g. from nominal to ratio 
scales. The later contains more information and is more sensitive to small differences. 
This factor is important, when there is relevant, but not pronounced difference in 
covariates between different countries or settings. In this case, the impact of covariate 
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on mean and incremental parameters may go undetected due to small sample size. 
Careful consideration of casual associations between the parameters is always 
commendable. 
Generalizability beyond the study setting: predictive ability of covariates for 
effectiveness and resource use estimates (external generalizability) 
   Generalization of the study results to non-study settings, e.g. countries not 
participating in the specific trials, has relevance for health policy and research. 
Evaluation of the effects of country-level covariates (contextual effects) on parameters 
of interest is one possible option to facilitate generalizability beyond the study setting. 
   The access to longitudinal health, resource use and economic data has forced 
empirical research to comparisons of various aspects of international health systems, 
health spending, and outcomes (Retzlav-Roberts et al., 2004). The results of these 
studies suggest very complex relationship between health spending, outcomes and 
contextual effects. For example, Babazono and Hillman (1994) stated no association 
between health outcomes and health care expenditures per capita across 21 OECD 
countries. Authors suggested that the resource distribution across health and non-health 
expenditures, and not the total level of funding, have impact on health outcomes. 
Anderson and colleagues (2003) hypothesized that the difference in health expenditures 
across OECD countries is forced by high prices of health care services in USA. In 
addition, they pointed out, that allocation of real resources is critical for health care 
system efficiency and costs. Or (2000) explored the determinants of population’s health 
status using health production function approach. He identified positive association 
between health status and expenditures in women and relevance of environmental 
factors in explaining of prematurely mortality in 21 OECD countries. 
   In our case study we established association between selected country-level covariates 
and mean resource use and costs: high antibiotics resistance, number of hospital beds 
per capita have positive impact on mean costs and LOS. However, country-level 
covariates showed small effect on incremental costs and resource use, what is the 
central question for the decision-making about the reimbursement of new therapy. The 
results of the case study support conclusion of Manca and colleagues (2007), that 
country-level covariates alone can not be used to predict estimated differences in costs 
and effects for the countries beyond the study setting. Indeed, finding “good” predictors 
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for costs and effectiveness parameters is difficult (Nixon & Thompson, 2005; Briggs & 
Gray, 1999). This issue and selection of relevant covariates out of many possible 
parameters is particularly important for assessment of impact on incremental differences 
between the therapies. 
   Based on results of our case study, we outlined several aspects to consider while 
selecting the covariates as presented in Table 31. Our case study was based on 
assessment of the effects of different antibiotic treatments in acute clinical condition. It 
is plausible to assume, that where new treatment course is not substantially changing 
current clinical practice comparing to standard treatment, the country-level parameters 
may not have strong effect on incremental costs and effectiveness. When country-by-
treatment interaction is not expected to be strong, use of patient-level covariates may be 
more appropriate and informative. For example, new treatment may be more efficacious 
in such groups as elder patients, smokers, patients with co-morbidities. Treatment of 
patients with co-morbidities and impacted health status will usually require increased 
resource utilization. Competitive recruitment may lead to imbalanced inclusion of the 
patients with potentially different co-morbidities and resource utilization (e.g. inclusion 
of elder patients in particular sites) and these patient-level differences may contribute to 
between-country variability in incremental resource use and effectiveness. Thus, 
inclusion of both patient-level and higher-level covariates will aid to understanding of 
heterogeneity. However, prediction of incremental results based on country-level 
covariates may not be feasible without applying of decision-analytical techniques (e.g. 
economic models). 
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Table 31: Selection Criteria of Covariates with Potential Effect on Incremental Health Economic Parameters 
Level Technical requirement Considerations for selection of covariates Potential covariates 
Contextual/ higher-
level (country, 
region, centre, 
investigator) 
Recruited patients/study 
procedures are 
relevant/representative 
for the clinical 
population in particular 
setting with available 
macro-level parameters 
? Clinical condition is chronic;  
? New treatment introduces or substantially modify 
current clinical practice;  
? New treatment may influence capacity utilization 
in provision of health-care services comparing to 
standard therapy;  
? New treatment may change/influence incentives 
for health care providers and other relevant actors;  
? New treatment require utilization/employment of 
cost-intensive techniques and/or high-skilled 
clinical personnel. 
Clinical: 
Availability of prevention, screening, 
cessation programms; ratio of high-
skilled to supportive personnel in 
hospitals; ratio of clinical personnel to 
number of beds.  
Socio-economic: 
%GDP dedicated to health care, number 
of hospital beds per capita, remuneration 
of clinical personnel, level of co-
payment, location big city/country-side, 
university/excellence clinical site. 
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Level Technical requirement Considerations for selection of covariates Potential covariates 
Compositional/lower-
level (individual 
patients) 
Patient-level data 
available in study 
dataset 
? Clinical condition is acute;  
? Availability of clinical guidelines or treatment 
conventions suggesting different approaches (e.g. 
using of co-therapies) to different patients’ sub-
groups; 
? Available evidence or indication for different 
efficacy and tolerability of new therapy in 
different sub-groups (elder patients, smokers, co-
morbid, etc). 
Clinical: 
Sex, age, co-morbidity, severity of 
condition, genetic predisposition.  
 
Socio-economic:  
Smoking, alcohol consumption, living 
environment, income, education, 
employment. 
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Comparative evaluation of the applied analytical generalizability methods  
   Table 32 summarizes advantages and limitations of selected generalizability methods 
for practical implementation of data analysis. Descriptive analysis of trial-wide and 
country-level results, while being easy to compute, have major limitations such as 
requirements of a large sample size and impossibility to account for covariates.  
   Qualitative and quantitative homogeneity tests are simple methods to access 
pronounced between-country heterogeneity. However, similar to descriptive statistics, 
the results can not be used as ultimate confirmation of the absence of treatment-by-
country interaction. The calculation of test power is needed to evaluate robustness of 
test conclusions.  
   Hierarchical models offer flexible analytical framework using patient-level data with 
the option to include both patient- and country-level covariates, which is particularly 
useful to explain and account for observed between-country variability. The critics on 
the use of hierarchical models is that the exchangeability assumption can not hold when 
country-level covariates failed to explain between-country variability. Gelman and 
colleagues (2004) and Manca and Willan (2006) oppose to that suggesting, that despite 
between-country differences, it is feasible to consider the data drawn from a common 
distribution through conditional independence when building-in the covariates.  
 
Table 32: Comparative Evaluation of Analytical Methods to Improve Generalizability 
Method Strengths Limitations 
Descriptive 
country-level 
analysis 
- Direct estimation using 
country-specific parameters. 
- Applicable to large samples 
for sub-group analysis. 
- High uncertainty about estimates 
of the small sub-groups. 
- Impossible formally to account for 
heterogeneity and covariates. 
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Method Strengths Limitations 
Qualitative 
homogeneity 
test 
Simple computation for 
detection of heterogeneity in 
effect’s direction. 
-Impossible to quantify sources of 
variation and account for 
covariates. 
- Low test power for economic 
parameters. 
- Absence of statistical significance 
should not mean absence of 
important economic differences.  
Quantitative 
homogeneity 
test 
Simple computation for 
detection of heterogeneity in 
effect’s magnitude. 
- Of limited use for country-level 
estimates since heterogeneity in 
magnitude can be expected. 
- Impossible formally to account for 
covariates. 
Hierarchical 
models without 
covariates 
- Estimation of country-level 
parameters taking into 
account hierarchical patient-
level data.  
- Selections of appropriate 
distribution for costs or 
resource use parameters. 
- Limited use if only few a priori 
different countries participated.  
- Assumption of “exchangeability” 
of patient-level data. 
Hierarchical 
models with 
covariates 
- Overcoming 
“exchangeability” 
assumption. 
- Exploring and explaining 
between-country differences 
with covariates. 
- Possibly arbitrary selection of 
covariates.  
- High uncertainty of prediction of 
impact of covariates on incremental 
costs and effectiveness (and not on 
mean parameters only). 
Source: compiled by the author. 
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What this case study adds   
   Methodology of this case study builds on previous research by Willan and Kowgier 
(2007), Nixon and Thompson (2005), Manca and colleagues (2005) and others. Our 
analysis contributes to the health economic literature on generalizability issue and 
methodology by following:  
• Case study is first study in CAP indication, which explicitly addressed between-
country heterogeneity and generalizability of the results of multinational patient-
level health economic study.  
• Case study demonstrated simultaneous application of several methods for 
assessment of between-country heterogeneity and improvement of 
generalizability in patient-level health economic study. Homogeneity test was 
found a complimentary method to hierarchical models to assess homogeneity 
and possibly “exchangeability” assumption for hierarchical modelling.  
• Case study evaluated effect of selected country-level and patient-level covariates 
on mean and incremental costs and resource use in treatment of CAP indication. 
   In general, studying of between-country variability, analytical strategies to improve 
generalizability and use of appropriate methodology is still at the early development 
stage. Some findings of our case study may be valid for CAP indication only, however, 
analytical approach and major conclusions may to greater extend be relevant for other 
indications and medical treatments. 
Limitations of the case study 
   Case study analysis has several limitations. The important limitation is a moderate 
sample size. This issue is important for the analysis of cost-effectiveness estimates 
based on data from 333 patients from 5 countries (hierarchical models 1-3). The issue 
with sample size is less relevant for the analysis of length of stay in the hospitals, as it 
was based on a larger sample of 622 patients from 10 countries. Nonetheless, health 
economic studies conducted along clinical trials are rarely powered to detect differences 
in economic parameters. Also, multinational studies are often conducted in many 
countries with the unbalanced and small sample size per country due to competitive 
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recruitment. Finally, depending on the indication, recruiting and conducting the trial 
with large sample size is often resource intensive. Thus, our case study could be 
considered as a representative dataset available for health economic analysis. In 
addition, cost-effectiveness analysis was conducted based on data from Western 
European countries. This fact supports assumptions about exchangeability of data in 
hierarchical models. The other limitation is the fact, that country-level covariates were 
not collected during the study conduct and analysis with covariates was not pre-
specified in advance. As implication, we may not exclude spurious findings. 
Implications and directions for future research 
   Studying variability and improving generalizability remain important future research 
topics in health economics. Both practical and theoretical aspects should be addressed. 
While methodology for analysis of multinational data made substantial progress, 
practical recommendations for the study design and conduct deserve more attention. In 
particular, guidelines for selection of countries, sites, number of patients per unit, 
selection and collection of potential covariates are needed. In addition, best practice and 
guidelines in application of costing methods are relevant to reduce variability caused by 
different methodological approaches to quantify resource use in different studies. 
   It will remain of interest to predict the cost-effectiveness outcomes beyond the study 
setting. This type of analysis would inevitably require evidence synthesis with help of 
meta-analysis and decision modelling. Exploring effects of country-level covariates on 
cost-effectiveness parameters might be helpful to make appropriate adjustment to the 
input data, while modelling cost-effectiveness for a setting of interest. For this purpose, 
theoretical and empirical basis for selection of appropriate covariates is needed taking 
into account both the nature of the condition (e.g. chronic or acute disease) and 
characteristics of the treatment options. In addition, the considerations about selection 
of appropriate covariates should be supported by the empirical health care system 
research and understanding which macroeconomic parameters are indicative for 
particular health care environment and could be associated with differences in mean and 
incremental cost-effectiveness estimates.  
   Another avenue for the research of statistical methods may explore usability of latent 
class modelling to uncover potential patient sub-groups or confirm/reject between- or 
within-country heterogeneity while simultaneously adjusting for covariates. It can be 
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also beneficial to explore impact of alternative distributional assumptions for dependent 
variables on cost-effectiveness estimates and covariates coefficients. There are a variety 
of possible extensions to the way covariates may be included in the model, such as non-
linear transformations of variables, interactions among variables, and non-parametric 
regression effects, all of which can be incorporated into Bayesian hierarchical models.   
   Finally, assessment of between country-variability in different indications and study 
settings using various approaches and statistical techniques will contribute both to 
empirical and methodological  knowledge in addressing generalizability issue in future 
research.  
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6 Conclusions 
   Health economic analysis will continue to inform and guide decision in health policy. 
Thus, generalizability of health economic evidence collected in multinational context, 
i.e. applicability of the study results to all participated countries and non-study settings, 
is important question for Public Health research and policy. In this work we explored 
the methods applicable for patient-level studies to improve generalizability of clinical 
and economic outcomes. The major findings can be summarized as following: 
1) Common theoretical foundation rooted in Public Health and Economics 
is needed to guide health policy, study between-country variability and 
develop generalizability methods. 
2) Homogeneity test and hierarchical models should be routinely used in the 
analysis to improve generalizability of the outcomes generated in patient-
level studies. 
3) Further practical, empirical and methodological research needed to 
explore requirements, applicability and limitations of the generalizability 
instruments in different datasets and contexts. 
   Numerous clinical and socio-economic factors are discussed in the literature and 
hypothesized to impact efficacy, resource use and costs of different technologies across 
the sites, countries and geographic areas. Research about the differences in health care 
delivery and outcomes is mainly driven by availability of empirical sources and lacks 
common theoretical foundations within Public Health and Economic realms. The 
approaches and methodology to explore between-setting variability and methods to 
improve generalizability of multinational health economic evaluations are yet to be 
developed and tested in different indications and datasets.  
   We applied homogeneity test and hierarchical models in secondary analysis of 
multinational study evaluating efficacy, resource use and costs of novel antibiotic 
treatment for acute respiratory condition. Homogeneity test supported assessment of 
significant between-country variability in clinical and economic parameters; 
hierarchical modelling allowed for calculation of trial-wide and country-level clinical 
and economic outcomes. Both methods complement standard health economic analysis 
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in assessment of statistical between-country heterogeneity and calculation of country-
level and trial-wide clinical and economic endpoints with appropriate quantification of 
uncertainty. 
   Decision about homogeneity of the targeted outcomes may not exclusively rely on the 
results of homogeneity test, in particular, when comparing results across the countries 
with small samples. Hierarchical models support estimation of trial-wide and setting-
specific results. Validity of “exchangeability” assumption for application of hierarchical 
modelling, i.e. no a priori reasons to consider the settings explicitly different, is vital 
and should be addressed in the analysis. In addition, the method allows for adjustment 
of differences in patient-level baseline variables. Predictive ability of country-level 
covariates to support generalizability of incremental costs, resource use and 
effectiveness to the countries not participated in the study merits further investigation. 
The differences in socio-economic context across the countries, such as proportion of 
GDP dedicated to health care, capacity of health facilities and other factors, may or may 
not have effect on incremental clinical and economic parameters. Reliable assessment of 
the association between country-level covariates and incremental effects requires large 
sample size from several countries. 
   Generalizability subject should be routinely addressed at the design and analysis 
phases of multinational health economic studies. Future research should focus on both 
methodological development, as well as application of available methods in different 
data sets and clinical indications. The collected empirical data will provide further 
inside on requirements and limitations of used instruments. 
   Analysis of multinational evidence has several implication for health policy. 
Assessment of the sources of between-country variability will contribute to better 
understanding of the potential reasons of (in)efficient health production and thus 
contribute to formulation of informed health policy. 
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Appendix A. Assessment of Multicollinearity 
5 countries sample: 
pwcorr totallos cost x4age smoknum y3smok x2cap, sig sidak 
 
             | totallos     cost    x4age  smoknum   y3smok    x2cap 
-------------+------------------------------------------------------ 
    totallos |   1.0000  
             | 
             | 
        cost |   0.6610   1.0000  
             |   0.0000 
             | 
       x4age |   0.3176   0.2352   1.0000  
             |   0.0000   0.0002 
             | 
     smoknum |   0.1227   0.0872  -0.2158   1.0000  
             |   0.3170   0.8328   0.0011 
             | 
      y3smok |  -0.0039   0.0338  -0.2505   0.8031   1.0000  
             |   1.0000   1.0000   0.0001   0.0000 
             | 
       x2cap |   0.1104   0.1870   0.1160   0.0428  -0.0066   1.0000  
             |   0.4918   0.0090   0.4081   0.9998   1.0000 
 
10 countries sample: 
pwcorr totallos x4age smoknum x2cap y3smok, sig sidak 
 
             | totallos    x4age  smoknum    x2cap   y3smok 
-------------+--------------------------------------------- 
    totallos |   1.0000  
             | 
             | 
       x4age |   0.3376   1.0000  
             |   0.0000 
             | 
     smoknum |   0.0762  -0.2331   1.0000  
             |   0.4465   0.0000 
             | 
       x2cap |   0.0845   0.0242  -0.0249   1.0000  
             |   0.2999   0.9996   0.9995 
             | 
      y3smok |  -0.0367  -0.2855   0.8052  -0.0386   1.0000  
             |   0.9887   0.0000   0.0000   0.9834
 
   Bivariate correlation of dependent variable LOS and covariates age, smoking and 
severity of CAP at admission does not indicate strong correlation and therefore potential 
multicollinerity between covariates. Thus, all covariates can be used in hierarchical 
models. 
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Appendix B. WinBUGS code for HM 3 
model 
{ 
for(i in 1:Npatients) 
{ 
effectiveness[i] ~ dbern(meanE[i]) 
alpha[i] <- muES+gammaE[country[i]] 
tau[i] <- (capital.deltaE+deltaE[country[i]])*j[i] +(thetaEX4+omegaEX4*j[i])*(X4AGE[i]-
X4AGE.bar) 
meanE[i] <- min(max(alpha[i], -tau[i]), 1 - tau[i]) + tau[i] 
cost[i] ~ dgamma(shapeC[country[i]], rateC[i]) 
rateC[i] <- shapeC[country[i]]/meanC[i] 
meanC[i] <- muCS*(1-j[i])+muCT*j[i]+gammaC[country[i]]+deltaC[country[i]]*j[i] 
+(thetaCX2+omegaCX2*j[i])*X2CAP[i]+(thetaCX4+omegaCX4*j[i])*(X4AGE[i]-
X4AGE.bar)+(thetaCY3+omegaCY3*j[i])*(Y3SMOK[i]-
Y3SMOK.bar)+beta[j[i]+1]*(effectiveness[i] - meanE[i]) 
dC[i] <- -loggam(shapeC[country[i]])+shapeC[country[i]]*log(rateC[i]) 
+(shapeC[country[i]]-1)*log(cost[i])-rateC[i]*cost[i] 
dE[i] <- log(pow(meanE[i],effectiveness[i]) 
*pow(1-meanE[i],1-effectiveness[i])) 
} 
for(k in 1:M) 
{ 
deltaEE[k] ~ dnorm(0, tau.deltaE) 
gammaEE[k] ~ dnorm(0, tau.gammaE) 
gammaCC[k] ~ dnorm(0, tau.gammaC) 
deltaCC[k] ~ dnorm(0, tau.deltaC) 
deltaE[k] <- deltaEE[k] - (inprod(country.n[], deltaEE[])/sum(country.n[])) 
gammaE[k] <- gammaEE[k] - (inprod(country.n[], gammaEE[])/sum(country.n[])) 
gammaC[k] <- gammaCC[k] - (inprod(country.n[], gammaCC[])/sum(country.n[])) 
deltaC[k] <- deltaCC[k] - (inprod(country.n[], deltaCC[])/sum(country.n[])) 
} 
# Overall parameters 
capital.deltaCcov <- muCT - muCS 
capital.deltaEcov <- capital.deltaE 
EC <- capital.deltaEcov*capital.deltaCcov # used for estimating C(De, Dc) for X4AGE = 0 
for(i in 1:101) {ceac0[i] <- step(capital.deltaEcov*1000*(i - 1) - capital.deltaCcov)} 
ProbSE <- step(capital.deltaEcov)*step(-capital.deltaCcov) 
# Country 1’s parameters 
capital.deltaE.c1 <- capital.deltaEcov+deltaE[1] 
capital.deltaC.c1 <- capital.deltaCcov+deltaC[1] 
EC.c1 <- capital.deltaE.c1*capital.deltaC.c1 # used for estimating C(De, Dc) for X4AGE = 0
for(i in 1:101) {ceac.c1[i] <- step(capital.deltaE.c1*1000*(i - 1) - capital.deltaC.c1)} 
ProbSE.c1 <- step(capital.deltaE.c1)*step(-capital.deltaC.c1) 
# Country 2nd parameters 
capital.deltaE.c2 <- capital.deltaEcov+deltaE[2] 
capital.deltaC.c2 <- capital.deltaCcov+deltaC[2] 
EC.c2 <- capital.deltaE.c2*capital.deltaC.c2 # used for estimating C(De, Dc) for X4AGE = 0
for(i in 1:101) {ceac.c2[i] <- step(capital.deltaE.c2*1000*(i - 1) - capital.deltaC.c2)} 
ProbSE.c2 <- step(capital.deltaE.c2)*step(-capital.deltaC.c2) 
# Country 3rd parameters 
capital.deltaE.c3 <- capital.deltaEcov+deltaE[3]  
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capital.deltaC.c3 <- capital.deltaCcov+deltaC[3] 
EC.c3 <- capital.deltaE.c3*capital.deltaC.c3 # used for estimating C(De, Dc) for X4AGE = 0
for(i in 1:101) {ceac.c3[i] <- step(capital.deltaE.c3*1000*(i - 1) - capital.deltaC.c3)} 
ProbSE.c3 <- step(capital.deltaE.c3)*step(-capital.deltaC.c3) 
# Country 4th parameters 
capital.deltaE.c4 <- capital.deltaEcov+deltaE[4] 
capital.deltaC.c4 <- capital.deltaCcov+deltaC[4] 
EC.c4 <- capital.deltaE.c4*capital.deltaC.c4 # used for estimating C(De, Dc) for X4AGE = 0
for(i in 1:101) {ceac.c4[i] <- step(capital.deltaE.c4*1000*(i - 1) - capital.deltaC.c4)} 
ProbSE.c4 <- step(capital.deltaE.c4)*step(-capital.deltaC.c4) 
# Country 5th parameters 
capital.deltaE.c5 <- capital.deltaEcov+deltaE[5] 
capital.deltaC.c5 <- capital.deltaCcov+deltaC[5] 
EC.c5 <- capital.deltaE.c5*capital.deltaC.c5 # used for estimating C(De, Dc) for X4AGE = 0
for(i in 1:101) {ceac.c5[i] <- step(capital.deltaE.c5*1000*(i - 1) - capital.deltaC.c5)} 
ProbSE.c5 <- step(capital.deltaE.c5)*step(-capital.deltaC.c5) 
X4AGE.bar<-mean(X4AGE[]) 
Y3SMOK.bar<-mean(Y3SMOK[]) 
muES ~ dunif(0, 1) 
capital.deltaE ~ dunif(-1, 1) 
for(k in 1:M) {shapeC[k] ~ dunif(0, 30)} 
muCS ~ dunif(300, 25000) 
muCT ~ dunif(300, 25000) 
omegaCX2~ dnorm(0, 1.0E-2) 
omegaCX4~ dnorm(0, 1.0E-2) 
omegaCY3~ dnorm(0, 1.0E-2) 
omegaEX4~ dnorm(0, 1.0E-2) 
thetaCX2~ dnorm(0, 1.0E-2) 
thetaCX4~ dnorm(0, 1.0E-2) 
thetaCY3~ dnorm(0, 1.0E-2) 
thetaEX4~ dnorm(0, 1.0E-2) 
for(i in 1:2) {beta[i] ~ dnorm(0, 1.0E-2)} 
tau.deltaE <- 1/ss.deltaE 
ss.deltaE <- exp(lnss.deltaE) 
s.deltaE <- sqrt(ss.deltaE) 
lnss.deltaE ~ dunif(-10, 5) 
tau.gammaE <- 1/ss.gammaE 
ss.gammaE <- exp(lnss.gammaE) 
s.gammaE <- sqrt(ss.gammaE) 
lnss.gammaE ~ dunif(-10, 5) 
tau.gammaC <- 1/ss.gammaC 
ss.gammaC <- s.gammaC*s.gammaC 
s.gammaC ~ dunif(1,4000) 
tau.deltaC <- 1/ss.deltaC 
ss.deltaC <- s.deltaC*s.deltaC 
s.deltaC~dunif(100,4000) 
dev <- -2*(sum(dC[])+sum(dE[])) 
}  
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Appendix C. Histogram of LOS and Costs 
 
Figure 18: Cost Histogram for Treatment and Comparator Arms Combined 
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Figure 20: Cost Histogram for Comparator Arm 
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Figure 21: Cost Histogram for Treatment and Comparator Arms per Country 
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Figure 22: LOS Histogram for Treatment and Comparator Arms Combined 
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Figure 23: LOS Histogram for Treatment Arm 
0
5
10
15
20
P
er
ce
nt
0 5 10 15 20
TOTAL LOS
10 CNTR Total LOS j==1
 
 
  222 
Appendix D. Costing Methodology Applied In Case Study 
Table 33: Case Study Resource Costing: Study Medication 
  Route Cost Unit 
In Hospital 
Cost/EUR 
Out Hospital 
Cost/EUR Source Comment 
France             
Moxifloxacin IV 400 mg 46.85 30.45 BSP information Price at market introduction 
Moxifloxacin PO 400 mg 5.18 3.37 BSP information Official market price 
Co-amoxiclav IV 1.2 g 4.21 2.73 Official public selling price of Augmentin 
Co-amoxiclav PO 625 mg 0.91 0.59 Official public selling price of Augmentin 
Clarithromycin IV 500 mg 17.53 11.39 Official public selling price of Klacid iv 
Clarithromycin PO 500 mg 2.00 1.30 Vidal-Semp, 2001 Official public selling price of Klacid/Clarithomycin PO 
Germany             
Moxifloxacin IV 400 mg 60.83 59.91 BSP information Price at market introduction 
Moxifloxacin PO 400 mg 5.65 5.19 BSP information Official market price 
Co-amoxiclav IV 1.2 g 11.28 10.36 Official selling price of Augmentan out of pharmacy 
Co-amoxiclav PO 625 mg 3.00 2.77 
Weighted average based on market share: 33% Augmentan  and 66% generics 
(IMS Health, 2002) 
Clarithromycin IV 500 mg 31.59 30.67 
IV form not available in Germany; cost assumed to be 8.8 times PO cost as per 
corresponding ratio in France 
Clarithromycin PO 500 mg 3.59 3.36 Rote Liste®, 2001 
Weighted average based on market share:  60% Klacid, 5% Biaxin, 35% 
reimported Klacid (IMS Health, 2002) 
Spain             
Moxifloxacin IV 400 mg 40.93 31.11 BSP information Price at market introduction 
Moxifloxacin PO 400 mg 3.61 2.75 BSP information Official market price 
Co-amoxiclav IV 1.2 g 3.18 2.42 Based on price of Augmentine 100% market share (IMS Health, 2002) 
Co-amoxiclav PO 625 mg 0.40 0.30 
Weighted average based on market share:  67% Augmentine, 15% Duonasa, 12% 
Eupeclanic, 3% Clavumox, 3% Clavucid (IMS Health, 2002) 
Clarithromycin IV 500 mg 13.71 10.42 Based on price of Klacid and Bremon  
Clarithromycin PO 500 mg 1.69 1.29 
Vademecum, 2001; 
Portalfarma, 2001 Based on price of Klacid and Bremon 
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  Route Cost Unit 
In Hospital 
Cost/EUR 
Out Hospital 
Cost/EUR Source Comment 
Switzerland             
Moxifloxacin IV 400 mg 60.61 54.55 BSP information Price at market introduction 
Moxifloxacin PO 400 mg 4.74 4.27 BSP information Official market price 
Co-amoxiclav IV 1.2 g 19.05 17.15 Official public selling price of Augmentin 
Co-amoxiclav PO 625 mg 1.87 1.68 Official public selling price of Augmentin 
Clarithromycin IV 500 mg 29.04 26.14 Official public selling price of Klacid iv 
Clarithromycin PO 500 mg 1.93 1.74 Documed, 2001 Official public selling price of Klacid/Clarithomycin PO 
UK             
Moxifloxacin IV 400 mg 51.41 51.41 BSP information Price at market introduction 
Moxifloxacin PO 400 mg 3.43 3.43 BSP information Official market price 
Co-amoxiclav IV 1.2 g 4.66 4.66 Based on price of Augmentin 100% market share (IMS Health, 2002) 
Co-amoxiclav PO 625 mg 1.17 1.17 
Weighted average based on market share:  71% Augmentin, 29% Non-branded  
(IMS Health, 2002) 
Clarithromycin IV 500 mg 17.55 17.55 Based on price of Klaricid 100% market share (IMS Health, 2002) 
Clarithromycin PO 500 mg 2.77 2.77 
British National 
Formulary, 2001;  
NHS Drug Tariff, 
2001 Based on price of Klaricid 100% market share (IMS Health, 2002) 
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Table 34: Case Study Resource Costing: Concomitant Medication 
  Data Source     Comment 
The complete list with unit prices for concomitant medications available on request   
France Vidal-Semp, 2001  Reimbursement rate of 65% was applied 
Germany Rote Liste®, 2001  Patient co-payment of 4.60 EUR (for medium sized pack) was assumed  
Spain Vademecum, 2001; Portalfarma, 2001  Reimbursement rate of 76% was applied 
Switzerland Documed, 2001   Reimbursement rate of 90% was applied 
UK 
British National Formulary 
2001; NHS Drug Tariff, 2001     
Reimbursement rate of 100% was applied, medication prices include a wholesaler margin 
of 12.5% 
 
Table 35: Case Study Resource Costing: Hospitalization and Radiological Procedures 
Ward Type  Unit Unit/EUR  Source Comment 
France         
General 1 day 419.45 
Intensive Care 1 day 1058.07 
All Others 1 day 419.45 PMSI, 2000 
Cost for 1999 updated to 2000 by factor 1.02; 4% has been removed representing cost of study 
medications; costs of other ward types assumed to be equal to general ward 
Germany      
General 1 day 201.10 
Intensive Care 1 day 775.21 
All Others 1 day 201.10 PKV, 1999/2000 
Cost for 1999 updated to 2000 using the consumer price index for health care (113.6/107.6); 4% has been 
removed representing cost of study medications, costs of other ward types assumed to be equal to general 
ward 
Spain         
General 1 day 286.08 
Intensive Care 1 day 1055.04 
All Others 1 day 286.08 SOIKOS, 2001 
4% has been removed representing cost of study medications, costs of other ward types assumed to be 
equal to general ward 
Switzerland         
General 1 day 256.89 
Intensive Care 1 day 1262.01 
All Others 1 day 256.89 Taxordnung, 2002 
Cost for 1999 updated to 2000 using the consumer price index for health care (113.6/107.6); 4% has been 
removed representing cost of study medications 
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Ward Type  Unit Unit/EUR  Source Comment 
UK         
General 1 day 237.56 
Cost represents mean per diem for non-elective patients with bronchopneumonia; 4% has been 
substracted 
Intensive Care 1 day 1795.11 Cost represents mean cost for all types of admissions; 4% has been substracted 
All Others 1 day 237.56 
NHS Reference costs, 
2001/2002 Assumed General ward cost for all other ward types 
 
  
Cost 
Unit Unit/EUR Source Comment 
France         
Chest X-Ray 1 X-ray 17.24 
CT Scan - Chest 
1 CT 
scan 94.08 NGAP, 2001 A reimbursement rate of 70% was applied to radiological procedures. 
Germany         
Chest X-Ray 1 X-ray 16.32 
CT Scan - Chest 
1 CT 
scan 134.06 GOA, 2000 No co-payments were applied to these costs 
Spain         
Chest X-Ray 1 X-ray 18.00 
CT Scan - Chest 
1 CT 
scan 130.00 SOIKOS, 2001   
Switzerland         
Chest X-Ray 1 X-ray 58.41 Tarmed, 2002 Reimbursement rate of 90% was applied 
CT Scan - Chest 
1 CT 
scan  NA   
UK         
Chest X-Ray 1 X-ray 20.38 
CT Scan - Chest 1 CT scan 73.67 NHS Drug Tariff, 2001 Reimbursement rate of 100% was applied 
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Table 36: Case Study Resource Costing: Therapeutic Adjuncts 
Procedure Cost Unit 
Healthcare 
System Cost/Unit Source Comment 
France       Reimbursement rate of 65% was applied 
Aerosol Breathing 
Therapy 1 session 0.86 Without a humidifier, not including medication 
Chest Physiotherapy 20 minutes 1.84 Assumed 5 visits per week 
Inhalation Therapy 1 session 5.97 Assumed therapy for <12 hours/day 
Nasal C-Pap 1 session 6.34 Cost includes C-PAP and oxygen 
Oxygen (Face Mask) 1 session 4.81 Assumed short-term treatment (< 4 weeks) 
Oxygen (Nasal Cannula) 1 session 4.51 
NGAP, 2001 
TIPS, 2001 Assumed short-term treatment (< 4 weeks) 
Germany    Reimbirsement is item-specific 
Aerosol Breathing 
Therapy 1 session 9.87 
Cost for general physical therapy from West Germany; co-pay of 15% has been 
removed 
Chest Physiotherapy 20 minutes 9.87 
Cost for general physical therapy from West Germany; co-pay of 15% has been 
removed 
Inhalation Therapy 1 session 13.08 
Physiotherapy offices 
in Northrhein-
Westphalia, 2001 Cost includes therapy and inhalation; cost from West Germany; 15% co-pay removed 
Nasal C-Pap 1 session 0.00  Not reimbursed 
Oxygen (Face Mask) 1 session 0.00  Not reimbursed 
Oxygen (Nasal Cannula) 1 session 0.00  Not reimbursed 
Spain       Reimbursement rate of 100% was applied 
Aerosol Breathing 
Therapy 1 session 3.00 Assumed 5 sessions per week 
Chest Physiotherapy 20 minutes 0.00 Not reimbursed 
Inhalation Therapy 1 session 4.00 Cost not found; assumed same cost as oxygen (face mask) 
Nasal C-Pap 1 session 4.00 Cost not found; assumed same cost as oxygen (face mask) 
Oxygen (Face Mask) 1 session 4.00 Assumed 5 session per week 
Oxygen (Nasal Cannula) 1 session 4.00 SOIKOS, 2001 Cost not found; assumed same cost as oxygen (face mask) 
Switzerland    Reimbursement rate of 90% was applied 
Aerosol Breathing 
Therapy 1 session 29.96 
Chest Physiotherapy 20 minutes 29.96 
Inhalation Therapy 1 session 29.96 
Nasal C-Pap 1 session 29.96 
Physioswiss, 2001 
Allgemeine Physiotherapie, Cost for 1999 updated to 2000 using the consumer price 
index for health care (113.6/107.6) 
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Procedure Cost Unit 
Healthcare 
System Cost/Unit Source Comment 
Oxygen (Face Mask) 1 session 29.96 
Oxygen (Nasal Cannula) 1 session 29.96 
UK       Reimbursement rate of 100% was applied 
Aerosol Breathing 
Therapy 1 session 25.08 Clinic visit to a physiotherapist; assumed 5 sessions per week 
Chest Physiotherapy 20 minutes 25.08 Clinic visit to a physiotherapist; assumed 5 sessions per week 
Inhalation Therapy 1 session 25.08 Clinic visit to a physiotherapist; assumed 5 sessions per week 
Nasal C-Pap 1 session 11.30 Cost not found; assumed same cost as oxygen face mask 
Oxygen (Face Mask) 1 session 11.30 
Set up and supplies provided through pharmacist; assumed cost of 1 set paid for over 1 
year plus 1 cyclinder of oxygen per day 
Oxygen (Nasal Cannula) 1 session 11.30 
NHS Drug Tariff, 
2001 Cost not found; assumed same cost as oxygen face mask 
Note: unit costs data was available for UK, France, Germany and Spain (BSP study report, 2000), unit costs data for Switzerland was collected by 
the author.  
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